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ABSTRACT. 
The aim of this project was to create an inducible 
thyroxine-deficient mouse model which could be used to 
investigate the role of thyroxine in gene expression. This 
was achieved by using the HSV1-tk ablation technique. 
Transgenic mice were produced containing 3.1kb of the 
bovine thyroglobulin promoter linked to 1.8kb of the HSV1-
tk gene. Expression of the transgene was detected in the 
thyroid and testes. Transcription of the transgene in 
transgenic thyroid tissue was correctly initiated at the 
cap site of the thyroglobulin promoter. Treatment of female 
transgenic mice with 4.5mg/day of an anti-herpetic agent, 
such as ganciclovir, resulted in a reduction in the number 
of thyroid follicle cells within 3 days and their complete 
absence after 7 days. After 14 days of treatment the mice 
lacked circulating thyroid hormones, the HSV1-TK activity 
of the thyroid rudiments was comparable to non-transgenic 
controls and the total soluble protein remaining was 
approximately 20% of controls. 
The thyroid gland comprises two cell types, thyroxine 
producing thyrocytes and calcitonin producing C-cells. The 
gland is also in intimate contact with the parathyroid 
gland which secretes parathyroid hormone. The expression of 
the transgene was restricted to the thyroid follicle 
epithelial cells. Transgenic ablation resulted in the 
precise removal of HSV1-TK expressing cells with no 
secondary effect on either the C-cells or the parathyroid 
gland. My results also demonstrate that the normal function 
of the C-cells and parathyroid gland are not dependent on 
thyroid hormones. 
When treatment with ganciclovir was terminated no 
recovery of thyroid hormones in the circulation or HSV1-TK 
activity in the thyroid rudiment were observed (for up to 
113 days). This suggests that young adult mice do not 
contain a non-differentiated stem cell that is capable of 
repopulating the follicle cells of the thyroid. 
The mouse major urinary proteins (MUP) genes in the 
liver are regulated by thyroid hormones and growth hormone. 
I investigated the role of thyroid hormones on the 
expression of resident MUP genes and also a MUP transgene 
and demonstrated that hepatic MUP gene expression is 
absolutely dependent on the presence of thyroid hormones. 
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CHAPTER 1. 
INTRODUCTION. 
HORMONES AND GENE EXPRESSION. 
The endocrine system operates through extracellular 
messengers - hormones, which act on target cells to 
modify their activity. This control is important not only 
for development and growth but also in allowing the 
organism to adapt to changes in its internal and external 
environment. Hormones are synthesised in specialised 
cells which are either collected into distinct endocrine 
glands for example, the pituitary, the thyroid, and the 
pancreas, or are found as single cells within other 
organs for example, the gastrointestinal tract. Endocrine 
cells secrete hormones into the blood system where they 
are carried to target cells, which may be at some remote 
site in the organism. In contrast paracrine hormones for 
example, Insulin-like growth factor I (IGF-I), can act 
locally without being released into the blood system. 
Hormones can be divided into three groups according 
to their chemical composition. Firstly the hormones which 
are derivatives of the amino acid tyrosine, secondly 
peptide/protein hormones and thirdly the steroid 
hormones. They act on target tissues through specific 
receptors found on or within the cell. The steroid 
hormones are soluble in lipid membranes and can therefore 
enter the target cell, where they bind to nuclear 
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receptors, by diffusion. The receptor-hormone complex 
binds directly to specific sequences in the gene. Due to 
similarities in their structures and DNA response 
elements the thyroid hormone receptor is included in the 
steroid hormone receptor superfamily (Evans, 1988). In 
contrast, peptide and protein hormones for example, 
thyroid stimulating hormone (TSH), are hydrophilic 
molecules that act by binding to their specific cell 
surface receptors inducing intracellular secondary 
messengers for example, cAMP (cyclic adenosine _31,5l 
monophosphate) or a calcium ion. This leads to the 
activation of specific trans-acting factors (Darnell et 
al., 1986). Many trans-acting factors are phosphoproteins 
and their actions can be modulated by phosphorylation! 
dephosphorylation (Rozengurt, 1986, reviewed in Berk and 
Schmidt, 1990). For example, the trans-acting factor CREB 
(which binds to cAMP response elements within the 
promoter of cAMP responsive genes) exists as an 
equilibrium mixture of transcriptionally active dimers 
and inactive monomers. Phosphorylation shifts the 
equilibrium in favour of dimer formation (Yamamoto et 
al., 1988, Gonzalez et al., 1989). 
The major effect of hormones on target cells is at 
the level of gene expression. For example in Drosophila 
development the steroid hormone ecdysone directly induces 
changes in chromosome structure, resulting in the 
appearance of chromosome puffing. This puffing has been 
shown to be the result of an increase in transcription at 
the relevant loci, suggesting a link between steroid 
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hormones and activation of gene expression (reviewed in 
Ashburner, 1980). Although hormonal control of gene 
expression can occur at several levels, the primary level 
is transcriptional via protein-DNA and protein-protein 
interactions around the controlled gene. This is 
described in more detail in the following sections. 
I. CIS-ACTING DNA SEQUENCE ELEMENTS. 
A. ELEMENTS THAT REACT WITH TRANSCRIPTIONAL ACTIVATORS. 
Promoter elements. 
Promoter elements are usually found within several 
hundred base pairs upstream from the transcription 
initiation site (the cap site) of a gene and are 
responsible for accurate and efficient transcription. 
Most of the early work on promoters concerned the £3-
globin promoter and viral promoters (for example, those 
of the herpes simplex virus thymidine kinase, 
adenoviruses and SV40). From these studies it was shown 
that the promoter consists of multiple cis-acting 
regulatory elements that are required for appropriate 
function. For example, the SV40 early promoter has three 
21bp repeats that each contain two GC boxes. Each GC box 
has been shown to bind a trans-acting factor, Spi, in a 
sequence-specific manner (Gidioni et al., 1984). 
Transcription initiation requires the assembly of a 
transcriptional preinitiation complex bound upstream of 
the cap site. This occurs at a sequence termed the TATA 
box, which is found 20-30bp 5' of the cap site. The TATA 
box has been shown to bind the trans-acting factor TFIID 
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(Savadogo and Roeder, 1985) with the sequential binding 
of TFIIA, TFIIB, RNA polymerase II and lastly TFIIE. In 
the absence of TFIID no complex can form (Buratowski et 
al., 1989). 
Studies of cellular and viral genes has revealed 
that many do not contain a TATA box. The promoters of 
these genes can be divided into two groups. Firstly the 
GC rich promoters mainly found in "house-keeping" genes 
such as hypoxanthine phosphoribosyl transferase and 
dihydrofolate reductase (reviewed in Dynan, 1986). These 
usually have several transcriptional initiation sites 
which act as potential binding sites for Spi. The second 
class of promoters appear not to have a TATA box nor to 
be GC rich. The transcription of one such gene, the 
lymphocyte-specific terminal deoxynucleotidyl transf erase 
gene, is dependent on the presence of a llbp motif (the 
initiator) 5' to the structural gene (Smale and 
Baltimore, 1989). The initiator is required for the 
assembly of the transcription preinitiation complex, thus 
allowing transcription in the absence of a TATA box. 
Enhancer elements. 
These are cis-acting elements which determine the 
frequency of transcription from the promoter. They are 
either located 5' or 3' to the coding region of a gene or 
within an exon and/or intron. They act in either 
orientation over large distances and often determine 
tissue specific expression of a gene (see below). 
Enhancers have been shown to be composed of multiple cis- 
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acting elements. For example the SV40 enhancer comprises 
a tandem duplication of 72bp. The generation of point 
mutations within this region revealed that the enhancer 
comprises three functional elements. These elements are 
able to enhance gene transcription through the 
association of two different elements and tandem 
repetition of one of the elements can compensate for the 
absence of another (Herr and Clarke, 1986). 
Inducible Enhancers. 
Some genes, for example the heat shock protein (hsp) 
genes of Drosophila (Pelham & Bienz, 1982) and hormone 
responsive genes (Yamamoto, 1985), are activated in 
response to extracellular stimuli. The human 
metallothionein hA gene contains both glucocorticoid and 
mineralocorticoid response elements (Lee et al., 1987). 
Maximal transcription of this gene is dependent, in part, 
on hormonal regulation. This is discussed in more detail 
below. 
DNA sequences responsible for regulation by hormones 
(hormone response elements, HRE), have been identified in 
many genes. For example progesterone and glucocorticoid 
response elements (PRE & GRE) have been found in the 
chicken lysozyme gene (Renkawitz et al., 1984, Steiner et 
al., 1987), in the long terminal repeats of the murine 
mammary tumor virus (Miksicek et al., 1987, Cato et al., 
1988) and in the human metallothionein hA gene (Lee et 
al., 1987). GRE complexes have been shown to operate as 
enhancers that regulate the rate of transcription from 
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nearby promoters (Yamamoto, 1985). They act in an 
orientation-and-position independent manner and can 
confer glucocorticoid responsiveness to a heterologous 
promoter when linked to it (Ross and Solter, 1985, 
Hollenberg and Evans, 1988). 
The steroid and thyroid receptors, which have 
related sequences, bind to the HRE as dimers. 
The consensus sequence of the response element is 
palindromic with a 6 base pair half site A The GRE and 
oestrogen response element (ERE) consensus sequences 
differ by two base pairs in each half site, while the ERE 
and thyroid response element (TRE) half-site consensus 
sequence are identical but are spaced differently (Beato 
et al., 1989). 
TABLE 1. 
SEQUENCE COMPARISON OF HORMONE RESPONSE ELEMENTS. 
OESTROGEN 5' A G G T C A N N N T G A C C T 3' 
GLUCOCORTICOID 5' A G A A C A N N N T G T T C T 3' 
THYROID 5' A G G T C A T G A C C T 3' 
Schüle et 	al., 	(1988) 	showed that several 
transcription factors, for example, Spi, octomer binding 
proteins and nuclear factor I, when correctly located 
could act synergistically with the steroid response 
elements, indicating that maximum gene transcription 
involves interactions between trans-activating proteins. 
B. ELEMENTS THAT REACT WITH REPRESSORS. 
These elements are responsible for restricting the 
expression of a gene to a specific cell type and/or 
specific developmental stage. They are often in close 
proximity to promoter or enhancer elements. Specific 
types include the following: a) Silencers restrict 
expression in a position-and orientation-independent 
manner. For example a region of the GH gene located at 
-200 to -300 is required for the repression of 
transcription in non-pituitary cells (Larsen et al., 
1986), and a similar region has also been described in 
the human albumin gene (Frain et al., 1990). B) Some 
position-dependent negative regulatory elements are 
located between the enhancer and the promoter elements. 
For example Muglia et al., (1986), using chimeric 
flanking regions and deletion analysis, described a 
region between the promoter and enhancer of the a-
fetoprotein gene which down regulates transcription in a 
cell type specific manner. C) Intron repressor sequences 
have also been reported. For example, an intron in the 5' 
untranslated region of the chicken feather keratin genes 
represses transcription in xenopus oocytes (Koltunow et 
al., 1986). Similarly, sequences in the immunoglobulin 
kappa gene major intron silence expression in non-B cells 
(Pierce et al., 1991). 
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II. TRANS-ACTING FACTORS. 
Trans-acting factors bind cis-acting elements within 
a gene. They either act positively (activators) or 
negatively (repressors) to affect the rate of gene 
transcription by specific interaction with other 
proteins. 
A. TRANSCRIPTIONAL ACTIVATORS. 
Activators are composed of several domains which are 
important for efficient transcription. An activation 
domain is required to interact with target protein(s). 
The regulatory domains include regions that determine 
nuclear localisation, phosphorylation and glycosylation 
and a DNA binding region or a region which interacts with 
a DNA-binding protein. The binding region is responsible 
for positioning the protein on or at specific cis-acting 
elements. Activators can be divided into several 
different classes according to their binding motifs, 
namely the helix-turn-helix proteins, helix-loop-helix 
proteins, octamer-binding proteins, leucine zipper 
proteins and proteins having zinc fingers. 
Helix-turn-helix proteins, helix-loop-helix proteins, 
octamer-binding proteins and leucine zipper proteins. 
Helix-turn-helix proteins were first identified in 
the bacteriophage lambda repressor protein, Cr0 and the 
E. Coli catabolic activator protein (reviewed by Pabo and 
Sauer, 1984). The proteins contain two a helical regions 
separated by a 13 turn. They bind as dimers to the DNA, 
using both subunits to recognise the target sequences and 
to stabilise the DNA-protein interaction. The 
developmental regulatory genes of segmented organisms 
contain a highly conserved region of 60 amino acids 
termed the homeobox. This region was shown to have 
sequence homology with the bacterial helix-turn-helix 
proteins (Laughon and Scott, 1984, Shepherd et al., 
1984). Specific DNA binding is specified by sequences 
within the homeobox (Desplan et al., 1988). 
The helix-loop-helix domain is a DNA-binding and 
dimerisation motif common to many proteins involved in 
cell determination. For example, the muscle determination 
gene MyoD (Davis et al., 1987) and genes in Drosophila 
involved in cell type determination for example, 
daughLerless which is involved in both neural and sex 
determination (Cronmiller et al ., 1988) and twist which 
has a role in germ line determination (Thisse et al., 
1988). The helix-loop-helix region consists of 2 segments 
which can form a-helices connected by a non-conserved 
"loop". 
The octamer transcription factor DNA binding domain 
contains a homeobox and another conserved region 
designated the POU-domain. Most of these transcription 
factors are cell type specific or are developmental 
regulatory factors. 
The leucine zipper motif was first proposed for the 
CCAAT enhancer binding protein, C/EBP (Landschulz et al., 
1988). It consists of four leucine residues that are 
spaced exactly seven residues apart. This segment was 
named the "Leucine zipper" and is required for the 
dimerisation and subsequent activation of the protein. In 
addition to the "zipper", a 30 amino acid segment located 
immediately N-terminal to the leucine repeat must remain 
intact in order for the protein to bind to the DNA 
(Landschulz et al., 1988). Many trans-acting factors 
belong to families of proteins. Within the family the 
proteins can form either homodimers or heterodimers 
through interactions between their leucine zipper 
domains. Different combinations have been shown to bind 
DNA with altered specificity which in turn affects 
transcriptional activation. For example, in the Jun/fos 
family the heterodimer of Jun and fos binds to the AP-1 
binding site with a higher specificity than the homodimer 
of Jun. The formation of dimers will therefore depend on 
the relative abundance and distribution of different 
members of the Jun/fos family and may be cell type 
dependent (Hirai et al., 1989). 
The zinc finger. 
This motif was originally identified as a DNA 
binding structure in the RNA polymerase III transcription 
factor TFIIIA, which binds to the internal control region 
of the 5s RNA gene (Miller et al., 1985). The motif is 
orientated around a zinc ion, co-ordinated to invariant 
cysteine and/or histidine residues, and has been termed 
the "zinc finger". Subsequent work has identified at 
least two classes of zinc fingers (Table 2). 
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TABLE 2. 
ZINC FINGER CONSENSUS SEQUENCES 
TFIIIA type proteins (C 2H2 fingers). 
(tyr, phe) -X-cys-X24-cys-X3-phe-X 5-leu-X2-
his-X34-his-X 
Steroid receptor superfamily (C 2C2 fingers). 
cys-X2-cys-X 13-cys--X2-cys-X1 517-cys-X 5-cys-X 9-cys- 
X2- cy 5- X4 - C y S 
Where X represents a variable amino acid (Taken 
from Berg, 1989). 
The first class includes the TFIIIA type proteins 
(C2H2 finger), while the second class (C2C2 finger) 
includes the steroid receptor superfamily (Evans, 1988, 
Beato, 1989). It has been shown, in the case of the 
latter, that DNA binding and transcriptional activation 
require two zinc fingers (Hollenberg and Evans, 1988) 
which are encoded by separate exons of the receptor gene 
(Arriza et al., 1987, Huckaby et al., 1987). Although 
similar, these two classes of zinc fingers have been 
shown to differ in their secondary and tertiary 
structures (reviewed in Schwabe & Rhodes, 1991) 
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Inducible trans-acting factors. 
The steroid hormone receptor superfamily includes 
the oestrogen, progesterone, glucocorticoid, androgen, 
retinoic acid, vitamin D3 and thyroid hormone receptors. 
The physiological responses to these hormones are 
mediated through the binding of the ligand to the 
receptor. Binding induces an allosteric change that 
allows the receptor-hormone complex to bind its DNA 
response element in the gene. Dalman et al., (1990), 
using a cell free translation system, showed that the 
newly synthesised glucocorticoid receptor is bound to a 
90 kDa heat shock protein (hsp90). Binding of the hormone 
to its receptor dissociates it from hsp90 and transforms 
the receptor to its binding form. Therefore, the hsp90 
can be regarded as a repressor. In contrast, the thyroid 
receptor can bind to DNA in the absence of hormone. 
However, the hormone may be required to allow the 
receptor to initiate transcription by interacting with 
other trans-acting proteins or by altering the DNA 
structure. 
Site directed mutagenesis revealed that the 
functional domains of the human oestrogen receptor 
include a hormone binding site, a dimerisation region, a 
domain which directs sequence-specific DNA binding and a 
region required for nuclear localisation which is 
important for hormone activation of gene expression 
(Kumar et al., 1987, Picard & Yamamoto, 1987). 
i WA 
DNA binding specificity. 
The DNA binding domain of the receptor contains an 
approximately 70 amino acid sequence which is highly 
conserved and folds to form two zinc fingers that mediate 
DNA binding. The formation of a chimaeric receptor by 
replacing the zinc finger region of the oestrogen 
receptor with that of the glucocorticoid receptor, the so 
called "finger swapping" experiment, changed the DNA 
binding specificity of the oestrogen receptor to that of 
the glucocorticoid receptor, demonstrating that the zinc 
fingers confer DNA binding specificity. In addition the 
replacement of either pair of cysteines with histidines 
within the zinc finger prevented transcriptional 
activation (Green and Chambon, 1987). Green et al., 
(1988) created a series of mutations in the oestrogen 
receptor and showed that the first finger was responsible 
for binding specificity. More recently it was shown to 
contain 3 non-conserved amino acids at its base which are 
required to discriminate between the GRE and ERE (Table 
1, Mader et al., 1989). The second finger contains 5 non-
conserved amino acids which are located in a loop on the 
surface of the molecule. This region is required to 
recognise the spacing difference between the ERE and TRE 
(Table 1, Umesone et al., 1989). 
B. TRANSCRIPTIONAL REPRESSORS. 
As outlined above correct transcriptional initiation 
involves both protein-DNA interactions and protein-
protein interactions. Selective repression of gene 
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expression relies on the same mechanisms and is also an 
important factor in transcriptional control. 
Most of the early studies on repression of 
transcription were investigated in prokaryotes where the 
binding of a repressor protein to a region near the 
initiation site disrupts the binding of general trans-
acting factors such as RNA polymerase (Jacob & Monod, 
1961, Ptashne, 1986). Other models for repression have 
been proposed. The "Quenching" mechanism requires a 
repressor and an activating protein to bind adjacent DNA 
sequences. The repressor protein prevents correct 
protein-protein interaction of the activator with the 
transcription complex. "Squelching" repression results 
from the overexpression of an activating protein. This 
mechanism was first proposed by Gill and Ptashne, (1988) 
who showed that the over production of the yeast GAL4 
regulatory protein resulted in down regulation of 
expression. This form of repression requires neither 
specific DNA binding sites nor an intact DNA binding 
domain. 
A number of Drosophila homeotic genes have been 
studied in Drosophila cell culture. The studies reveal 
that these proteins can either activate or repress other 
homeotic genes. This mechanism is important for the 
temporal and spatial pattern of expression shown by these 
genes. For example the Ultrabithorax gene product can 
induce expression from its own promoter but inhibits 
expression by "quenching" from the Antennapedia p1 
promoter (Krasnow et al., 1989). In contrast the 
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Engrailed protein blocks the transcription of the Fushi-
Larazu gene by competing for homeodomain binding sites 
(Jaynes and O'Farrell, 1988). Certain combinations of 
activating proteins have been shown to either enhance or 
repress transcription (Han et al., 1989) suggesting that 
protein-protein interactions are a crucial step in 
regulation (Biggins and Tjian, 1989). 
The steroid hormones are known to act sometimes as 
inducers and in other cases as repressors of 
transcription. For example the rat prolactin gene is 
induced by oestrogen (Ryan et al., 1979) and repressed by 
glucocorticoids (Camper et al., 1985). Repression was 
shown to be due to a region of 63 amino acids adjacent to 
the DNA binding domain of the glucocorticoid receptor 
(Alder et al., 1988). Sakai et al., (1988) identified a 
region in the bovine prolactin gene that conferred 
repression by glucocorticoids (negative GRE - nGRE). 
However unlike the GRE the nGRE enhances promoter 
activity in the absence of the hormone or of the 
receptor, presumably through interaction with a non-
receptor protein. The authors speculate that the hormone-
receptor complex either competes with or inactivates this 
second factor. 
As outlined above, the thyroid hormone receptor 
binds to a variation of the palindromic motif 
5' AGGTCATGACCT 3', which is identical to the oestrogen 
response element, except that the latter contains three 
non-palindromic nucleotides at the centre of the dyad 
symmetry. Glass et al., (1988) showed that the thyroid 
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receptor did not activate transcription from an ERE in 
vivo, but that it did bind to the response element and 
inhibited induction by oestrogen. Similarly, Graupner et 
al., (1989) showed that in the absence of thyroid hormone 
receptor the retinoic acid receptor/retinoic acid complex 
could induce transcription from two distinct TREs. 
However when the thyroid hormone receptor was present, 
but thyroid hormone was not, the retinoic acid 
receptor/retinoic acid complex failed to induce 
transcription. The authors therefore suggested that the 
thyroid receptor may have a dual regulatory role. In the 
presence of hormone it acts as a transcriptional 
activator while in the absence of hormone it functions as 
a TRE dependent repressor. 
III. TISSUE SPECIFIC GENE EXPRESSION. 
A. CIS-ACTING ELEMENTS. 
The first tissue specific enhancer to be identified 
was in an intron of the immunoglobin heavy chain (Gillies 
et al., 1983). Using deletion analysis and transient 
expression assays many other tissue specific elements 
have been identified. To quote a few examples of many, 
within the prolactin and growth hormone genes (Nelson et 
al., 1986) and in the insulin gene (Walker et al., 1983, 
Edlund, 1985). Analyses of the human al-antitrypsin gene, 
in tissue culture, revealed a macrophage specific 
promoter which is located approximately 2kb upstream from 
a hepatocyte specific promoter, causing transcription 
initiation from a more 5' site and inclusion of extra 
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non-coding exons in the mature message (Perlino et al., 
1987). 
The ability to introduce foreign DNA into the germ 
line of animals allows the evaluation in many tissues of 
the effects of elements responsible for developmental and 
tissue specific expression (Ornitz et al., 1985, Grosveld 
et al., 1987, Hammer et al., 1987, Pinkert et al., 1987, 
Behringer et al., 1988). Transgenic technology also led 
to the discovery of sequences acting over large 
distances. Pinkert et al., (1987) found an enhancer 
located 10kb upstream of the albumin gene. They proposed 
that this enhancer interacts with the promoter by 
"looping out" of the intervening sequences. The same 
element may also be responsible for selective repression 
in other tissues. These results, however, do not exclude 
the possibility that there are elements working at even 
greater distances which are used to "finely tune" the 
levels of expression. 
For genes to be regulated their response elements 
have to be available to bind trans-acting proteins. Most 
chromosomal DNA is associated with histones, making it 
relatively insensitive to attack by DNase I. The binding 
of trans-acting factors to cis-acting sequences causes 
localised disruption of the DNA-histone complex resulting 
in the DNA becoming sensitive to DNase I. Thus the 
presence of tissue-specific elements is often associated 
with DNase I hypersensitivity. For example, Hammer et 
al., (1987) identified a regulatory element in the 5' 
flanking region of the elastase gene, which could direct 
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expression of the human growth hormone gene specifically 
to the exocrine cells of the pancreas in transgenic mice. 
This element generated a coincident DNase I 
hypersensitive site in pancreatic DNA but not in other 
tissues. The sequence also generated a DNase I 
hypersensitive site when it was relocated 3kb upstream, 
or within the first intron. 
The state of DNA methylation, specifically the 
hypo-methylation of C's in CpG dinucleotides, could be 
involved in allowing trans-acting factors to bind to the 
DNA (reviewed in Dynan, 1989). Studies in which 
methylated and non-methylated genes were introduced into 
cultured cells suggested that methylation is often 
incompatible with transcription. Similarly, in vivo the 
control regions of tissue-specific genes tend to be 
undermethylated in expressing relative to the same 
sequence in non-expressing cell types. These observations 
suggest that methylation may play a role in tissue-
specific gene expression. Methylation could disrupt 
transcription in at least two ways. Firstly, it might 
prevent transcription factors from binding to the DNA. 
For example, in vitro methylation at a cytosine residue 
within a tissue-specific element in the rat tyrosine 
aminotransf erase gene prevented a trans-acting protein 
from binding (Becker et al., 1987). This mechanism is not 
universal, however. The GC box transcription factor, Spi, 
has been shown to bind to methylated and undermethylated 
DNA with equal affinity (Harrington et al., 1988, Holler 
et al., 1988). Secondly, methylation might allow the 
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binding of repressor proteins. Saluz et al., (1988) 
showed that in the avian vitellogenin II promoter, a CpG 
at position +10 was fully methylated in tissues which did 
not express the gene but undermethylated in expressing 
cells. Footprinting analysis identified a protein which 
bound only to methylated sites in the promoter suggesting 
that it may act as a repressor in non-expressing tissues. 
More recently Meehan et al., (1989) described a protein, 
methyl-CpG binding protein, which binds to methylated 
CpG's in a variety of unrelated DNA sequences. 
B. TRANS-ACTING FACTORS. 
Growth hormone (GH) and prolactin (Pri) receptors 
have been shown to belong to the same family of membrane 
proteins (Boutin et al., 1988). These receptors show 
heterogeneous forms. For example two major hepatic GH 
receptors have been identified in man (Hocquette et al., 
1990) and three in pregnant mice (Smith and Talamantes, 
1987). To quote another example, in the rabbit different 
Pri receptors were found in the liver and the mammary 
glands (Edery et al., 1989). 
The thyroid hormone receptor has been shown to be 
encoded by two cellular genes, c-erbAa and c-erbAl3. In 
the rat the a gene is alternatively spliced to give 
erbAal and erbAa2. The latter binds DNA but not thyroid 
hormones and can therefore act as an inhibitor of thyroid 
hormone action (Koenig et al., 1989). The 13 gene also 
codes for more than one protein. Hodin et al., (1989) 
showed that the erbI32 receptor variant was only found in 
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the pituitary. The biological significance of these 
different receptor forms is not yet clear but they may be 
involved in mediating the tissue-specific actions of the 
hormones. 
Footprinting analysis has demonstrated that the 
expression of some trans-acting proteins is restricted to 
a limited number of cell types. For example, in the 
pituitary, the GH and Prl genes have been shown to bind 
a trans-acting protein pit-1/GHF-1 which is only 
expressed in the pituitary lactotrophs and sommatotrophs 
(Ingraham et al., 1988, Nelson et al., 1988, Castrillo et 
al., 1989). 
Similar results have been obtained for other genes 
expressed in a tissue specific manner for example, in the 
liver (cxl- antitrypsin - De Simone et al., 1987, Courtois 
et al., 1988, Grayson et al., 1988, Monaci et al., 1988, 
Costa et al., 1989, Albumin, Lichtsteiner et al., 1987) 
and the pancreas (Insulin - Edlund et al., 1985, Hanahan, 
1985). It would appear that the binding of a tissue-
specific trans-acting factor on its own is not sufficient 
for maximum transcriptional activity. For example, Costa 
et al., (1988) identified three sites in the albumin 
enhancer two of which bound liver specific factors while 
the third bound a common factor. All three interactions 
were required for maximal expression. Similar results 
were obtained for al-antitrypsin (Costa et al., 1989). 
Thus transcription involves multiple interactions with 
tissue-specific and non-tissue-specific transcription 
factors. 
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In summary, a given gene contains binding sites for 
several trans-acting factors. These binding sites in 
conjunction with qualitative and quantitative differences 
in the trans-acting factors in different cell types 
determine the tissue-specific transcriptional activity of 
the gene. Transcriptional activity can be modulated by 
the formation of protein dimers, where homodimer and 
heterodimer combinations have different affinities for 
the target binding site. Transcriptional factor activity 
may also be modulated by ligand binding, 
(de)phosphorylation, or binding of a repressor to the 
factor or its target site. 
ANIMAL MODELS FOR ENDOCRINE STUDIES. 
The role of hormones in regulating the expression of 
hormone-responsive genes can often be examined in 
cultured cells. Deletion analyses and transient 
expression assays have led to the identification of 
hormone response elements. Although such studies are 
invaluable in providing information regarding the 
hormonal control of gene expression, they suffer from the 
disadvantage that gene regulation is examined in an 
isolated cell type. This situation differs from the case 
in vivo where the availability of a particular hormone 
may depend on the presence or absence of another hormone. 
Hormonal feedback loops, the developmental onset of 
hormone action and the effects of the hormone during 
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development can only be addressed in vivo. Our present 
understanding of the role a particular hormone plays in 
vivo has come from the study of naturally occurring 
hormone-deficient animals and from surgically or 
pharmacologically altered animals. In this thesis I shall 
discuss only examples of either GH or thyroxine 
deficiency. 
I. HORMONE-SECRETING CELLS OF THE THYROID AND PITUITARY 
AND THE REGULATION OF SECRETION. 
Hormone-secreting cells are often close to or 
interspersed with other cell types. The thyroid gland 
contains thyroxine-producing thyrocytes and calcitonin-
producing C-cells and is in intimate contact with the 
parathyroid gland which secretes parathyroid hormone. The 
secretion of thyroid hormones (T 4 and T3 ) is under the 
control of the pituitary thyroid stimulating hormone 
(TSH). Similarly, the anterior pituitary contains 
phenotypically distinct cell types which express 
different hormones, namely somatotrophs (GH); lactotrophs 
(Prl); thyrotrophs (TSH); adrenocorticotrophs 
(adrenocorticotrophin) and gonadotrophs (luteinizing 
hormone and follicle stimulating hormone). Secretion of 
these hormones is largely under the control of the 
hypothalamus which releases hormones that act to 
stimulate hormone-secretion by specific cell types in the 
pituitary. For example growth hormone releasing factor 
(GRF) acts on the somatotrophs and TRH acts on the 
thyrotrophs. Some factors act in an inhibitory manner for 
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example, somatostatin inhibits GH secretion. Hormone 
synthesis and release is also modulated by negative 
feedback loops, initiated by the induced target cell, or 
by the hormone itself. 
II. ALTERING THE HORMONAL STATUS OF AN ANIMAL. 
Classical methods for generating animal models with 
either GH or thyroxine deficiencies involved the removal 
of the anterior pituitary, the thyroid or the 
hypothalamus. This was achieved either by surgery or 
laser ablation. Since these tissues contain several 
hormone-secreting cell types, removal results in several 
hormone systems being affected, either directly by the 
removal of hormone-producing cells or indirectly by the 
disruption of feedback loops. This makes the attribution 
of an effect to a particular hormone difficult in many 
cases. However, if hormone replacement by a physiological 
administration regime reverses the induced defect 
completely, the problem of the potentially pleiotropic 
effects of surgery is averted. 
Several other approaches have also been used. These 
can be divided into three groups according to their 
actions: (1) inhibition of hormone synthesis, (2) 
inhibition of hormone secretion and (3) inhibition of 
hormone action. 
Synthesis of the thyroid hormones can be inhibited 
by the administration of anti-thyroid drugs such as 
methimazole. These drugs prevent the iodination of the 
tyrosyl residues in the thyroglobulin protein (Narayan et 
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al., 1985). The drug propyithiouracil acts in a similar 
manner and in addition decreases the peripheral 
deiodination of thyroxine to its active form 
triiodothyronine. However these drugs are associated with 
side affects and show varying degrees of penetrance 
(Horvath et al., 1989, Wilson et al., 1990). Removal of 
the drug results in the restoration of normal thyroid 
hormone formation. 
Secretion of hormones can be inhibited by preventing 
the production of the regulatory hormones. For example, 
treating neonatal rats with high levels of monosodium 
glutamate destroys the neurons in the hypothalamus 
required for the production of GRF. This results in the 
complete inhibition of GH release from the pituitary 
(Bakke et al., 1978, Waxman et al., 1990). Somatostatin 
can also be used to inhibit GH release but secretion of 
gastrin, glucagon, vasoactive intestine peptide and 
insulin is also inhibited (reviewed in Wass, 1988). 
Antibodies or antagonists have been used to prevent 
the actions of a hormone. The biological activity of GRF 
has been neutralised by antibodies (Celia et al., 1990) 
and its induction of GH secretion have been blocked by 
the use of peptide antagonists (Lumpkin et al., 1989). 
Similarly the action of GH in rats was blocked by 
treatment with anti-GH antiserum (Gause et al., 1983, 
Madon et al., 1986, Flint and Gardner, 1989). 
III. MUTANT HORMONE-DEFICIENT ANIMAL MODELS. 
Naturally occurring mutations have been extensively 
24 
used in endocrine studies. There are several mouse 
mutants which exhibit dwarfism: Ames dwarf (df), Snell 
dwarf (dw) and little (lit). All three have autosomal 
recessive modes of inheritance but exhibit differences in 
their pituitary hormone deficiencies (Phillips et al., 
1982). The little mouse has decreased levels of GH and 
Pri but can be corrected by Gil treatment. However the 
pituitary is unresponsive to GRF suggesting that the 
primary defect in these mice involves the GRF receptor 
(Jansson et al., 1986). The Ames and Snell dwarfs are 
phenotypically similar (they resemble the 
panhypopituitary dwarfs in humans) but the mutations are 
non-allelic. Recently the Snell dwarf has been shown to 
be the result of a mutation in the Pit-I gene (Camper et 
al., 1990). Pit-I is a pituitary specific trans-acting 
factor that is required for transcription of the Gil and 
Prl genes. The Ames and Snell dwarfs show decreased serum 
levels of Gil, Pri and TSH. The reduced TSH level results 
in the mice also being hypothyroid. The pituitaries lack 
detectable somatotrophs and Gil mRNA (Cheng et al., 1983). 
Another dwarf mutation, Pygmy, appears to result in a 
lack of response to Gil in the target tissue. Serum levels 
of Gil and Pri are normal although pituitary mRNA levels 
are low. These mice do not respond to treatment with GH 
(Rimoin et al., 1972) or Prl treatment (Sinha et al., 
1979). 
There are two mouse models for hypothyroidism. The 
hyt/hyt mice show congenital hypothyroidism in the 
absence of goitre (enlargement of the thyroid gland is 
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often associated with a reduction of thyroid hormones). 
The mutation is first detected 15 days after conception 
when the thyroid becomes active (Kawaori and Tsuneda, 
1985). Mature mice show decreased levels of circulating 
thyroid hormones and a 100 fold increase in TSH levels 
due to the disruption of the feedback loop whereby 
thyroid hormones regulate TSH production. Thyroglobulin 
synthesis is normal and the protein is iodinated (Stein 
et al., 1989). The histology of the gland shows follicle 
structures which are smaller, and fewer than normal 
(Beamer et al., 1981). Hyt/hyt mice show secondary 
somatic and behavioral defects, for example retarded eye 
opening, ear raising and a decrease in body length and 
weight (Adams et al., 1989), probably due to the 
deficiency of thyroid hormones in uLero and during early 
neonatal life. The lesion in hyt/hyL mice is thought to 
be a lack of response of the thyroid gland to TSH. The 
second hypothyroid model, cog/cog, presents goitre. 
ve cog/cog mice are a model for human hypothyroid goitre, 
which is caused by a defect in thyroglobulin synthesis 
and/or processing (Mayerhofer et al., 1988). 
The use of naturally occurring mutations in 
endocrine studies is not always ideal as other hormone 
systems may be affected (for example, the dwarf mice 
referred to above) and secondary defects can occur during 
development (for example, the hypothyroid mice referred 
to above). Furthermore all mice carrying the above 
mentioned mutations are characteristically sub-fertile. 
IV. TRANSGENICS IN THE STUDY OF ENDOCRINE SYSTEMS. 
Foreign DNA introduced either by proviral infection 
(Jaenisch, 1976, 1977) or by pronuclear injection (Gordon 
et al., 1980) can integrate into the chromatin of the 
germ line and somatic cells. Microinjection usually 
results in multiple copies of the transgene being 
integrated into the chromosome at random, often forming 
concatemers lying in a head-to-tail configuration. 
Expression levels of the transgene between individual 
transgenic mice are highly variable due to the random 
integration of the transgene into the chromosome. For 
example, the foreign DNA may integrate into a "silent" 
region of genomic DNA. The level of expression of most 
transgenes introduced into transgenic animals does not 
correlate with the number of transgenes present in the 
genome. This is thought to be due to the influence of the 
DNA sequences flanking the site of transgene integration 
(reviewed in Bishop & Al-Shawi, 1990, Al-Shawi et al., 
1990). However, exceptions to this have been observed. 
For example, in the study of human 13-globin genes the 
expression was shown to be dependent on the site of 
integration and to be copy-number-independent. The 
discovery of a locus control region which, when included, 
made the expression of the transgene more position-
independent and more copy-number-dependent (Grosveld et 
al., 1987, Ryan et al., 1989). A similar locus control 
region has also been identified in the CD2 genes (Lang et 
al., 1988) and the 13-lactoglobulin genes (Whitelaw et 
al., 1992). The effect of chromosomal position on the 
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expression of transgenes may be the result of the 
organisation of chromosomes into topologically 
constrained loops which serve as functional domains. 
These loops are thought to be established by scaffold 
attachment regions. By flanking transgenes with a 5' 
scaffold attachment site the expression of a transgene is 
protected from the positional effect of integration 
(Stief et al., 1989). Recently the expression of a whey 
acidic protein transgene was shown to be accurately 
expressed in a position-independent, hormonal and 
developmental manner in transgenic mice only when the 
transgene was flanked with scaffold attachment sites 
(McKnight et al., 1992). 
The use of transgenic mice in studying hormonal 
action in vivo has the advantage that the effects of over 
expressing a particular hormone can be examined in an 
otherwise normal physiological context. Most of the 
reported transgenics, which have involved the over 
production of a hormone, have mainly been concerned with 
the regulation of somatic growth. This was investigated 
through the over production of foreign GH (Palmiter et 
al., 1982, 1983, reviewed in Brem et al., 1989), GRF 
(Hammer et al., 1985) or IGF-I (Behringer et al., 1990). 
These studies confirmed that GH plays a central role in 
regulating IGF-I expression and that GH and IGF-I exert 
separate growth promoting actions (Behringer et al., 
1990). 
Transgenics have also been used to create animal 
models lacking a particular hormone. This can be achieved 
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by two methods namely by homologous recombination and by 
the selective destruction (ablation) of a particular cell 
type. 
HOMOLOGOUS RECOMBINATION. 
Mutations can be generated through gene targeting 
which allows mice to be generated which carry a null 
mutation and may theoretically allow modification of a 
gene to affect transcription, translation or post 
translational events. Gene targeting involves the use of 
recombinant DNA technology to introduce a mutation into 
the cloned DNA sequence of interest. The DNA sequence 
carrying the mutation is then transferred by homologous 
recombination to the genome of embryo-derived stem (ES) 
cells. Cell clones containing the mutated sequence can be 
selected for or identified by using the polymerase chain 
reaction. Cells from an appropriate clone are then 
microinjected into a mouse blastocyst. Germline 
transmission of the mutated gene from the resulting 
chimaeras results in offspring with the acquired 
characteristic (reviewed by Capecchi, 1989). To quote one 
example of many, using this method Dechiara et al., 
(1990) showed IGF-II has an important physiological role 
in embryonic growth. 
TRANSGENIC ABLATION. 
Ablation of specific cell types in transgenic 
animals relies on the fact that specialised cells often 
produce a single major protein product for export. Cell 
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culture and deletion studies have identified cis-acting 
regulatory regions within the promoter of the genes which 
encode these proteins. These regulatory regions are 
involved in the tissue-specific expression of the protein 
and can be linked to the coding region of a foreign gene 
to drive its expression in a tissue-specific manner in 
transgenic animals. By linking these regulatory regions. 
to genes coding for a toxic product the target cell is 
effectively knocked out. 
Two methods of transgenic ablation have been 
successfully employed: direct and conditional. In the 
direct method the toxic gene product is expressed under 
the control of the transgene promoter and thus takes 
affect as soon as the promoter is developmentally 
activated. In the conditional method the product of the 
foreign gene, although expressed, shows no toxicity until 
a toxigenic substrate is administered. 
Direct Ablation. 
Diphtheria toxin (DT - Uchida et al., 1973) and 
ricin are potent toxins, each of which consists of two 
subunits A and B. The B subunit is necessary for the 
entry of the toxic A subunit into cells. Thus if only the 
A subunit is produced, neighbouring cells cannot take it 
up from dying cells. In the first demonstration of direct 
ablation the expression of the DT-A gene was directed to 
the pancreatic exocrine cells under the control of the 
elastase I promoter (Palmiter et al., 1987). This 
promoter becomes active at day 14 of gestation. 
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Transgenic mice were born with no pancreas and death 
followed several days later. 
Other systems have been studied using the direct 
ablation method. These include expression of the DT-A 
gene in the pituitary under the control of the GH 
promoter (Behringer et al., 1988) or the pituitary 
hormone glycoprotein a-subunit (Kendall et al., 1990) and 
in the lens under the control of the gamma-2-crystallin 
promoter (Breitman et al., 1987), and expression of the 
ricin A subunit in the lens under the control of the a-A-
crystallin promoter (Landel et al., 1988). 
The direct method of ablation has several drawbacks. 
Firstly since the toxin is expressed directly under the 
control of the transgene promoter, it is produced and 
takes affect as soon as the tissue-specific promoter 
becomes developmentally active. This allows no 
experimental control over the extent or timing of 
ablation. This drawback has been recently addressed in 
Drosophila. By expressing a temperature-sensitive mutant 
ricin A subunit under the control of an eye specific 
enhancer, Moffat et al., (1992) demonstrated controlled 
specific ablation of Drosophila eye cells at the 
permissive temperature. Clearly, however, this method is 
not applicable to mammals. A second drawback is that, 
since the DT-A gene cannot be removed from the transgenic 
animal, the regeneration potential of cell lineages can 
not be assessed. Thirdly, direct ablation may result in 
embryonic or early neonatal lethality for example, the 
transgenic mice in which the DT-A gene was directed to 
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the pancreas died a few days after birth (Palmiter et 
al., 1987), thus allowing no pedigree lines to be 
established. Fourthly, the toxicity of the DT-A gene 
itself may pose a potential problem. It has been 
estimated that 1 molecule of DT-A is sufficient to kill 
a cell (Yamaizumi et al., 1978). Due to the extreme 
toxicity of the DT-A gene successful ablation therefore 
requires that the expression of the transgene is confined 
to one cell type. If the promoter used for the transgene 
permits even low levels of expression outside the 
intended lineage, ablation could be lethal to the 
developing embryo. To overcome this problem an attenuated 
form of the DT-A subunit has been used in ablation 
studies (Maxwell et al., 1987). This subunit is 
approximately 50-fold less toxic than the wild type A 
subunit (Breitman et al., 1990). 
Homologous recombination has the advantage over 
transgenic ablation that only the product of the gene of 
interest is disabled, as opposed to ablation of the cell-
type in which it is produced. As a consequence, many 
questions that cannot be addressed by ablation are open 
to investigation by homologous recombination. However, as 
in the case of direct ablation this method does not 
allows external control over the timing of functional 
disruption. Furthermore in some instances the function of 
a cell type may be of more physiological importance than 
that of an individual gene. Thus transgenic ablation can 
be an important tool in specific cases 
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Conditional Ablation. 
The technique of conditional ablation presently in 
use is based on the expression of herpes simplex virus 
type 1 thymidine kinase (HSV1-TK) in specific cell types. 
HSV1-TK is itself not deleterious to most cells. However 
HSV1-TK is able to convert certain nucleoside analogues 
such as acyclovir, ganciclovir and FIAU, by 
phosphorylation, into nucleoside monophosphates and 
diphosphates (Elion et al., 1977, Fyfe et al., 1978). 
These are in turn phosphorylated by cellular kinases to 
nucleotide triphosphates, which are incorporated into the 
DNA resulting in cell death (St. Clair et al., 1987). 
These analogues are phosphorylated to a lesser degree or 
not at all by cellular kinases. The degree of ablation is 
proportional to the levels of HSV1-TK expression and to 
the analogue concentration (Borrelli et al., 1988). By 
altering the concentration of the analogue used and/or 
manipulating the duration of the time of application the 
degree of ablation can be controlled. The analogue can be 
administered at different times in the life of the 
animal, thus allowing some control of the time of 
ablation. An additional advantage is that the animal 
develops normally up to the time of ablation. Removal of 
the analogue potentially allows cell lineages to 
regenerate thus giving both information about and access 
to stem cells in a particular tissue. It appears however 
that one important prerequisite for the success of this 
method may be ongoing division of the target cells. 
Heyman et al., (1989) placed the HSV1-tk gene under 
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the control of an immunoglobulin promoter. The transgenic 
mice generated expressed the protein in a tissue-specific 
manner. The effect of ganciclovir treatment on thymic 
cells expressing the T-cell surface antigens L3T4 and 
Lyt2' was investigated. Cells expressing both markers were 
depleted by a factor of 4, while single positives and 
double negatives were enriched 3- to 5-fold and 6-fold 
respectively. Such enriched populations contain 
progenitor cells capable of repopulating thymic tissue in 
irradiated animals (Fowifes et al., 1985). Following 
removal of the ablating agent the thymic cells were 
repopulated indicating that the stem cell population that 
survived ablation allowed regeneration of the tissue. 
Similarly, Borrelli et al., (1989) directed the 
expression of HSV1-TK to the mouse somatotrophs and 
lactotrophs using the rat GH and Pri promoters 
respectively. In the mice carrying the GH-TK construct 
HSV1-TK was expressed in the sommatotrophs. Mice were 
treated with FIALJ from embryonic day 5 to birth and from 
2 days to 8-10 weeks. Weight gain of both transgenics and 
non-transgenic littermates were similar up to three weeks 
of age. Subsequently the transgenics developed as dwarfs. 
The pituitaries of these mice showed a massive depletion 
of both somatotrophs and lactotrophs. A similar effect 
was observed when somatotrophs were directly ablated 
using a GH-DT-A transgene (Palmiter et al., 1987), and 
can be explained by supposing that the GH promoter is 
active in a cellular precursor of lactotrophs and 
somatotrophs. When the administration of FIAU to GH-TK 
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mice was delayed until 5 and 10 days after birth, the 
number of somatotrophs that developed increased 
progressively, although there was no increase in the 
number of lactotrophs. This result argues against the 
lineal pathway of lactotrophs differentiation from 
somatotrophs proposed by Behringer et al., (1988). 
In contrast the mice containing the Prl-TK transgene 
showed no morphological change to their pituitaries 
following FIAU treatment. Based on the assumption that 
ablation requires cell division in the target tissue the 
authors concluded that the lactotrophs escaped ablation 
due to differentiation being a post mitotic event. 
However although HSV1-TK activity was present in the 
pituitary of Prl-TK mice, localisation to the lactotrophs 
was not demonstrated. The conclusion is therefore 
questionable. 
THE THYROID GLAND. 
I. HISTOLOGY OF THE THYROID GLAND. 
The thyroid gland consists of two lobes which lie 
between the thyroid cartilage and the fifth and sixth 
tracheal rings. The lobes are connected by a thin 
isthmus. 
The hormone secreting unit of the thyroid is the 
follicle. This comprises a single layer of epithelial 
cells (thyrocytes) surrounding a cavity (lumen). The 
latter is filled with colloid containing a store of 
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thyroglobulin. The follicles vary in size depending on 
the activity of the gland. In hypothyroidism they are 
flat and narrow, whereas in hyperthyroidism they develop 
a columnar appearance. The follicles are close to a 
network of capillaries, which allows a large flow of 
blood to pass through the gland. Sympathetic nerve 
fibres, comprising adrenergic and cholinergic fibres, are 
also abundant. These nerves influence the blood flow 
through the gland as well as follicle activity. In the 
rat, immunoreactive thyroglobulin is first detected in 
the cytoplasm of the immature thyroid epithelium on the 
15th day of gestation with formation of the thyroid 
hormones (thyroxine: T4 and triiodothyronine: T 3 ) two days 
latter (Kawaori and Tsuneda, 1985). 
The thyroid gland contains another hormone producing 
cell type, the C-cells, which secrete calcitonin. These 
cells lie between the follicle structures or on the 
follicle wall. The thyroid is also in contact with the 
parathyroid gland. In the mouse there are two parathyroid 
glands which are bilaterally attached to the thyroid 
lobes. 
II. EXAMPLES OF THYROID HORMONE ACTION. 
Thyroxine deficiency during development has long 
been associated with mental retardation. This is due to 
the involvement of thyroid hormones in brain maturation. 
For example hypothyroidism results in retardation in 
nerve fibre myelination, a decrease in the density of the 
axon network and reduced interactions between the nerves 
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(Eayrs, 1960, Cbs et al., 1973). 
Thyroid hormones act on the myosin multi-chain 
family in a developmentally specific manner. There are at 
least six different myosin heavy chain (MHC) genes, which 
all respond to thyroid hormones (Izumo et al., 1986). The 
B MHC gene is predominantly expressed during late fetal 
stages and declines after birth, with the subsequent 
activation of the a MHC gene. In hypothyroid rats, the B 
MHC gene predominates but declines with the subsequent 
activation of the a MHC gene, following T 4 treatment, 
suggesting that the switch between a and B MHC genes is 
regulated by thyroid hormones (Mahdavi et al., 1984). A 
similar effect is observed in the expression of the 
ubiquitous transmembrane protein Na-K-ATPase which 
consists of a and B subunits. The a subunit has three 
distinct isoforms that are expressed in a developmental 
sequence which is directly regulated by both thyroid 
hormones and glucocorticoids (Orlowski and Lingrel, 
1990). 
Species-specific effects of thyroid hormones are 
also observed. For example, there is a functional TRE in 
the promoter region of the rat GH gene but not in the 
promoter of the human gene (Glass et al., 1987, Koeing et 
al., 1987). There is a second TRE in the third intron of 
the rat GH gene which can confer thyroid hormone 
responsiveness to a heterologous promoter in vivo (Sap 
et al., 1990). 
Thyroid hormones are the main product of the thyroid 
gland. The structure of the gland, its role in thyroid 
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hormone synthesis and secretion, and the regulatory 
influences controlling these processes are discussed in 
detail below. 
III. CIRCULATING THYROID HORMONES. 
The structure of the iodotyrosine hormones are 
depicted in Figure 1. In addition to the biologically 
active T4 and T3 , an inactive triiodothyronine (reverse 
TO is also found in significant concentrations in the 
serum. 
In the thyroid gland the thyroid hormones form an 
integral part of the thyroid-specific protein, 
thyroglobulin, as part of which they are synthesised and 
stored. In the circulation the thyroid hormones are 
reversibly bound to serum liver proteins: thyroxine-
binding globulin, thyroxine-binding prealbumin and 
albumin. Studies on the kinetics of release and 
metabolism of iodothyronines in the body show that T4 has 
a longer half-life (approximately 7 days) than has T 3 
(approximately 1 day: Sterling & Lazarus, 1977). 
T4 is the principal secretory product of the 
thyroid. However the active form of the hormone is T 3 
which is produced by a 5'-deiodination of T 4 . 
Deiodination is also important in the inactivation of the 
thyroid hormones (Figure 2). Deiodination is brought 
about by deiodinating enzymes (see Nunez, 1988). Type I 
is the major enzyme found in the liver, kidney and 
skeletal muscle; it carries out either 5'- or 5-
deiodination of T4 to yield T3 or rT3 respectively. Type 
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FIGURE 1. 
STRUCTURE OF MONO AND DIIODOTYROSINE. 
Structures of mono and diiodotyrosine, the precursors to 
the thyroid hormones: thyroxine (T 4 ) and 
3, 5, 3 9 -triiodothyronine (T 3 ). 
Also shown is the structure of the biologically inactive 
3, 3' ,5'-triiodothyronine (reverse T3 ). 
(Taken from O'Riordan et al., 1988). 
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MONOIODINATION OF THYROID HORMONES. 
Monodeiodination of iodothyronines, giving rise to the 
conversion of T 4 to T3 and eventually the inactivation of 
the hormone by conversion to 3,3'-diiodothyronine. 
(Taken from Dumont et al., 1989). 
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II is found in the brain, pituitary and brown adipose 
tissue. It is responsible for 5'- deiodination of T 4 
which is important for providing the brain with T 3 and 
also in controlling TSH secretion and synthesis. Lastly 
type III is found in the heart, liver and central nervous 
system and is responsible for metabolising T 4 to rT3 . 
Selenium deficiency results in abnormal thyroid 
hormone metabolism. The abnormality arises because 
selenium is required for the synthesis of active type I 
deiodinase (Beckett et al., 1989, 1990). The mRNA that 
ltrA 
specifies this deiodinase contains a selenocysteine,codon 
(Berry et al., 1991), and when selenocysteine is 
unavailable an inactive enzyme is produced. 
IV. THYROID HORMONE SYNTHESIS AND SECRETION. 
Thyroid hormone synthesis is a multi-step process 
which includes the uptake of iodide ions, the synthesis 
of thyroglobulin, the iodination of thyroglobulin and the 
release of T4 and T3 . The mechanisms of hormone synthesis 
and release are discussed below. 
A. THE IODIDE PUMP. 
The kidney and the thyroid gland are the main organs 
in the body which can clear significant amounts of iodide 
ions from the circulation. In addition, the thyroid gland 
takes up iodide ions and concentrates it in the follicle 
lumen. The iodide ions pass through both the basal and 
the apical membrane (Andros and Woliman, 1967). Transport 
across the basal membrane is an active process involving 
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Na/K ATPase to pump the iodide against a concentration 
gradient (up to 5-300 times higher in the thyroid than 
the plasma, see Dumont et al., 1989). Iodide ion uptake 
is TSH-dependant and is regulated by a-adrenergic nerves 
(Santisteban et al., 1987). Within the follicle lumen the 
iodide ion undergoes oxidation by a membrane-bound 
thyroid peroxidase, at a rate linked to the iodination of 
thyroglobulin. 
B. THE THYROGLOBULIN GENE. 
Thyroglobulin (Tg) is the major product of the 
thyroid gland. Civitareale et al., (1989) identified a 
thyroid specific trans-acting factor, TTF-I, which acts 
positively in mediating the thyroid-specific expression 
of the Tg gene. Transcription of the gene constitutes 
approximately 10% of the total polymerase II activity of 
the gland (van Heuversywn et al., 1984). The bovine Tg 
gene spans 200 kb, and contains at least 42 exons 
(de Martynoff et al., 1987). Transcription is regulated 
by the anterior pituitary hormone TSH (also known as 
thyrotropin, Van Heuverswyn et al., 1984), which mediates 
its effects through the production of cAMP (Van 
Heuverswyn et al., 1985). A cAMP response element (CRE) 
has been identified in the first 250bp of the Tg promoter 
(Christophe et al., 1989). The CRE differs from those of 
other higher eukaryotes both in its position and 
sequence, having more homology with those of lower 
eukaryotes, where cAMP alone is not sufficient to 
activate transcription (Christophe et al., 1989 and 
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references therein). This is consistent with the 
observation that maximal expression of the Tg gene also 
requires stimulation of the thyrocytes by IGF-I and 
insulin (Santisteban e1 al., 1987). Thus expression of 
the Tg gene involves multi-hormone stimulation. 
The thyroglobulin protein is synthesised on the 
rough endoplasmic reticulum and is primarily glycosylated 
as it enters the cisternae. Transport vesicles move the 
protein to the Golgi apparatus where it is further 
glycosylated (to approximately 10% of total weight). The 
resultant protein, Mr = 660,000, comprises two chains of 
equal length. The glycoprotein is transported to the 
apical membrane, where the protein is emptied into the 
lumen of the follicle by exocytosis (see below). 
C. IODINATION OF THE THYROGLOBULIN PROTEIN. 
Thyroglobulin iodination occurs in the lumen of the 
follicle structure, primarly at the interface between the 
apical membrane of the thyrocyte and the lumen. The 
iodide ion undergoes oxidation by a membrane-bound 
peroxidase associated with the endoplasmic reticulum and 
the apical membrane. It is activated by hydrogen peroxide 
(H202 ) and iodide ions. However little is known about how 
the H202 is generated (see Nunez and Pommier, 1982). 
Oxidation of the iodide ion yields an active form which 
diffuses into the lumen where it is transferred to an 
acceptor tyrosyl residue of the thyroglobulin protein at 
position 3 or at position 3 and 5 to yield 
monoiodotyrosine (MIT) and diiodotyrosine (DIT) 
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respectively (Figure 1). 
Approximately one third of the tyrosyl residues of 
thyroglobulin are iodinated and about a quarter of those 
iodinated are joined to form the thyroid hormones. The 
positions of the iodinated tyrosyls have been shown to be 
evolutionary invariant (Palumbo, 1987). 
Formation of T 4 and T3 involves a molecular 
rearrangement between two iodotyrosyl residues (two 
molecules of DIT or one of each DIT and MIT). The bond 
between the aromatic ring of a mono or diiodotyrosyl 
residue and its alanyl side chain is broken and the ring 
is transferred to the phenolic hydroxyl group of another 
peptide-linked diiodotyrosyl residue. The coupling 
reaction occurs within the thyroglobulin protein (Figure 
3) to yield either T 4 or T3 . The iodinated protein is 
stored in the lumen of the follicle where some further 
iodination may occur. The ratio of MIT to DIT produced is 
dependent on dietary iodide ion intake, with greater 
amounts of MIT being produced during dietary deficiency. 
D. SECRETION OF THE THYROID HORMONES. 
For the thyroid hormones to be released the 
iodinated thyroglobulin protein has to undergo 
proteolytic cleavage. Before this can occur the iodinated 
protein has to re-enter the thyroid follicle cell, and 
this occurs by endocytosis. Two types of endocytosis have 
been described: macropinocytosis and micropinocytosis. 
The former involves the formation of pseudopodia which 
trap colloid as they retreat, forming membrane-enclosed 
46 
FIGURE 3. 
IODINATION OF THE THYROGLOBULIN PROTEIN. 
Synthesis of the thyroid hormones. Two chains of 
thyroglobulin (labelled A and B) each carrying a tyrosyl 
residue are shown. Iodination by the thyroid peroxidase 
introduces two atoms of iodide into each tyrosyl residue. 
The dotted line indicates the molecular rearrangement 
which follows to yield the structure of thyroxine (T 4 ). 
If the tyrosyl residue on the B-chain is a 
monoiodotyrosine then T3 is formed. 



























colloid droplets. These droplets fuse with lysosomal 
vesicles in the follicle cell, which leads to the 
breakdown of the thyroglobulin protein to yield T 4 , T31  
rT3 and iodinated amino acids. The latter are recycled 
within the gland. This process involves a large turnover 
of the apical membrane, and is the first response of the 
thyroid to TSH. The thyroid hormones are released into 
the plasma where they are transported bound to specific 
serum binding proteins. In contrast, micropinocytosis is 
thought to be responsible for the constitutive production 
of the thyroid hormones which is not dependent on TSH 
stimulation. 
V. REGULATION OF THYROID GLAND ACTIVITY. 
The activity of the follicle cell is controlled by 
the anterior pituitary hormone TSH. Serum levels of TSH 
are the result of positive hypothalamic control exerted 
by the thyrotrophin releasing hormone (TRH) and 
negatively by circulating T 3 feeding back onto the 
pituitary. This control is described below. 
A. THYROTROPHIN RELEASING HORMONE. 
TRH is a weakly basic tripeptide which is secreted 
by the hypothalamus into the specialised portal system 
that drains to the anterior pituitary where TRH binds to 
specific cell surface receptors on the thyrotrophs (TSH 
producing cells of the anterior pituitary). The action of 
TRH on the pituitary is rapid, resulting in the release 
of TSH and synthesis of new hormone. Delan et al., 
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(1977), using pituitary cells, showed that thyroid 
hormones and oestrogen respectively decrease and increase 
the binding capacity of the thyrotrophs for TRH. The 
decrease in capacity induced by thyroid hormones was 
subsequently shown to be due to modulation of the level 
of the TRH receptor (Gershengam, 1978, Hinkle et al., 
1981, 1982). Thyroid hormones may also act directly on 
the adrenergic neurons in the hypothalamus to reduce the 
rate of TRH secretion (Belchetz et al., 1978). 
B. THYROID STIMULATING HORMONE. 
TSH comprises two subunits which are encoded by 
separate genes. The a-subunit is shared with other 
pituitary hormones, follicle stimulating hormone and 
luteinizing hormone, and biological specificity is due to 
the 13-subunit (Pierce and Parsons, 1981). The 
transcription of the a- and, and a greater extent, the 13-
subunit genes has been shown to be induced by T 3 (Shupnik 
et al., 1985). The subunits join to form a glycoprotein 
with Mr = 28,000. TSH stimulation of thyrocytes leads to 
increased transcription of the Tg gene and to increased 
iodide ion uptake by the thyroid gland. TSH also controls 
the growth of the gland, with prolonged chronic 
administration inducing proliferation of thyrocytes, 
capillaries and fibroblasts (Dumont, 1971). TSH binds to 
a specific seven-pass transmembrane receptor on the 
plasma membrane of the thyrocyte leading to the 
activation of adenylate cyclase (Moore and Wolff, 1974). 
Transcription activation by cAMP is regulated by cAMP- 
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dependent protein kinase (PKA). PKA phosphorylation leads 
to the activation of CREB which binds to the CRE in the 
Tg gene leading to transcriptional activation. Although 
most of the actions of TSH on the thyroid gland are 
mediated by cAMP it has recently been shown that the 
binding of TSH to the membrane receptor also activates 
phospholipase C (Van Sande et al., 1990), which leads to 
the hydrolysis of PIP 2 to 1P3 with the subsequent release 
of Ca2 . The activation of diacylglycerol activates PKC 
which in turn activates the serum response factor, and 
members of the Jun/fos and AP-1 groups of transcriptional 
factors. 
The thyroid gland itself can regulate the rate of 
production and secretion of thyroid hormones 
(autoregulation). Little is know about this control 
mechanism but hormone secretion in the absence of TSH 
stimulation occurs in response to small changes in the 
plasma iodide ion levels or total thyroid iodide ion 
content (Same and Degroot, 1989). In addition, 
circulating thyroid hormones and thyroglobulin have been 
reported to act directly on the thyroid gland to decrease 
hormone production and secretion (Friedman et al., 1977, 
Bech et al., 1981). 
VI. CELLULAR ACTIONS AT THE TARGET TISSUE. 
Biological responses to the thyroid hormones are 
initiated by the binding of the hormone to nuclear 
receptors in the target cell. This requires the thyroid 
hormones to cross the membrane of the target cell. The 
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uptake of the hormones involves both a carrier-mediated 
process, which is dependent on Na/K ATPase, and passive 
entry (Krenning et al., 1978, 1980, Maxfield et al., 
1981). Inhibition analyses indicates that T4 and T3 cross 
the membrane via separate transport systems but also, at 
least in the case of the liver, that each can inhibit the 
transport of the other in a competitive manner (Krenning 
et al., 1981). 
In summary, the synthesis and secretion of the 
thyroid hormones is principally controlled by TSH which 
in turn is positively controlled by TRH and negatively by 
circulating thyroid hormones. T 4 functions primarily as 
a prohormone for the more biologically potent form T 3 
with the majority of T 4 being deiodinated to T 3 in the 
peripheral tissues. T 3 acts directly on gene 
transcription in the target cell by binding to receptors 
which are located in the nucleus, and associated with DNA 
response elements. 
52 
THE AIM OF THE PROJECT. 
The aim of the work described here was to generate 
thyroxine-deficient mice by using the method of 
transgenic ablation. By linking the bovine thyroglobulin 
promoter to the HSV1-thymidine kinase gene the expression 
of the HSV1-tk gene was directed to the thyroid gland of 
transgenic mice. Thyroxine deficiency was achieved by 
treating transgenic mice with the anti-herpetic drug, 
ganciclovir. The thyroxine deficiency in the mice is 
inducible and the animal may therefore be allowed to 
develop normally prior to ablation. 
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CHAPTER TWO. 
CHARACTERISATION OF THE THYROGLOBULIN-THYMIDINE KINASE 
TRANSGENE. 
The thyroglobulin gene is expressed exclusively in 
differentiated thyroid cells under the positive control 
of TSH. In order to create an inducible thyroxine-
deficient mouse by using the conditional ablation 
technique (Borrelli et al., 1988, 1989, Heyman et al., 
1989) the expression of the HSV1-tk gene was directed to 
the thyroid by linking it to a bovine thyroglobulin 
promoter. The TG-TK transgene was constructed by M. 
Richardson (Figure 4). 
A 3050bp fragment of the bovine thyroglobulin gene 
contains the cap site, 13 nucleotides of the 5'-non-
coding region and about 3kb 5' to the cap site. This 
region contains two tissue specific hypersensitive sites 
(Hansen et al., 1988) and a cAMP response element (CRE) 
which is contained within the first 250bp upstream of the 
cap site (Christophe et al., 1989). Since the TG-TK 
construct was made Ledent et al., (1990) have shown that 
2000bp of the promoter is sufficient to direct the 
expression of a chioramphenicol acetyltransf erase gene 
specifically to the thyroid in transgenic mice. 
The TG-TK transgene was excised by means of unique 
restriction sites in the polylinkers flanking the 
transgene and purified by gel electrophoresis prior to 
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FIGURE 4. 
THE TG-TK TRANSGENE. 
The fragment used for microinjection was excised by 
digestion with XhoI and KpnI. 3050bp of the bovine 
thyroglobulin promoter (-3041bp to 13bp relative to the 
cap site, a gift of G. Vassart), was linked to 1765bp of 
the HSV1-tk gene through a junction in the non-coding 
regions (AluI/BglII). The bacterial supF gene was present 



















microinjection into the pronuclei of C57BL/6 x CBA/ca F 2 
eggs. 255 embryos were transferred to pseudopregnant 
recipients and 90 pups were born (microinjection and 
embryo transfers were carried out by Dr. R. Al-Shawi). 
Transgenic mice were identified by polymerase chain 
reaction on tail biopsies as described in Material and 
Methods. The 15 transgenic pups identified comprised 4 
sterile males, 7 fertile males and 4 fertile females. The 
female mice were used to establish the pedigree lines 
TG14, TG26, TG62 and TG66.19. The sterile males plugged 
female mice in the normal way but failed to sire pups. 
Their sterility has been shown to be a direct consequence 
of high levels of HSV1-TK expression in the testes 
resulting in a low sperm count. The sperm are also 
morphologically defective (Al-shawi et al., 1988, 1991, 
Braun et al.., 1990). The fertile males sired offspring 
but did not transmit the transgene and are therefore 
probably germ-line mosaics produced when the transgene 
integrates into the DNA after the first round of DNA 
replication. The transgenic germ cells of these animals 
are assumed to generate defective spermatozoa, while the 
non-transgenic germ cells generate functional spermatozoa 
(Al-Shawi et al., 1991). 
Southern blot analysis of the four established lines 
revealed that in lines TG14, TG62 and TG66.19 multiple 
copies of the transgene had integrated into the 
chromosome at a single site in a head-to-tail tandem 
configuration containing approximately 5, 10 and 5 copies 
of the transgene respectively. Line TG26 in contrast 
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contained 1 copy of the transgene. 
Transgenic ablation requires that the expression of 
the transgene is limited to one tissue type. To 
investigate whether the TG-TK transgene is expressed only 
in the thyroid gland, HSV1-TK assays were carried out on 
a number of tissues. Expression was detected in the 
thyroid and testes and very low expression was detected 
in the submaxillary gland (Table 3). The brain, heart, 
kidney, muscle, ovary, liver and preputial gland showed 
levels of HSV1-TK activity indistinguishable from the 
levels of endogenous activity present in the same tissues 
of a non-transgenic mouse. The level of thyroid HSV1-TK 
activity varied between the lines with line TG66.19 
having a level more than 10 fold higher than the other 
lines (Table 3). 
TRANSCRIPTION AND TRANSLATION OF THE TRANSGENE. 
Transgenes containing the same sequences of the 
HSV1-tk gene as TG-TK, but linked to a variety of 
different promoters, have been studied in transgenic 
mice. They consistently show HSV1-TK activity in the 
testes, suggesting that testes expression is a property 
of the HSV1-tk gene (Al-Shawi et al., 1991). Nuclease 
protection assays showed that the HSV1-TK transcripts in 
the testes map to sites downstream of the normal 
initiation codon of HSVI-tk (ATG 1 ), most frequently at 
positions +150 and +160. Examination of the translation 
products in the testes by Western blot analysis revealed 
two major immunoreactive polypeptides of Mr 39,000 and 
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TABLE 3 
THYMIDINE KINASE ACTIVITY IN THE TISSUES OF TRANSGENIC 
MICE CONTAINING THE TG-TK TRANSGENE. 
Thymidine kinase activities are expressed in pmol/min/mg. 
TG14, TG26, TG62 and TG66.19 refer to established 
pedigree lines, derived from progenitor female mice, 
where M is male, F is female, non-T is a F 2 C57BL/6 x 
CBA/ca, non-transgenic control, na, not applicable. -, 
not determined. 
Submaxillary gland is abbreviated to submax. 
The number of mice analysed is shown in subscript. 
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Transgeni.c Lines 
TG14 IG26 TG62 TG66.19 Non-T 
Tissue M F NI F NI 
F NI F M F 
Thyroid 11.90 10.60 18.05 11 .4 
02 0.65' 1 . 20 2 219 . 10 2 178.80 0.64 2 0.03 
Liver 0.04' 0 . 05 2 0.03' 0.04' 0.04' 0.03' 0.02' 
0.04 2 0.03 2 0.03 2 
Brain 0.30' 0.28 2 0.07' 0.17' 0.09' 0.05' 0.09' 
Q372 0.22 2 0.27' 
Muscle 0.08' 0.03' 0.02' 0.06' 0.30' 0.01' 0.02' 
0.01 1 0.03 2 0.03 2 
Submax. 0.06' 0.17 2 0.06' 0 . 11 1 0.04' 
0 . 11 1 0.13' 0.32 2 0.06' 0.012 
Kidney 0.06' 0.05' 0.04' 0.12' 0.04' 0.24' 0.03' 0.05' 
0.06 2 0.18 2 
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37,000; both shorter than the expected full length 
peptide of Mr 43,000. These truncated products probably 
result from translational initiation occurring from the 
second and third ATG codons of the HSV1-tk reading frame 
(Al-Shawi et al., 1991). These results suggest that the 
testes contain one or more trans-acting factors that 
activate a cryptic promoter element in the HSV1-tk gene, 
initiating transcription downstream of the first ATG 
codon. 
To determine whether the TG-TK transgene initiates 
transcription correctly in the thyroid, primer extension 
analysis was carried out. A 20 nucleotide oligonucleotide 
complementary to the region +438 to +419 of the HSV1-tk 
gene was used as a probe (Al-Shawi et al., 1991). A 
positive control was generated by cloning a 312bp 
fragment (MscI-Ec0RV), which spans the cap site of the 
TG-TK transgene, into a Bluescript SK vector. This clone 
was used to generate a positive control template by in 
vitro RNA transcription. Figure 5A shows primer extension 
products obtained with thyroid RNA and positive control 
template. The expected lengths of the primer extension 
products are 114bp and 208bp respectively. Lanes 1-3 show 
a 208bp product obtained with the control template while 
lanes 5+6 show a 114bp product obtained with thyroid RNA. 
As expected lane 4 shows no extension product with 
thyroid RNA from non-transgenic mice. Thus transcription 
of the TG-TK gene in the transgenic thyroid is correctly 
initiated at the cap-site of the thyroglobulin gene. The 
limit of detection of the assay is between lpg (lane 2) 
61 
FIGURE 5. 
A) PRIMER EXTENSION OF POOLED THYROID TOTAL mRNA. 
Annealing of the primer and the extension reaction are 
described in Material and Methods. Autoradiograph 
exposed for 7 days. 
lanes:- 1) lOpg in vitro transcribed RNA. 
lpg in vitro transcribed RNA. 
0.2pg in vitro transcribed RNA. 
5j.g non transgenic pooled male thyroid RNA. 
5p.g TG6619 pooled male thyroid RNA. 
1g TG66.19 pooled male thyroid RNA. 
7-10) sequence reaction of M13mp18 with ddTTP; 
ddCTP; ddGTP and ddATP respectively. 
B) WESTERN BLOT ANALYSIS OF TESTES AND THYROID EXTRACTS. 
Blot was challenged with anti-HSV1-TK serum (Al-Shawi et 
al., 1991). Detection system is biotin/streptavidin 
alkaline phosphatase. 
lanes:- 1) 50p.g TG62 testes extract. 
50jig TG14 testes extract. 
50jig TG26 testes extract. 
4 & 5) 50jig TG66.19 testes extract. 
6) 50pg non-transgenic testes extract. 
50g HSV1-tk infected cell extract. 
20j.tg TG14 female thyroid extract. 
20j.tg TG66.19 male thyroid extract. 
20)ig TG66.19 female thyroid extract. 
20j.ig non-transgenic female thyroid extract. 
C = control; TG = transgenic; F = female; M = male; T 3 = 
T3 RNA polymerase transcripts. 
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and 0.2pg (lane 3). The intensities of the signals 
obtained with thyroid RNA indicates that the TG-TK mRNA 
in the thyroid constitutes approximately 0.002% of the 
total thyroid RNA. Translation products of the transgene 
in thyroid and testes extracts were detected by Western 
blot analysis, challenging with anti-HSV1-TK serum (a 
gift of Dr W. Summers). The main reactive protein present 
in the thyroid extracts was full length 43kDa HSV1-TK 
(Figure 5B, lanes 8, 9 & 10) suggesting that translation 
initiation occurs at the first ATG codon of the HSV1-tk 
reading frame. In contrast, the majority of 
immunoreactive protein products in the testes were 
shorter than the expected full length peptide (Figure 5B, 
lanes 1-5). The pattern of immunoreactive proteins 
present in the testes of TG-TK mice was similar to the 
patterns obtained from other transgenic lines which 
express the HSV1-tk gene in the testes (Al-Shawi et al., 
1991). Thus the mechanism by which the HSV1-tk gene is 
expressed in the testes of mice containing the TG-TK 
transgene would appear to be the same as in other 
transgenic mice which express HSV1-tk in their testes. 
The site of HSV1-TK expression in the thyroid was 
determined by immunocytochemistry using anti-HSV1-TK 
serum. In an untreated transgenic mouse staining was 
confined to thyroid follicle epithelial cells (Figure 6A) 
showing that significant transgene expression was 
directed exclusively to the thyrocytes. 
In conclusion it would appear that 3050bp of the 
bovine thyroglobulin promoter is sufficient to direct the 
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FIGURE 6. 
A. SITE OF HSV1-TK EXPRESSION IN THE THYROID GLAND. 
Immunohistochemical visualisation of HSV1-TK expression 
(positively stained cells) in 3m sections of female 
thyroid gland. Sections were challenged with an anti-
HSV1-TK serum and developed using horseradish peroxidase. 
The sections were counter stained with haematoxylin. 
Non-transgenic control. 
Untreated TG66.19 female. 
Magnification: xlOO. 
B. THE EFFECT OF GANCICLOVIR TREATMENT ON THE THYROID 
GLAND. 
Thyroid glands of: 
Non-transgenic mouse. 
Untreated transgenic. 
Transgenic mouse treated with 4.5mg/day ganciclovir 
for two weeks. 
In each case the right lobe of the thyroid gland, 
indicated with an arrow, is exposed above the trachea. 






majority of HSV1-tk gene expression to the thyroid. 
Although the submaxillary gland also has detectable 
levels of HSV1-TK activity the level is approximately 
0.2% of that observed in the thyroid gland of transgenic 
mice. In the thyroid the transgene is transcribed from 
the correct start site and is translated correctly to 
yield a full length TK polypeptide of 43kDa. In contrast 
the majority of HSV1-TK expression in the testes results 
from transcription initiated at sites downstream of the 
first ATG codon, giving rise to truncated polypeptides of 
39kDa and 37kDa. 
To avoid any complications that may be caused by 
HSV1-TK expression in the testes, most of the experiments 
were carried out on female mice from line TG66.19 which 
showed the highest HSV1-TK activity in the thyroid gland. 
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CHAPTER THREE. 
CREATING THE INDUCIBLE THYROXINE-DEFICIENT MOUSE MODEL. 
TRANSGENIC ABLATION. 
Mature female transgenic mice (up to 18 weeks of 
age), containing the TG-TK transgene, were implanted with 
Alzet osmotic mini-pumps for two weeks. These pumps are 
designed to allow a constant rate of infusion over a set 
period of time. The mini-pumps were filled either with 
phosphate-buffered saline (PBS) or with ganciclovir. The 
concentration of the drug was set to give a delivery rate 
of 4.5mg/day. 
At the end of two weeks the animals were sacrificed. 
Figure 6B shows the effects of ganciclovir on the thyroid 
gland over this period of time. In each case the right 
lobe was exposed above the trachea. The mouse exposed to 
ganciclovir shows an almost complete regression of the 
thyroid gland. This correlates with the total soluble 
protein obtained from the rudiment, which is less than 
20% of the control value (Table 4). Due to the difficulty 
in dissecting out the rudiment without removing neck 
muscle, this value is likely to overestimate the 
remaining protein. 
Any thyrocytes which escaped ablation might be 
expected to retain HSV1-TK activity. HSV1-TK activity was 
therefore measured in residual thyroid tissue to assess 
the extent of thyrocyte ablation. Table 4 shows the total 
TABLE 4. 
THYROID HORMONE LEVELS AND HSV1-TK ACTIVITY IN ABLATED 
MICE. 
Mice were treated with ganciclovir (4.5mg/day) or PBS by 
minipump for two weeks. Circulating thyroid hormone 
levels were measured using ELISA competitive assays 
(Kodak Diagnostics). The total protein obtained from the 
thyroid is expressed in pg. The HSV1-TK activity is in 
units of TK activity/thyroid. 
Treatment T 4 	(nmol/L) T 3 	(nmol/L) TK Total 
& Exp. 	Nos. Activity Protein 
(pg) Before After Before After 
Transgenic & 
PBS 	 1 44.9 15.8 - 0.00 8.60 60 
1 44.1 24.0 0.86 0.27 - - 
1 20.3 20.6 - - 11.50 30 
Average 36.4 20.1 0.86 0.14 10.05 45 
Transgenic & 
ganciclovir 	1 52.3 0.0 0.96 0.00 0.01 7 
1 51.4 0.0 0.98 0.00 0.03 10 
1 50.7 0.0 0.83 0.00 0.01 10 
3 57.7 0.0 - - - - 
5 48.8 0.0 - - 0.04 10 
Average 52.2 0.0 0.92 0.00 0.02 9 
Non-Transgenic & 
ganciclovir 	3 66.4 40.4 0.73 0.48 0.01 100 
5 49.1 33.4 - - 0.01 100 
Average 57.8 36.9 0.73 0.48 0.01 100 
C 
units of HSV1-TK activity and protein per thyroid 
rudiment in the ablated mice. In each case the ablated 
mice had essentially zero HSV1-TK values. Thus after two 
weeks of ganciclovir treatment there appears to be little 
or no expression of the transgene. From the results in 
Table 4 the ablated mice have an average HSV1-TK value of 
0.02 units/thyroid compared to 10.05 units/thyroid in a 
PBS treated transgenic control.. The background level of 
HSV1-TK activity in the assay is 0.01 units/thyroid (non-
transgenic control). Based on the assumption that any 
remaining thyrocyte is expected to retain HSV1-TK 
activity the value of 0.02 units/thyroid in the ablated 
mice suggest that no more than 0.1% of the thyrocytes 
escape ablation during the two weeks of ganciclovir 
treatment. 
HORMONE LEVELS. 
To determine whether the mice were deficient in 
thyroxine after two weeks of drug administration, serum 
samples were analysed for the presence of circulating T 4 
and T3 . Circulating T4 and to a lesser degree T3 are 
mainly bound to serum proteins (see Chapter 1). The 
blocking agent 8-anilino-1-naphthalene sulphonic acid was 
included in the assay to dissociate the hormones from the 
binding proteins so that total circulating hormone could 
be measured by a competitive ELISA system (enzyme linked 
immunoabsorbent assay). I used the Amerlite system (Kodak 
Diagnostics) which depends on competition for a limited 
number of binding sites on a specific antibody between 
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antigen in the sample and a horseradish peroxidase-
labelled antigen conjugate. The amount of bound labelled 
antigen is inversely proportional to the concentration of 
antigen in the sample. In each case (Table 4) mice 
treated with ganciclovir had levels of serum T 4 and T3 
below the sensitivities of the assays (8.Onmol/L and 
0.15nmol/L for T4 and T3 respectively) with actual 
readings of 0.0 being obtained. The control mice, that is 
transgenics with PBS or non-transgenics with ganciclovir 
pumps, still had detectable thyroid hormone levels after 
two weeks. However the values obtained were generally 
lower at the end of the experiment (T 4 fell by about 40% 
on average). This appears to be a direct affect of the 
experiment due to surgery or from mini-pump implantation. 
The levels of T 4 in untreated non-transgenic control 
mice, sampled at the same time of day on different days, 
were also quite variable (Table 5). However in these 
mice, which were not implanted with minipumps, the 
variation between samples and within mice was similar to 
the variation between mice, suggesting that differences 
in T4 levels did not follow any obvious pattern. This 
contrasts with the consistent difference observed before 
and after minipump implantation. 
In conclusion, administration of 4.5mg/day of 
ganciclovir over a period of - two weeks resulted in mice 
with undetectable levels of circulating T 4 and T3 . The 
thyroid gland showed almost complete regression with 
residual tissue having negligible HSV1-TK activity, 
suggesting that few if any thyrocytes escaped ablation. 
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TABLE 5. 
ANALYSIS OF VARIANCE IN THYROID HORMONE LEVELS IN NON-
TRANSGENIC MICE. 
Five age-matched male and female mice were tail bled 
several time over a period of eight days. T 4 levels were 
assessed using a commercial assay kit (Amerlite- Kodak 
Diagnostics). 
The F-distribution analysis (F) was applied with degrees 
of freedom (DF) as indicated in Table 5. The difference 
between male mice, between female mice and between all 





mouse Day 1 Day 4 Day 6 Day 8 
Male 22.5 80.0 60.0 55.0 
Male 35.0 57.5 72.5 47.5 
Male 37.5 82.5 80.0 47.5 
male 20.0 62.5 80.0 50.0 
Male 47.5 75.0 40.0 62.5 
Female 70.0 45.0 35.0 12.5 
Female 70.0 40.0 37.5 30.0 
Female 60.0 50.0 40.0 5.0 
Female 40.0 70.0 47.5 30.0 
Female 52.5 87.5 52.5 42.5 
F Significance DF 
Male mice/Diff 0.94 NS 4 	& 	12 
Female mice/Diff 1.27 NS 4 	& 	12 
All mice/Diff 0.90 NS 9 & 	27 
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SPECIFICITY OF ABLATION. 
The thyroid contains two cell types of different 
embryonic origin: thyrocytes, which secrete T4 and T3 and 
C-cells which secrete calcitonin (CT). The C-cells are 
distinct endocrine cells found on the follicle wall or 
interspersed with the follicle cells and hence are often 
referred to as parafollicular cells (Figure 7A). 
Morphologically they differ from thyrocytes in being 
larger with a more granular appearance. The thyroid gland 
is also in intimate contact with the parathyroid gland 
which secretes parathyroid hormone (PTH). The two 
parathyroid glands are bilaterally attached to the 
thyroid lobes, and each consists of a densely packed mass 
of cells separated from the thyroid gland by a connective 
tissue capsule. In conjunction with CT and 1,25, (OH) 2-
vitamin D31  PTH is involved in calcium homeostasis and 
bone remodelling in the adult. 
The results shown in Figure 6A demonstrate that the 
expression of the transgene is specifically directed to 
the thyrocytes in female transgenic mice with 
administration of ganciclovir resulting in regression of 
the thyroid gland (Figure 6B). I investigated the 
specificity of ablation in the thyroid gland to determine 
whether ablation was restricted to one cell type or 
whether it caused the destruction of the other cell 
types. Destruction of the other cell types could occur in 
at least two ways. Firstly the thyrocytes and the C-cells 
may be connected by gap junctions allowing the transfer 
of phosphorylated nucleotides from one cell type to 
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FIGURE 7. 
A. DISTRIBUTION OF C-CELLS IN THE MOUSE THYROID GLAND. 
Immunohistochemical visualisation of C-cells (positively 
stained cells) in 3jim sections of female thyroid gland. 
Sections were challenged with an anti-human calcitonin 
antibody and developed using horseradish peroxidase. The 
sections were counter stained with haematoxylin. 
Non-transgenic mouse. 
Untreated transgenic. 
Transgenic mouse treated with 4.5mg/day ganciclovir 
for two weeks. 
Sections show areas of C-cells that have been brought 
together by the removal of the thyrocytes and by the 
overall shrinkage of the gland. 
Magnification: xlOO. 
B. HISTOLOGY OF THE PARATHYROID GLAND. 
Histological examination of the thyroid gland showing the 
parathyroid gland (P) 
Non-transgenic control. 
Untreated transgenic. 
Transgenic treated with 4.5mg/day ganciclovir for two 
weeks. 
Sections were cut at 5m and stained with H&E. 
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another. Secondly leakage of toxic compounds which could 
be taken up by surrounding cells might occur. Although 
cells do not take up nucleotides, other toxic compounds 
might escape from the dying thyrocytes. 
C-CELLS. 
CT levels were assessed, using a radioimmunoassay 
(RIA), in transgenic mice treated with ganciclovir for 
two weeks. The assay is based on competition between a 
radioactive standard antigen and non-radioactive 
experimental antigen for a limited number of antibody 
binding sites. The amount of bound radioactive antigen is 
inversely proportional to the concentration of antigen in 
the sample. The hormone levels observed before and after 
ablation showed little variation (Table 6), demonstrating 
that the C-cells were still functional in the absence of 
detectable levels of thyroid hormones. In contrast, a 
thyroidectomised mouse showed no circulating CT (Table 
6). The persistence of normal levels of CT is consistent 
with the identification of functional C-cells in thyroid 
sections taken from a transgenic mouse treated with 
ganciclovir (Figure 7A). The distribution of the cells 
had altered. After ablation the C-cells were found 
clustered together rather than distributed around the 
follicles as before (Figure 7A). This configuration would 
be expected if, when the thyrocytes disappear, the 
follicles themselves collapse. Electron microscopy 
indicated that ablation had not caused any intracellular 
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TABLE 6. 
CALCITONIN LEVELS IN ABLATED MICE. 
Serum samples, collected at the start and completion of 
the experiment were pooled and assessed for circulating 
calcitonin using a commercial RIA kit (Kodak 
Diagnostics). A thyroidectomised mouse was included as a 
negative control. T 4 was determined using an ELISA 
system. 
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Caicitoniri (pg/mi) T4 (nmoi/L) 
Treatment & 
Exp. Nos. Before After Before 
After 
Transgenic & 
PBS 	 1 - 34 44.9 15.8 
3 36 29 20.3 20.6 
5 25 28 47.5 28.5 
Average 30 30 37.6 21.6 
Transgerlic & 
ganciciovir 1 - 22 51.4 0.0 
3 24 26 48.3 0.0 
38 33 
5 30 27 - - 
Average 31 27 49.8 0.0 
Non-Transgenic 
& gariciclovir 
3 23 25 - - 
5 42 39 49.1 33.6 
Average 32 32 49.1 33.6 
Thyroid- 27 0.0 56.5 8.1 
ectomized I 
alterations to the C-cells (Figure BA - Dr. C. McLaren, 
Pathology Department, Edinburgh University). Thus the C-
cells are unaffected by ablation of the thyroid gland. 
The serum assays also demonstrate that the activity of C-
cells is independent of thyroid hormones. 
PARATHYROID GLAND. 
The effect of ganciclovir treatment on the 
parathyroid gland was assessed. Circulating levels of PTH 
were measured by RIA. Table 7 shows that ganciclovir 
treatment had little or no effect on the circulating 
levels of PTH over the two week ablation period. The 
integrity of the gland was confirmed by histology (Figure 
7B). These results indicate that there is no direct or 
indirect damage to the parathyroid during thyrocyte 
ablation and, furthermore, that thyroxine has no role in 
regulating the function of the parathyroid gland. 
In conclusion, the results indicate that the 
expression of the TG-TK transgene is directed to the 
thyrocytes. The administration of ganciclovir results in 
the destruction of HSV1-TK expressing cells and affects 
only one hormone secreting cell type in the thyroid 
gland, with no secondary effect on either the C-cells or 
the parathyroid gland. Thus ablation is restricted to the 
site of HSV1-TK expression. This is in agreement with the 
observations of Borrelli et al., (1989) who demonstrated 
the precise ablation of somatotrophs and lactotrophs in 
the pituitary, while other pituitary cell types were 
unaffected. The results also show that the normal 
81 
FIGURE 8. 
A. ELECTRON MICROSCOPY OF THE THYROID GLAND. 
Transgenic mice were administered ganciclovir (4.5mg/day) 
by minipump for two weeks. The thyroid glands were 
removed and prepared for EM. Sections 1-3 show granulated 
C-cells (C). However after two weeks of ganciclovir 
treatment the C-cells form clusters. 
Non-transgenic control (x 6200). 
Untreated transgenic (x 8200). 
Transgenic treated with ganciclovir for two weeks 
(x 8200). 
( (. Mc(L.aren , Pathology Department, University of 
Edinburgh). 
B. ADIPOSE TISSUE IN THE THYROID GLAND. 
Cryosections (lOjim) of thyroid glands stained for adipose 
tissue (Sudan black). 
Non-transgenic control. 
Untreated transgenic. 
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PARATHYROID HORMONE LEVELS IN ABLATED MICE. 
Circulating levels of parathyroid hormone (PTH) from 
pooled samples, were assessed using a commercial RIA kit 
(Kodak Diagnostics). T 4 was determined by competitive 
ELISAs (Kodak Diagnostics). 
Treatment & 
PTH (pmol/L) T 4 (nmol/L) 
Exp. Nos. Before After Before After 
Transgenic & 
PBS 	 1 - 36 44.9 15.8 
2 54 49 44.1 39.5 
Average 54 42 44.5 27.6 
Transgenic & 
ganciclovir 	1 - 48 51.4 0.0 
2 71 65 29.8 0.0 
Average 71 56 40.6 0.0 
Non-Transgenic 
& ganciclovir 
2 63 84 21.0 10.8 
functioning of the C-cells and the parathyroid gland are 
not dependent on thyroid hormones. 
ABLATION STUDIES IN THE MALE MOUSE. 
Male mice carrying a transgene with the HSV1-tk gene 
as a reporter have significant levels of HSV1-TK activity 
in the testes (Chapter 2). Moderate and high levels of 
HSV1-TK expression, but not low levels, cause male 
sterility. The mechanism by which HSV1-TK activity in the 
testes causes sterility is not understood (Al-Shawi et 
al., 1988, 1991, Braun et al., 1990) 
I investigated whether ganciclovir could ablate the 
cells in the testes (spermatids) that express the HSV1-tk 
gene. A line of transgenic mice in which HSV1-TK 
expression is confined to the testes and preputial gland 
(J. Whitaker, PhD Thesis Edinburgh University 1989) was 
used in the first instance to avoid complications which 
might arise due to thyroid ablation. HSV1-TK activity in 
the testes was analysed after two weeks of drug treatment 
and found to be unchanged compared to a PBS treated 
control transgenic of the same line. TG66.19 male mice 
were then examined. The effect on the level of thyroid 
hormones was similar to that observed in female 
transgenic mice treated in the same way. At the end of 
two weeks of ganciclovir treatment there was no 
detectable T 4 or T3 in the serum and the HSV1-TK activity 
of the thyroid had effectively decreased to zero (Table 
8). In contrast, HSV1-TK expression in the testes was 
unchanged by ganciclovir treatment, levels of transgene 
TABLE 8, 
MALE ABLATION: HORMONE LEVELS AND HSV1-TK ACTIVITY IN THE 
TESTES AND THYROID GLAND. 
Male TG66.19 mice were treated with 4.5mg/day ganciclovir 
or PBS by minipump for two weeks. Serum levels were 
measured using ELISA competitive assays (Kodak 
Diagnostics). The total protein obtained from the thyroid 
is expressed in j.tg and the HSV1-TK activity is in 
units/thyroid. The HSV1-TK activity in the testes is 
expressed in units/mg 
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Treatment T 4 	(nmol/L) T 3 	(niuol/L) Testes TK Thyroid 
Activity 
(units/mg) Before After Before After TK activity Total Protein 
per gland (jig) 
Transgenic 
& PBS 






Average  79.4 32.2 118 
Transgenic & 48.2 0.0 0.72 0.00 74.2 0.0 20 
ganciclovir 104.9 0.0 45 
25.1 0.0 0.29 0.00 59.5 0.2 49 
97.9 0.0 35 
Average 36.6 0.0 0.50 0.00 84.1 0.05 37 
Non-Transgenic 67.4 54.3 0.81 0.69 0.79 0.1 140 
& ganciclovir  
9 
expression being similar to that of a PBS treated control 
transgenic animal (Table 8). Histological studies 
revealed no morphological alteration to the structure of 
the testes following ganciclovir treatment (Department of 
Pathology, Western General Hospital, Edinburgh). It would 
therefore appear that male mice can be used in ablation 
studies without any complications caused by the 
expression of HSV1-tk in the testes. 
The persistence of HSV1-TK expression in the 
testes following ganciclovir treatment could be due to 
any of several causes. (1) HSV1-TK activity is mainly 
detected in haploid spermatids (Al-Shawi et al., 1991) at 
which time the sperm are near maturity and thus may be 
insensitive to the affects of ganciclovir. (2) The cells 
expressing the HSV1-tk gene may be inaccessible to the 
ablating agent due to the possible presence of a blood 
membrane barrier in the testes. (3) The truncated 
proteins present in the testes may not be able to 
phosphorylate the drug. This latter question could be 
addressed in a tissue culture system by manipulating the 
HSV1-tk gene so that only truncated protein products were 
produced. Cell viability following drug treatment could 
then be assessed. 
CHAPTER FOUR. 
FURTHER ASPECTS OF THYROID ABLATION AND THE EFFECT 
OF PROLONGED THYROXINE DEFICIENCY ON THE MOUSE. 
EFFECTS OF GANCICLOVIR TREATMENT ON THE THYROID GLAND. 
The thyroxine-deficient mouse (Chapter 3) was 
generated by treating transgenic mice continuously with 
ganciclovir for a period of two weeks. I was therefore 
interested to determine the time-course of ablation. 
Accordingly, ganciclovir was administered to transgenic 
female mice for 1, 2, 3, 7 and 14 days, at which times 
the mice were sacrificed and the thyroid gland removed. 
The glands were analysed for changes in morphology and 
HSV1-TK activity 
The effects of ganciclovir treatment on thyroid 
gland morphology were investigated. A non-transgenic 
control thyroid (Figure 9A) and an untreated transgenic 
thyroid (Figure 9B) show typical follicle structures, 
with a layer of epithelial cells (thyrocytes) surrounding 
a cavity (lumen). The latter is filled with stained 
colloid. A change in the morphology of the thyroid gland 
was observed after two days of drug treatment (Figure 9D) 
with areas of the gland becoming devoid of follicle 
structures. By the third day (Figure 9E) follicle 
structures which contain colloid were nearly eliminated. 
After 7 days no follicle structures were observed in any 
of the sections studied (Figure 9F). Figure 9G shows a 
FIGURE 9. 
MORPHOLOGY OF THE THYROID GLAND DURING GANCICLOVIR 
TREATMENT. 
Histological sections (5pm) of thyroids from TG66.19 
female mice treated with ganciclovir (4.5mg/day) by 
minipump. Sections show typical follicle structures. 
Non- transgenic. 
Untreated transgenic. 
1-day of ganciclovir treatment. 
2-days of ganciclovir treatment. 
3-days of ganciclovir treatment. 
7-days of ganciclovir treatment. 
Two weeks ganciclovir treatment. 
The sections were stained with H&E. Magnification xlOO. 
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typical section taken from a transgenic mouse treated 
with ganciclovir for fourteen days. The section contains 
structures which resemble empty follicles. However these 
structures appear de novo between days seven and fourteen 
and are therefore unlikely to be empty follicles, indeed 
most have been identified as adipose tissue (Figure 8B). 
Figure 9G also demonstrates the presence of endothelial-
like cells and C-cells (Figure 7A). Others remain 
unidentified, but they are present in very much lower 
numbers than the follicle cells of the control thyroid. 
All the sections show nerve cells and blood vessels which 
were unaffected by ganciclovir treatment. 
The total protein and total HSV1-TK activity 
recovered from excised glands were consistent with the 
morphological changes observed (Table 9). Total protein 
was significantly reduced after 3 days of treatment and 
after 7 days had fallen to about 20% of the control 
value. Total HSV1-TK activity fell more rapidly and was 
already significantly reduced after just 1 day of 
treatment. Although the accuracy of the total protein 
values is uncertain, due to the difficulties of excising 
thyroid tissue, the specific activity (units/mg) provides 
an indicator of HSV1-TK activity which will be reliable 
if recovery of thyroid tissue is incomplete, provided 
there is no contamination by muscle or other non-thyroid 
tissue. The specific HSV1-TK activity was significantly 
reduced after 1 day (Table 9), lending support to the 
reduction in total HSV1-TK activity observed at that 
time. After 7 days of ganciclovir treatment total HSV1-TK 
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TABLE 9. 
CHANGES IN TRANSGENIC THYROID GLANDS DURING THE FIRST 
WEEK OF GANCICLOVIR TREATMENT. 
Female transgenic mice were administered ganciclovir by 
minipump at a rate of 4.5mg/day for 1, 2, 3, and 7 days. 
At the end of these times the mice were sacrificed. 
Thyroid glands were removed and assessed for HSV1-TK 
activity. HSV1-TK activity is expressed in units/thyroid 
and also as specific activity (per mg). Total soluble 
protein is expressed in j.g. 
T4 and T3 levels were measured by competitive ELISAs on 
serum samples collected at the start of the experiment 
and at the time of sacrifice. 
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Treatment T 4 	(nmol/L) T 	(nuiol/L) TK Activity Total 
Protein 
Before After Before After Units/gland Units/mg ()Ig) 
Control 52.4 - 0.52 - 21.8 310.4 70 
Transgenic 
58.2 - 0.68 - 15.7 112.2 140 
Average 55.3 - 0.60 - 18.8 211.3 105 
Transgenic & 40.7 16.6 0.74 0.42 13.6 113.4 120 
ganciclovir 
50.0 18.5 0.65 0.42 11.5 117.9 196 1 	day 
Average 45.4 17.6 0.70 0.42 12.6 115.6 158 
Transgenic & 55.8 11.3 0.63 0.22 9.2 152.8 60 
ganciclovir 
34.3 29.0 0.47 0.71 8.8 79.7 110 2 days 
Average 45.0 20.2 0.55 0.46 9.0 116.2 85 
Transgenic & 48.8 66.1 0.34 0.97 1.7 28.7 60 
ganciclovir 
26.1 10.7 0.29 0.20 3.7 104.7 35 3 days 
Average 37.4 38.4 0.32 0.58 2.7 66.7 48 
Transgenic & 34.4 30.6 - - 0.01 0.80 20 
ganciclovir 
32.4 0.0 - - 0.00 0.00 20 7 days 
Average 33.4 15.3 - - 0.01 0.4 20 
Non-TransgeniC 55.8 34.7 0.43 0.27 0.00 0.00 40 
& ganciclovir 
42.1 34.7 0.74 0.17 0.01 0.02 260 7 days 
Average 48.9 34.7 0.58 0.22 0.01 0.01 150 
LI) 
0) 
activity in the thyroid rudiment had fallen to zero. 
Extrapolation of the data suggests that the HSV1-TK 
activity in the thyroid gland fell to zero by day 5 of 
ganciclovir treatment (Figure 10C). 
Histological examination of the glands showed that 
disintegration of follicle cells preceded the loss of 
follicle contents. Since the follicle contents are likely 
to contribute a significant proportion of the total 
protein recovered, this can explain the fact that the 
total HSV1-TK activity and the HSV1-TK specific activity 
fell before there was a significant change in total 
protein. 
If, as seems likely, the fall in total HSV1-TK 
activity after 1 day of treatment is significant, it 
would appear that the expression of HSV1-TK was depressed 
before any morphological changes became apparent. This 
suggests that there may be a significant time delay 
between the metabolic death of the follicle cells and 
their disintegration. 
CIRCULATING LEVELS OF THYROID HORMONES. 
Circulating levels of T 4 and T3 fell below the limits 
of detection after 14 days of drug treatment (Table 4). 
The variation in circulating T 4 and T3 (Table 5) and the 
marked effect of surgery and the manipulation on control 
animals (Table 4) makes it difficult to define the time-
course of hormone levels during ganciclovir treatment 
with accuracy. Keeping this important reservation in 
mind, and despite considerable variation in the response 
W. 
FIGURE 10. 
THYROID HORMONE LEVELS AND HSV1-TK ACTIVITY DURING 
ABLATION. 
A) T4 levels and B) T3 levels in transgenic mice treated 
with 4.5mg/day ganciclovir for 1, 2, 3, 7 and 14 days. 
Points represent the ratio of hormone levels obtained 
c_er and 'ce.e-Q. the experiment. Graph shows line of best 
fit between data points. 
C) Total protein and HSV1-tk activity obtained from the 
thyroid glands of transgenic mice treated with 4.5mg/day 
ganciclovir for 1, 2, 3, 7 and 14 days. Curve represents 
an exponential decay curve where Y = A(Bx). 
(Courtesy of J. Bishop) 
Total 1K activity, units/gland 
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of different mice, the data suggests that after an 
initial decline the circulating levels of the thyroid 
hormones may recover after 2-3 days (Table 9). If so, 
this recovery is followed by a second decline which is 
complete before the 14 day time-point (Table 4 and Figure 
10A and lOB). 
The recovery, if it does in fact occur, could be due 
to any of several possible mechanisms: (1) Circulating 
levels of TSH may increase in response to declining 
levels of thyroid hormones. (2) At short times of 
treatment the residual thyrocytes might take up and 
process iodinated thyroglobulin more rapidly and/or 
iodinate intrafollicular thyroglobulin more actively. 
(3) The death of follicle cells might release into the 
follicles the enzymes which process iodinated 
thyroglobulin, leading to a surge in hormone production. 
The release of processing enzymes might also explain the 
eventual dispersal of the follicle content. (4) Iodinated 
thyroglobulin released from the follicles might be 
processed in the body fluids to release thyroid hormones. 
CELL DIVISION. 
Toxicity of the anti-herpetic agent is due to 
phosphorylation of the drug by HSV1-TK. The 
phosphorylated products are then converted to nucleoside 
triphosphates by the viral and cellular kinases and are 
incorporated into the DNA resulting in chain termination 
and ultimately cell death. Experiments in vitro 
demonstrated that the phosphorylated drug products are 
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capable of preventing DNA replication (Borrelli et al., 
1988), while in vivo experiments, for example, ablation 
of thymic tissue (Heyman et al., 1989), suggested that 
cell populations with high mitotic indices ablate more 
efficiently than those with a low mitotic activity. 
However prior investigations of the conditional 
transgenic ablation technique have always studied the 
effects of ablation in dividing cells (Borrelli et al., 
1988;1989, Heyman et al., 1989). This leaves open the 
question of whether the conditional ablation technique 
can be applied to non-dividing cells. The thyroid gland 
is an ideal tissue with which to address this question. 
The follicle cells in the adult thyroid are essentially 
non-dividing with mitotic indices less than 10 3 (Santler, 
1957, Woilman et al., 1968). TSH and EGF when present at 
elevated levels, can stimulate cell division (Dumont, 
1971). I therefore investigated whether either the 
expression of the TG-TK transgene or the addition of 
ganciclovir to a transgenic mouse induced cell division 
in the thyroid gland or whether instead ablation was 
occurring in the absence of cell division. Thyroid 
sections from transgenic female mice treated with 
ganciclovir for 1-3 days were challenged with an antibody 
directed to proliferating cell nuclear antigen (PCNA). 
PCNA (also called cyclin) is an intranuclear protein 
found in normal proliferating cells. The level of PCNA 
increases during the Gi phase of the cell cycle, reaching 
a maximum during S phase and declining during the G2/M 
phase (Kurki et al., 1988). PCNA is also induced during 
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the repair of DNA damage (Shivji et al., 1992). The 
section in Figure 11B (compare Figure hA) shows thyroid 
tissue from an untreated transgenic mouse. No PCNA-
positive cells were identified, indicating that the 
expression of the transgene in the thyroid gland does not 
induce a higher rate of cell-division or cause damage to 
the DNA. Treating transgenic mice with ganciclovir 
revealed PCNA-positive cells on day 2 of drug treatment 
(Figure liD). The positively-stained cells were not 
present in follicle structures, suggesting that they may 
not be thyrocytes. As shown previously, at this time of 
treatment the morphology of the thyroid gland has altered 
with fewer follicle structures being present (Figure 9) 
while the total HSV1-TK activity has fallen by 50% (Table 
9). This data therefore suggests that ablation of 
thyrocytes can occur in the absence of cell division and 
that the appearance of PCNA-positively stained cells at 
day 2 of ganciclovir treatment probably occurs as a 
result of ablation rather than a cause of ablation. Cell 
death results in the release of lysosomal enzymes which 
attach cellular structures, including the DNA. It is 
possible that an attack on the DNA induces PCNA in the 
dying cell. 
To conclude, the results above suggest that 
ganciclovir can kill non-dividing cells, bringing into 
question the general assumption that the incorporation of 
phosphorylated ganciclovir into the DNA of dividing cells 
is the only cause of cell death. However it is possible 
that phosphorylated ganciclovir is incorporated into the 
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FIGURE 11. 
CELL DIVISION IS NOT OBSERVED IN THE THYROID GLAND. 
Thyroids sections (3j.im) from female transgenic mice, 
treated with ganciclovir (4.5mg/day), were challenged 
with a mouse monoclonal proliferating cell nuclear 
antibody (Boehringer). Sections were developed using 
horseradish-peroxidase and counter stained with 
haematoxylin. Examples of positively stained cells are 
indicated by an arrow. 
Non-transgenic. 
Untreated transgenic. 
1-day of ganciclovir treatment. 
2-days of ganciclovir treatment.. 







DNA by a DNA repair mechanism. Recently it has been 
reported that PCNA is required for the DNA synthesis that 
repairs nicked DNA intermediates (Shivji et al., 1992). 
Alternatively, as ganciclovir is an analogue of guanosine 
and different G-proteins are involved in many 
intracellular processes, ganciclovir may be acting at a 
level other than incorporation into the DNA, for example, 
on a secondary messenger system within the thyrocyte. 
It is quite possible that ablation by ganciclovir of 
non-dividing cells that express HSV1-TK is unique to 
thyrocytes. The mechanism of cell death induced by 
ganciclovir in the presence of HSV1-TK requires further 
investigation. 
REGENERATION. 
Treatment with ganciclovir of transgenic mice 
carrying an immunoglobulin promoter linked to the HSV1-tk 
gene resulted in the ablation of specific lineages in 
the thymus (double positive cells for the cell surface T-
cell markers Lyt 2 and L3T4) while other populations 
showed selective enrichment (single positives and double 
negatives). Seven days following the removal of the 
ablating agent both the Lyt 2 and L3T4 populations in the 
thymus were similar to PBS treated control transgenics 
demonstrating that stem cells sufficient to repopulate 
the cell lineages had survived the treatment (Heyman et 
al., 1989). Similarly, Borrelli et al., (1989) observed 
regeneration of both somatotrophs and lactotrophs when 
the administration of FIAU was discontinued in mice 
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carrying a GH-TK transgene. 
The potential of the thyroid to regenerate after 
treatment with ganciclovir was investigated. The 
minipumps were removed after two weeks of drug 
administration. In the first instance, the mice were 
sacrificed at 10 day intervals for up to 30 days. At the 
end of 30 days the mice had no detectable levels of T4 or 
T3 in the serum and HSV1-TK activity in the thyroid gland 
was equivalent to a non-transgenic control (Table 10). 
IEF urinary protein gels were run in conjunction with the 
hormone assays to assess MUP expression (Chapter 5). The 
results were consistent with a lack of thyroid hormones. 
The experiment was therefore extended to a period of 
4 months. At the end of this time there was no indication 
that thyroid gland regeneration was occurring: T 4 and T3 
levels were still zero, the HSV1-TK activity of the gland 
was comparable to a non-transgenic control and the total 
soluble protein was approximately 30% of the control. 
These results suggest that young adult mice do not 
contain a non-differentiated stem cell that is capable of 
repopulating the follicle cells of the thyroid. This is 
consistent with the view that after thyroidectomy, in 
man, regeneration of the thyroid gland occurs through 
slow division of residual thyrocytes. However we cannot 
exclude the possibility that a distinct stem cell 
population exists because if the stem cells express the 
TG-TK transgene they will be sensitive to ganciclovir. 
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TABLE 10. 
THYROID HORMONE LEVELS OVER 113 DAYS POST ABLATION. 
Mice were administered ganciclovir (4.5mg/day) by 
minipump for two weeks at the end of this time the pumps 
were removed. The mice were sacrificed at interval 
indicated in Table 10. T 4 and T3 levels in mice where 
measured using a competitive ELISA, values are given in 
nmol/L. The units of HSV1-TK activity in the thyroid 
rudiment was also assessed, as was the total protein 
content of the rudiment (jtg). 
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Days following mini- T 4 	(nmol/L) i 3 	(nmol/L) TK Total 
pump removal. Activity Protein 
Before After Before After (pg) 
10 Post Ablation 37.7 0.0 0.92 0.00 0.03 10 
20 Post Ablation 61.5 0.0 1.01 0.00 0.00 20 
30 Post Ablation 73.5 0.0 0.97 0.00 0.00 7 
61.8 0.0 0.87 0.00 0.00 16 
Average 67.6 0.0 0.92 0.00 0.00 12 
Non-Transgenic 53.7 27.9 0.72 0.60 0.01 66 
&PBS  
57 Post Ablation 57.1 0.0 0.85 0.00 0.01 25 
Non-Transgenic 54.0 124.0 0.54 0.23 0.01 25 
& PBS  
85 Post Ablation 33.3 0.0 0.47 0.00 - - 
60.1 0.0 0.34 0.00 0.03 40 
Average 46.7 0.0 0.40 0.00 0.03 40 
Non-Transgenic 37.0 31.8 0.18 0.43 0.10 100 
& PBS 35.7 54.2 0.60 0.51 0.02 180 
Average 36.4 43.0 0.39 0.47 0.06 140 
113 Post Ablation 52.5 0.0 - - - - 
44.7 0.0 0.36 0.00 0.02 40 
Average 48.6 0.0 0.36 0.00 0.02 40 
Non-TransgeniC 59.5 43.3 - - - - 
& PBS 42.3 43.1 0.66 0.49 0.02 130 
Average 50.9 43.2 0.66 0.49 0.02 130 
r. 
Q 
EFFECTS OF PROLONGED THYROXINE DEFICIENCY. 
Thyroid hormone deficiency in man results in 
deteriorated functioning of 'several bodily systems, 
namely the cardiovascular, gastrointestinal and 
neuromuscular systems. Symptoms of hypothyroidism include 
weight gain, cold intolerance, weakness, slow movements 
and reflexes and coarse skin and hair. 
Weight gain was monitored during and after 
ganciclovir and PBS administration for a period of 83 
days (Figure 12). In contrast to the weight-gain observed 
in man traditional methods of creating hypothyroidism in 
animals, for example, by the anti-thyroid drug, 
methimazole (Narayan et al., 1985), or surgery, results 
in a cessation of weight-gain. Rather than a cessation of 
weight-gain the mean weight of the transgenic thyroxine-
deficient mice at any particular time point showed slowed 
weight-gain compared with the control mice. The reduced 
weight-gain is similar to that seen in immature GH-
deficient animals (Behringer et al., 1988, 1990), 
suggesting that the slowing down of growth observed in 
the transgenic ablated mice may be due to a lack or 
deficiency of both GH and IGF-I. As mentioned earlier T 31  
in the rat, is required for full expression of the GH 
gene (Glass et al., 1987, Koeing et al., 1987, Sap et 
al., 1990). The actions of GH are often direct. However 
its effect on growth are thought to be mediated partly 
directly and partly by induction of IGF-1. The production 
of IGF-1 is modulated by GH (Mathews et al., 1986, 
Roberts et al., 1986) with the main site of synthesis 
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FIGURE 12. 
WEIGHT GAIN OF THYROXINE-DEFICIENT MICE OVER 83 DAYS. 
Effects of prolonged thyroxine deficiency on weight over 
83 days. Data analysed by second degree polynomial 
regression analysis where Y= A + BX + CX 2 + DX3 + EX', and 
D and E are constants. 
Weight gain (g) is . 	 o.j 	 c-e. c- 	/ 
where circles represent the mean of weights in 
ablated mice at a particular time point and triangles 
represent control mice. Bars represent the deviation from 




































being the liver. Transgenic animals which over-express GH 
and IGF-I (Chapter 1) have been created in an attempt to 
elucidate their individual effects on growth (Palmiter et 
al., 1982, 1983, Hammer et al., 1985, Behringer et al., 
1988, 1990, Mathews et al., 1988a, 1988b, Brem et al., 
1989). The studies confirmed that both hormones exert 
growth promoting actions. 
The muscle weakness and shivering which are 
associated with methimazole treatment were not observed 
in the transgenic thyroxine-deficient mice. The movement 
of the mice appeared sluggish compared to their controls 
and their fur was dishevelled, in appearance which 
correlates with the signs of hypothyroidism mentioned 
earlier. 
Female mice which had been thyroxine-deficient for 
1 month successfully mated and maintained pregnancy to 
term. The resulting litters were developmentally normal. 
In conclusion, transgenic ablated mice exhibited a 
lower rate of weight gain which may be explained by a 
deficiency of GH and hence IGF-I. The thyroxine-deficient 
mice were fertile and able to rear successful litters. 
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CHAPTER FIVE. 
USING THE THYROXINE-DEFICIENT MOUSE MODEL. 
In this chapter the effect of administering thyroid 
hormones to thyroxine-deficient mice is examined and the 
use of the model to examine the role of thyroid hormones 
in the regulation of gene expression is explored. 
If ablation has induced a single hormonal 
deficiency, replacement of the hormone should restore the 
animal to normal. In order to address this issue I 
selected a single phenotypic characteristic known to be 
dependent on the thyroid hormone status of the animal. I 
chose to examine the role of thyroid hormones in the 
expression of hepatic mouse major urinary protein (MUP) 
genes and also of a MUP transgene. The results shown 
below demonstrate that thyroid hormone treatment of mice 
exposed to ganciclovir restores the animal to normal. In 
addition the results clarify the role of thyroxine in MUP 
hepatic gene expression. 
The MUP genes can be divided into four groups. Group 
1 contains approximately 15 genes. Many of the group 1 
genes are known to be expressed in the liver and, with 
the exception of one of these genes which is also 
expressed in the mammary gland (Held et al., 1987), none 
are expressed in other tissues. The proteins are 
synthesised as pre-proteins, secreted into the blood and 
ultimately excreted into the urine (Finlayson e1 al., 
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1965). MtJP expression in the liver is regulated by 
thyroxine and growth hormone (Knopf et al., 1983, Shaw et 
al., 1983, Norstedt and Palmiter, 1984, Spiegelberg and 
Bishop, 1988, Al-Shawi et al., 1992). The expression 
pattern of group 1 MUP genes in the liver is sexually 
dimorphic. The difference between the sexes can be 
examined by studying urinary proteins or liver mRNA. Male 
mice excrete 20 to 30 times more MUP protein than females 
(Szoka & Paigen 1978), and the spectrum of MUP proteins 
excreted by the two sexes is different (Knopf et al., 
1983, Clissold et al., 1984). The level of MUP mRNA in 
the male liver is at least 5 times greater than in the 
female due to differences in the transcription rate 
(Hastie et al., 1979, Derman, 1981, Derman et al., 1981). 
By probing liver mRNA with gene specific oligonucleotide 
probes it was shown that different genes have different 
levels of expression in the two sexes (McIntosh and 
Bishop, 1989). 
Secretion of GH from the pituitary, in the rat, is 
controlled by the hypothalamic hormones growth hormone 
releasing factor (GRF) which stimulates secretion and 
somatostatin which is inhibitory. It is generally assumed 
that this control mechanism is universal. The different 
hypothalamic secretion patterns are determined mainly by 
the sex steroid status of the animal (Jansson et al., 
1984, Jansson and Frohman, 1987). The sexually dimorphic 
expression of hepatic genes, for example the MUP genes, 
is thought to be due to differences in the pattern of GH 
secretion in the two sexes. The pattern of GH secretion 
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in the mouse shows no sex-dependent difference in either 
the amplitude of the GH peak or of the basal secretion 
level (MacLeod et al., 1991). In male mice, however, the 
level of circulating GH shows a sharp peak, on average, 
at intervals of 2.5 hours while in female mice the peaks 
occur at intervals of 1.4 hours. This contrasts to the 
situation in the rat where the male has regular high 
amplitude secretion bursts every 3-4 hours, and females 
show a more continuous, but highly variable secretion 
pattern, characterised by low amplitude secretion 
(Tannenbaum and Martin, 1978, Robinson and Clark, 1987). 
It has therefore been suggested the time interval between 
GH peaks is important in GH mediated masculinisation. 
By manipulating the levels of circulating GH in mice 
the levels of MUP mRNA can be masculinised or feminised. 
For example, the continuous infusion of GH by osmotic 
minipump decreased MUP mRNA synthesis in male mice 
(Norstedt and Palmiter, 1984). Similarly females given 
periodic treatment of GH (by injection) have increased 
levels of MUP mRNA (Al-Shawi et al., 1992). Mice 
homozygous for the recessive mutation little (lit) have 
low levels of circulating GH (Eicher and Beamer, 1976) 
and express MUP at a very low level (Knopf et al., 1983, 
Norstedt and Palmiter, 1984). GH administered to lit/lit 
mice of either sex, by injection to mimic the male GH 
pattern, induced a male level of MUP expression (Knopf et 
al.,1983, Norstedt and Palmiter, 1984, Al-Shawi et al., 
1992). 
Species specific actions of thyroid hormones are 
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observed. For example, there is a functional TRE in the 
promoter region of the rat GH gene but not in the 
promoter of the human gene (Glass et al., 1987, Koeing et 
al., 1987). There is a second TRE in the third intron of 
the rat GH gene which can confer thyroid hormone 
responsiveness to a heterologous promoter in vivo (Sap et 
al., 1990). The effect of thyroid hormones on GH 
transcription in the rat may explain the long-established 
observation that hypothyroidism results in reduced 
growth. In the mouse the role thyroid hormones play in GH 
transcription is unknown. However if thyroid hormones 
play a role analogous to their role in the rat, thyroid 
hormone deprivation would also affect GH levels and 
therefore MUP expression. 
Thyroid hormones may also affect MUP gene expression 
by a second route. This was indicated from experiments in 
which GH and T4 were administered separately and together 
to hypophysectomised female mice. Hypophysectomy 
eliminates GH secretion, and greatly reduces or abolishes 
thyroid hormone secretion because of a lack of TSH. MtJP 
levels in hypophysectomised mice were reduced 
approximately 100 fold compared to normal female levels. 
The administration of supra-physiological levels of 
either GH or T4 increased MUP mRNA levels 2-fold compared 
to normal female levels while the administration of both 
hormones increased MUP mRNA 14-fold (Knopf et al., 1983). 
This data suggest that the two hormones act 
synergistically, and also that each one on its own has an 
inducing effect. However it was not clear whether after 
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hypophysectomy the levels of either hormone were zero. 
Low levels of thyroid hormones are produced in the 
absence of TSH (autoregulation - see Chapter 1). Thus the 
effect seen upon administration of GH alone may have 
depended upon the presence of a low residual level of 
thyroid hormones. 
The aims of the experiments described below are two 
fold, firstly to determine whether thyroid hormone 
treatment can reverse the suppression of MUP gene 
expression induced by ganciclovir ablation of TG-TK mice 
and secondly to determine whether GH induces MUP 
expression in the total absence of T 4 . 
RESULTS. 
Mice treated with ganciclovir for two weeks had very 
slow levels of urinary MUP (Figure 13A lanes 3 and 4). In 
contrast, MUP levels were unaffected in a transgenic 
mouse treated with PBS and a non-transgenic mouse treated 
with ganciclovir (Figure 13A, lanes 1, and 2, 13 and 14). 
Administration of T 4 during the last five days of 
ganciclovir treatment restored the circulating level of 
T3 to near-normal levels (Table 11) and also restored the 
urinary MUP level (Figure 13A lanes 11 and 12). Ablation 
of the thyrocytes was complete as shown by the very low 
level of HSV1-TK activity in the residual thyroid tissue 
(Table 11). 
As would be expected administration of GH to 
transgenic mice during the last 5 days of ganciclovir 
treatment did not induce a detectable level of 
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FIGURE 13. 
A)ISOELECTRIC FOCUSING GEL OF URINARY PROTEINS FOLLOWING 
GANCICLOVIR TREATMENT AND HORMONE REPLACEMENT. 
Mouse urine samples were collected before and after 
treatment. Odd number lanes, before treatment, even 
number lanes, after treatment. Mice were TG66.19 
transgenic females unless otherwise indicated. Lanes 1 to 
14 were as follows: 
1+2) PBS treated; 3+4) ganciclovir treated; 
5+6) ganciclovir and T 4 diluent treated; 7+8) ganciclovir 
and GH treated; 9+10) non-transgenic and GH treated; 
11+12) ganciclovir and T4 treated; 13+14) Non-transgenic 
and ganciclovir treated. 
Variation in the MUP pattern between individual mice is 
due to heterozygosity at the MUP locus in C57/BL x CBA 
cross. 
NORTHERN BLOT ANALYSIS ON FEMALE TG66.19 MICE. 
Northern blot analysis of total liver RNA (30jg/lane). 
Probed using Mupi 1 (Group 1 gene). Autoradiograph exposed 
for 8 hours. 
Lanes 1) PBS treated female; 2) ganciclovir treated 
female; 3) ganciclovir and T 4 treated female; 4) 
ganciclovir and GH treated female; 5) GH treated non-
transgenic female; 6) non-transgenic male; 7) ganciclovir 
treated non-transgenic female. 
EXPRESSION OF THE BS6-a2 TRANSGENE IN TG/RL MALE AND 
FEMALE MICE. 
Northern blot of total liver RNA (30jtg/lane), probed with 
a 50 mer a2u  oligonucleotide (see Material and Methods) 
autoradiograph exposed for 8 hours. Mice were TG/RL males 
and females unless otherwise indicated. 
Lanes: 1) BS6-24 male; 2) PBS treated male; 3) PBS 
treated female; 4) ganciclovir treated male; 5) 
ganciclovir treated female; 6) ganciclovir and T 4 treated 
male; 7) ganciclovir and T 4 treated female; 8) 
ganciclovir and GH treated male; 9) ganciclovir and GH 
treated female; 10) ganciclovir, T 4 and testosterone 
treated female; 11) ganciclovir and testosterone treated 
female; 12) ganciclovir treated non-transgenic male; 13) 
ganciclovir treated non-transgenic female. 
Testosterone (T) pellets (30mg) were implanted in female 
mice at the time of ganciclovir administration and 
continued for a further two weeks post ablation. Growth 
hormone (GH) was administered i.p. (100j.ig/20g body 
weight) every 12 hours during the last 5 days of 
ablation. T 4 (5p.g/20g body weight) was injected every 24 
hours over the same time period. 




PBS 	G 	G + DIL G+GH C +011 0 + T4 	C +G 
1 	23 	4 	5 	67 8 9 	10 11 	12 	13 	14 
	
— -. 	- 	- - ---. 	- - - 	- - . — - — - -w - 
= . 	- 
- dpb 4w 
B 
T4 OH C 	 C 
PBS 0 G G OH 	M 0 




PBS 	G 	G+T4 G+GH 	G 0 
C 	M F M F M F M F F F 	M F 
1 	2 	3 	4 	5 	6 	7 	8 	9 	1011 	1213 
ago 	U 	S 
ii 
TABLE t1. 
THYROID HORMONE LEVELS IN ABLATED MICE AFTER HORMONE 
REPLACEMENT. 
Pooled serum samples were analysed for T 4 and T3 using a 
competitive ELISA (Kodak Diagnostics). The average HSV1-
TK activity per gland is given in units/thyroid. Total 
protein is the total recovered from the gland. 
Growth hormone was administered i.p. (100g/20g body 
weight) every 12 hours during the last 5 days of 
ablation. T 4 (5jig/20g body weight) was injected every 24 
hours over the same time period. 
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Treatment 
& Exp. Nos 




______ Before After Before After 
Transgenic & 
PBS 	2 44.1 39.5 0.58 17.50 144 
4 57.1 34.5 - 20.40 95 
Average 50.6 37.0 0.58 18.95 220 
Transgenic & 
ganciclovir 2 29.8 0.0 - 0.03 10 
4 38.1 0.0 - 0.02 30 
Average 33.9 0.0 - 0.02 20 
2  0.95  
'rransgenic & 
ganciclovir/GH 
2 20.1 0.0 0.00 0.03 8 
4 47.3 0.0 - 0.01 3 
Average 33.7 0.0 0.00 0.02 6 
Transgenic & 
qanciclovir/T4 
2 50.1 64.2 0.33 0.04 8 
4 47.5 266.3 - 0.02 7 
Average 48.8 165.2 0.33 0.03 8 
Non-Transgenic 
& ganciclovir 
2 21.0 10.8 3.90 0.02 170 
4 55.1 41.6 - 0.01 105 
Average 1 	38.0 1 	26.2 1 __________  3.90 1 	0.02 1 	138 
0 
r.4 
circulating T4 or T3 . Again ablation of the thyrocytes was 
complete as indicated by the lack of HSV1-TK activity 
(Table 11). In contrast to T4 treatment, GH did not 
restore the urinary MUP levels (Figure 13A lanes 7 and 
8). The biological potency of the GH was assessed by 
treating a female control mouse. This resulted in a male 
pattern of MUP protein (Figure 13A lanes 9 and 10). Thus, 
replacement of GH alone, in the absence of thyroid 
hormones, did not induce MUP gene expression. 
Availability of thyroid hormones is evidently an absolute 
requirement for the expression of MUP genes. 
The level of MUP mRNA present in the liver of 
control and treated mice correlated with the levels of 
urinary MUP (Figure 13B) and demonstrate that the 
analysis of urine provides a method for assessing the 
role of hormone regulation on MUP gene expression, and 
consequently the hormonal status of the mouse. 
EFFECTS OF THYROXINE ON EXPRESSION LEVELS OF A MUP 
TRANSGENE. 
To investigate cis-acting elements which are 
involved in T4 and GH induction of MUP gene expression a 
hybrid gene was constructed. It comprised 3 fragments as 
described in the Figure legend of Figure 14. Although a2 -
globulin genes are 81% homologous to MUP genes the degree 
of dissimilarity is sufficient to allow the RNA and 
protein products of the hybrid gene to be distinguished 
from endogenous MUP mRNA and protein. 
The expression of the hybrid gene was examined in 
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FIGURE 14. 
BS6-a2 HYBRID GENE. 
A hybrid gene was constructed comprising of 3 fragments: 
a 2.75kb 5' fragment (HindIII/EcoRI) of the group 1 MUP 
gene BS6 (Clarke et al., 1984), which extends 2.2kb 
upstream of the cap site to a site in exon 2 (EcoRI). The 
region extending from the restriction site in exon 2 to 
a restriction site in exon 6 (AvaI) was replaced by the 
homologous region of the a 2 -globulin gene ct207. This was 
flanked with a 3.4kb fragment (AvaI/BamHI) which includes 
1.8kb 3' flanking sequences of the group 1 MUP gene BS6. 
A 408bp sequence was included which contained the 
bacterial gene supF to allow recovery from transgenic DNA 
(Al-Shawl et al., 1990). 
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Hindlil 	 Ecorl 	 AvaI 	 BamHI 
[CYE I 
Exon numbers: 	1 	2 	3 	4 	5 	6 
SupF 
HindIII-Ecorl 	 Ecorl-AvaI 	 AvaI-BainHI 	(408bp) 
Mup BS6 	 a2 -globulin gene Mup BS6 
5' Flanking Sequence 	 (1900bp) 	 3' Flanking Sequence 
(2750bp) 	 (3400bp) rn 
transgenic mice of both sexes. High levels of expression 
were detected in the male liver whereas in the female 
liver there was no expression of the transgene, or 
expression at a very much lower level than in the male 
(Al-Shawi et al., 1992). Thus the sexually dimorphic 
expression of the hybrid transgene is similar to that of 
the resident a2.-globulin genes in the rat (Kulkarni et 
al., 1985). 
The role of thyroid hormones in regulating the 
expression of the BS6-a 2 transgene was investigated by 
crossing mice carrying the BS6-a 2 transgene with 
transgenic mice carrying the TG-TK transgene. F 1 mice 
were designated (TG/RL). TG/RL mice of both sexes were 
treated with ganciclovir for two weeks. Some of the 
ganciclovir treated mice were exposed to T4, GH and 
testosterone as described in the legend to Table 12A and 
12B. Expression of the BS6-a2 transgene was examined by 
Northern blot analysis of total liver mRNA (Figure 13C). 
Expression of the transgene in TG/RL control mice treated 
with PBS was sexually dimorphic (Figure 13C lanes 2 and 
3) and indistinguishable from its expression in the BS6- 
a2l parental line (Al-Shawi et al., 1992). 
The expression of the transgene in male TG/RL mice 
treated with ganciclovir was abolished just as expression 
of the resident MtJP genes was abolished in ablated female 
mice (Figures 13C lane 4). The absence of circulating T 4 
and T3 was confirmed by ELISA assays (Table 12A). 
Administration of T 4 treatment during the last 5 days of 
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TABLE 12A & B. 
LEVELS OF THYROID HORMONES IN TG/RL TRANSGENIC MICE 
FOLLOWING ABLATION. 
12A experiments on male TG/RL mice 
12B experiments on female TG/RL mice 
Ganciclovir (4.5mg/day) was administered by minipump to 
TG-TK mice crossed with BS6-24 mice, (TG/RL), for two 
weeks. Serum samples were analysed for T 4 and T3 levels. 
Average HSV1-TK activity per gland is expressed in 
units/thyroid and total protein is given in pg. A 
testosterone pellet (30mg) was implanted at time of 
ganciclovir administration and continued for a further 
two weeks post ablation. Growth hormone was administered 
i.p. (100jig/20g body weight) every 12 hours during the 
last 5 days of ablation. T 4 (5ig/20g body weight) was 
injected every 24 hours over the same time period. 
G = ganciclovir; M = male; F = female; C = control; T 4 = 
thyroxine; GH = growth hormone. 
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Treatment Hormones T 4 	(niuoi./L) T 	(nmol/r,) TK Total 
Administered Activity protein 
Before Aft:er Before After (pg) 
Male TG/RLJ 
51.1 35.2 0.77 0.46 28.5 40 PBS 
40.1 16.3 30.6 150 
Average  45.6 25.8  29.6 95 
ganciclovir 58.5 1.3 0.55 0.00 0.00 21 
38.7 0.0 0.01 20 
Average  48.6 0.6  0.01 20 
ganciclovir GH 47.0 0.0 0.69 0.00 0.00 10 
44.0 0.0 0.03 30 
Average  45.5 0.0 0.02 20 
ganciclovir T4 47.8 197.3 0.78 1.53 0.00 10 
34.6 279.1 0.01 10 
Average  41.2 238.2  0.01 10 
Non- 69.7 30.2 0.65 0.45 0.00 60 
Transgenic & 53.0 17.9 0.07 110 
ganciclovir 
Average  61.4 24.0 0.04 85 
LO 
Treatment Hormones T 4 	(niuol/L) T 3 (nmol/L) TK Total 
Administered Activity protein 
Before After Before After ()Ig) 
Female TG/RL 
66.8 34.2 0.77 0.40 17.6 60 PBS 
62.9 26.6 25.5 80 









Average  50.6 0.0  0.01 12 
ganciclovir GH 55.3 2.9 0.53 0.00 0.00 2 
44.1 0.0 0.04 20 
Average  49.7 1.4 0.02 11 








Average  48.5 226.6  0.06 18 
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Average  37.3 219.8  0.02  




















Average  44.4 29.7  0.02 90 
ganciclovir treatment restored transgene expression 
(Figure 13C lane 6). In contrast addition of GH during 
the same time period did not restore transgene expression 
(Figure 13C lane 8). Ablation of the thyroid gland in 
ganciclovir treatment mice was complete as indicated by 
the low HSV1-TK activity of the thyroid rudiments excised 
from the mice (Table 12A). 
The hormonal regulation of the BS6-cx 2 transgene was 
also investigated in female mice. Administration of 
testosterone to female mice induces the expression of the 
MUP genes (Al-Shawi et al., 1992) presumably by 
masculinising the GH profile. Administration of T 4 to an 
ablated female did not induce transgene expression 
(Figure 13C lane 7). Although testosterone induces 
transgene expression in normal females (AL-Shawi et al., 
1992) testosterone alone did not induce the transgene 
expression in ablated females (Figure 13C lane 11). 
However when both testosterone and T 4 were administered 
to an ablated female expression of the transgene was 
induced even to levels above those normally found in male 
transgenic mice (Figure 13C lanes 10 and 2 respectively). 
The treatment was shown to restore the level of 
circulating T3 (Table 12B). Ablation of the thyroid gland 
was complete as indicated by the low HSV1-TK activity of 
the thyroid rudiment (Table 12B). 
The results presented above demonstrate an absolute 
requirement for thyroid hormones in the expression of 
endogenous MUP expression and in the expression of a MUP 
transgene in male and female transgenic mice. Expression 
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of the transgene in female mice requires both the 
presence of T4 and testosterone indicating that 
expression requires a "male-like" GH status. Experimental 
evidence indicates that in addition to the possible role 
of thyroid hormones in GH transcription, thyroid hormones 
may be involved in potentiating the GH receptor on the 
liver membrane (Chernausek et al., 1982, Hochberg et al., 
1990). In addition thyroid hormones may also play a role 
in the GH signal transduction pathway (Meier et al., 
1991). These last two points are discussed in further 




Until now there has been no satisfactory animal 
model which could be used to examine the effects of 
complete thyroid hormone deficiency. The genetically 
hypothyroid mouse retains circulating levels of thyroid 
hormones (10%, Stein et al., 1989) and suffers from 
secondary defects possibly due to thyroxine deficiency in 
uLero and in the early neonate, while the surgical 
removal of the thyroid gland results in the loss not only 
of the thyroxine producing cells (thyrocytes) but also of 
the parathyroid gland and the C-cells. 
The work presented in this thesis demonstrates the 
use of transgenic ablation to generate an animal model 
which completely lacks thyroid hormones. The hormone 
deficiency in this model is inducible and therefore the 
animal is permitted to develop normally prior to 
ablation. 
The results reported in Chapter 2 revealed that the 
expression of the thyroglobulin-HSV1-tk transgene was 
highly restricted to the thyroid gland in female 
transgenic mice with the site of HSV1-TK expression being 
confined to the thyroid follicle epithelial cells. In 
Chapter 3 the effects of ganciclovir treatment on the 
thyroid gland in transgenic mice are described. Treatment 
with ganciclovir at a rate of 4.5mg/day for two weeks 
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resulted in an extensive regression of the thyroid gland 
while the expression of the transgene was rapidly reduced 
to zero due to destruction of the follicle epithelial 
cells. During the second week circulating levels of T 4 
and T3 fell below the limits of detection. The 
specificity of ablation in the thyroid gland was also 
assessed. The results indicated that, in the absence of 
T4, circulating levels of parathyroid hormone and 
calcitonin were normal. This was in agreement with the 
persistence of an intact parathyroid gland and functional 
C-cells in the treated mice. 
The time course of changes in the morphology of the 
gland and in the expression of the transgene was examined 
during ganciclovir treatment (Chapter 4). The changes 
were rapid with a significant reduction in the expression 
of the transgene being observed after 1 day of drug 
treatment. The morphology of the gland also changed 
rapidly and only a few colloid-containing follicle 
structures were present 3 days after the start of 
ganciclovir treatment. 
After terminating treatment with ganciclovir the 
potential of the thyroid gland to regenerate was 
examined. After a period of four months no recovery of 
circulating T 4 , T3 or regeneration of the thyrocytes was 
observed suggesting that the thyroid gland does not 
contain a non-differentiated stem cell population capable 
of repopulating the gland. The weight gain of the ablated 
mice was slower than that of age-matched controls. 
Although the mice showed no distress, they were sluggish 
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in their movements and their fur was dishevelled in 
appearance. 
The ablation studies were carried out in adult mice 
where the thyrocyte is essentially non-dividing. 
Successful ablation of the thyroid gland therefore brings 
into question the general assumption that phosphorylated 
ganciclovir kills cells exclusively by being incorporated 
into DNA. The practical use of the thyroxine-deficient 
mouse model to examine the role of thyroid hormones in 
gene expression was examined in Chapter 5. The results 
indicated that the hepatic expression of the mouse 
urinary protein genes was dependent on the presence of 
T4 . The following section discusses further applications 
of the thyroxine deficient mouse model. 
FURTHER APPLICATION OF THE THYROXINE-DEFICIENT MOUSE 
MODEL. 
GROWTH HORMONE RECEPTORS. 
Hypothyroidism has a profound affect on growth, 
which may be mediated by one or more different primary 
effects of the hormone. In the rat, the thyroid hormones 
stimulate GH transcription. Consequently, due to the 
regulatory role of GH in IGF-I expression, growth in 
hypothyroid animals may be reduced by decreased 
production of IGF-I. Indeed levels are decreased in 
hypothyroid rats (Chernausek et al., 1982, Mathews et 
al., 1986). However, the growth-promoting effect of 
exogenously administered GH is blunted in hypothyroidism 
(Lewinson et al., 1989). This might be due to an effect 
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on the cell-surface GH receptor, but published data on 
the role of thyroid hormones in potentiating the GH 
receptor is conflicting. Chernausek e1 al., (1982) 
reported a doubling of the binding capacity in 
chronically hypothyroid male rats, whereas Hochberg et 
al., (1990) showed in mice that the binding of both Pri 
and GH was inversely correlated with the thyroid hormone 
level, but was restored by thyroid hormone replacement. 
Consistent with this, binding was increased in 
hyperthyroidism. 
Thyroid hormones may also be involved in the GH 
signal transduction pathway in the liver. Although little 
is known about the pathways activated within a cell, 
following the binding of Gil to its membrane bound 
receptor, the hepatic GH receptor is associated with 
tyrosine kinase activity suggesting that the Gil receptor 
may initiate signal transduction by tyrosine 
phosphorylation (Foster et al., 1988). It has been 
suggested that thyroid hormones stimulate phosphorylation 
and dephosphorylation of rat liver cytosolic proteins 
(Nakamura and DeGroot, 1983). In hypothyroid rats levels 
of protein kinase C are increased 7.7 fold compared to a 
euthyroid control (Meier et al., 1991). Increased protein 
kinase C levels may inhibit transmembrane signalling by 
down regulating the signals which lead to it activation. 
For example, in the case of the EGF receptor, protein 
kinase C leads to phosphorylation of the receptor causing 
a decrease in EGF-stimulated tyrosine kinase activity 
(Schiessinger, 1986). 
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The effect of thyroid hormones in the regulation of 
the GH gene can be examined in the thyroxine-deficient 
mouse model by comparing levels of GH mRNA in the 
pituitary of ablated and non-ablated mice. The effects of 
thyroid hormones on the hepatic GH receptor can be 
assessed by determining the levels of GH receptor mRNA in 
the liver of thyroxine-deficient mice, in conjunction 
with hepatic membrane GH binding studies. This will give 
information regarding the role of thyroid hormones in the 
transcription of the GH receptor gene and in potentiating 
the GH receptor on the liver cell membrane. 
RENIN GENE EXPRESSION. 
Renin is stored in secretory granules in the 
convoluted tubular cells of the mouse submaxillary gland. 
The regulation of the renin-I gene in the submaxillary 
gland is under the control of testosterone and thyroid 
hormones (Wilson et al., 1982). Renin-I is expressed at 
lower levels in the female than in the male mouse. 
However, male-like levels of expression can be induced in 
females following treatment with testosterone. Similarly, 
an increase in the expression levels are observed 
following T 4 treatment (Wilson et al., 1982). Renin-I 
levels in hypophysectomised female mice are reduced 
approximately 300-fold compared to normal females. The 
administration of either T 4 or testosterone increased 
renin-I activity 5-fold and 3-fold respectively compared 
to normal female levels, while the administration of both 
hormones induced activity approximately 40-fold. The data 
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suggests that the two hormones act synergistically and 
that each hormone on its own has an inducing effect. 
However, since the presence of low levels of residual T 4 
was not excluded, it is possible that the action of 
testosterone would have no effect in the complete absence 
of T4 The action of T 4 on renin expression has been shown 
not to be mediated through testosterone (Wilson et al., 
1982). 
The congenitally hypothyroid mouse (hyt/hyt) has low 
basal secretion of renin. Female mice show a blunted 
response to either T4 or testosterone when administered 
separately, but a synergistic increase is observed in 
both renin activity and renin mRNA when the hormones are 
present together (McGowan et al., 1988). 
It seems possible that the stimulation of renin-I 
expression by testosterone is mediated by GH. T 4 may be 
required for GH action (compare MUP expression, Chapter 
5). The thyroxine deficient mouse could be used to 
address this question. GH and testosterone could be 
administered in the presence or absence of T 4 . In 
contrast to the hyL/hyt mouse the thyroxine-deficiency is 
inducible and the mouse develops normally prior to 
ablation. 
LACTATION. 
Lactating dairy cows treated with GH show increased 
milk yields compared with untreated lactating controls. 
The mechanism for this lactopoietic response, however, 
remains to be determined. The role of an intermediate 
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hormone in mediating the response has been indicated. For 
example, it has long been recognised that thyroid 
hormones are important in maintaining lactation. GH-
treated lactating dairy cows have been shown to have a 
tissue-specific increase in the mammary gland activity of 
the 5'-monodeiodinase enzyme, which catalyses the 
conversion of the relatively inactive T 4 to the active 
form of the hormone T 3 . In contrast GH treatment did not 
alter the activity of the deiodinase enzyme in the kidney 
or liver (Capuco et al., 1989). 
The data, above, indicates that the lactopoietic 
effect of GH on the mammary gland may involve an increase 
in the rate of conversion of T 4 to T3 This hypothesis can 
be examined by using the thyroxine-deficient mouse model. 
5' monodeiodinase activity in the mammary gland and milk 
yields from lactating thyroxine deficient female mice 
could be compared to lactating thyroxine deficient 
females treated with either GH or T 4 . 
BRAIN DEVELOPMENT. 
Dietary iodine deficiency, which is common in the 
third world, results in a high incidence of 
hypothyroidism. Foetal hypothyroidism results in 
neurological damage which occurs early in pregnancy. This 
is due to the involvement of thyroid hormones in brain 
maturation. For example, hypothyroidism results in 
retardation in nerve fibre myelination, a decrease in the 
density of the axon network and reduced interactions 
between the nerves (Eayrs, 1960, Cbs et al., 1973). The 
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hypothyroid state of the neonate can be reversed at birth 
by thyroid hormone supplements or by the addition of 
iodine to the water. However the neurological defects are 
not reversible, indicating that there may be a critical 
time in utero when thyroid hormones must be present. The 
thyroxine-deficient mouse model could be used 
successfully to address this question. By treating 
pregnant thyroxine-deficient transgenic mice with 
ganciclovir it should be possible to ablate the thyroid 
glands of the transgenic embryos (the thyroid gland is 
active in the embryo from day 15 of gestation onwards: 
Kawaori and Tsuneda, 1985). Replacement of thyroid 
hormones at different times during the remainder of 
gestation could reveal the precise time at which thyroid 
hormones act during brain development. 
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MATERIALS AND METHODS. 
MICE. 
All manipulations on live animals were carried out 
according to Home Office regulations (H.A.C.W. license 
holder). 
Mice carrying the thyrogiobulin-thymidifle kinase 
transgene (TG-TK) were maintained as heterozygotes on a 
C57BL/6 x CBA/ca background. Mice carrying the rat a2 
transgene were bred on a C57BL/6 background. F 1 TG/RL 
transgenics were created by crossing a female TG-TK mouse 
with a male transgenic mouse carrying the a2 transgene. 
Transgenic mice were identified by amplification of part 
of the transgene in a crude DNA preparation by the 
polymerase chain reaction (PCR). Briefly, 1cm was removed 
from the tip of the tail under anaesthetic. The tissue 
was broken down in 2mi containing 0.3M sodium acetate; 
0.5% SDS; 0.01M Tris pH 8.0; 0.02M EDTA pH 8.0; 2mg/mi 
proteinase K, at 43 0C overnight. 2.ii of the tail sample 
was used per reaction which contained 0.2mM of each dATP, 
dCTP, dGTP and dTTP, 2 units taq polymerase, 10% buffer 
(lOOmMol/L Tris-Ci, 15mMoi/L gelatine - Boehringer), 10% 
DMSO, and 20 pMol of each primer. Primers used amplified 
part of the SupF, tk, and HPRT genes (Al-Shawi e1 al., 
1992). The DNA was denatured at 95 °C for 10 minutes, then 
30 cycles of PCR were carried out containing 2 steps in 
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each cycle: 92°C - 0.6 minutes, 65 °C - 5 minutes and 
finally 65 °C for 10 minutes at the end. TG/RL transgenic 
mice were first identified by amplifying part of the tk 
gene and then part of the a2 -globulin gene. The a2-
globulin gene was amplified by PCR at the following 
conditions: 94°C - 2.5 minutes, 50 °C - 0.5 minutes, 72°C - 
1 minute, then 35 cycles of PCR containing 3 steps in 
each cycle: 91 °C - 0.5 minutes, 50 °C - 0.5 minutes, 72 °C - 
1 minute and finally 72 °C for 10 minutes at the end. 
Primers used for amplification were supplied by Oswel DNA 
services, Department of Chemistry, Edinburgh University. 
ENZYMES AND RADIO-LABELLED NUCLEOTIDES. 
All enzymes were purchased from Boehringer and used 
with the buffers supplied unless otherwise indicated. 
Radio-labelled nucleotides were purchased from Amersham 
International. 
URINE SAMPLES. 
Samples were collected by bladder massage. The urine 
was dialysed against 0.1mM NaCl, 10mM Tris-HC1 pH 7.6 for 
24 hours at 4°C, then against distilled water for a 
further 24 hours. The samples were stored at -20 °C. 
SERUM SAMPLES. 
Blood samples were collected at the start of the 
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experiment by tail snip and massage and at the end of the 
experiment by brachial pouch bleeds. The blood samples 
were allowed to clot then microfuged at 10,000 rpm for 10 
minutes at room temperature. Serum was collected and 
stored at -20 °C. 
DRUG AND HORMONE TREATMENT. 
Female mice were implanted with Alzet osmotic 
minipumps subcutaneously for up to 7 or 14 days (models 
2001 and 2002 respectively). Ganciclovir (Syntex) was 
dissolved in phosphate buffered saline (PBS) at 8;mg/ml 
for 2001 pumps and 376mg/ml for 2002 pumps, and 
administered at a rate of 4.5 mg/day. Control mice 
received pumps containing PBS. 
L-thyroxine (sigma) was injected intraperitoneally 
every 24 hours (5g/20g body weight: Knopf et al., 1983), 
for the last five days of ganciclovir administration. T 4 
was dissolved in 3mM NaOH, 1% NaCl. Bovine growth hormone 
(bGH - gifted by the National Pituitary and Hormone Agent 
Programme, Maryland, U.S.A.) was injected 
intraperitoneally (100jig/20g) every 12 hours for the same 
time period as T4 GH was dissolved at alkaline pH in 
900il distilled H20 and lOOjil 0.02M NaOH then neutralised 
with 100d 0.5M NaPO 4 pH 7.4. 30mg testosterone pellets 




Assays were carried out in duplicate according to 
the manufactures instructions (Kodak Diagnostics). 
Total T4 : 10jil of standard or serum was added to wells 
previously coated with a donkey anti-sheep T 4 antibody. 
100jil of horseradish peroxidase T4 conjugate and 100il of 
sheep anti-T 4 was added and the mixture was incubated at 
37°C for one hour. After washing the wells the amount of 
bound conjugate was determined by an enhanced 
luminescence reaction. 
Total T3 : As above, but 25p1 of sample or standard was 
added to well coated with donkey anti-sheep T 3 and using 
lOOjil of horseradish peroxidase T 3 conjugate and 100l 
sheep anti-human T3 antibody. 
Radio-immunoassays (RIA). 
Commercial kits were used according to the 
manufacturer's instructions (Kodak Diagnostics) with the 
following modifications. Samples were assayed in 
duplicate. 
Calcitonin: 50jil of goat anti-human calcitonin antibody, 
50l of standard or serum and 50jil of iodinated synthetic 
(human) calcitonin peptide were mixed together in a round 
bottom plastic tube and incubated overnight at 4 °C. imi 
of precipitating reagent containing donkey antiserum 
against goat gamma-globin was added and the reaction was 
incubated for a further 30 minutes. The tubes were 
centrifuged for 20 minutes at >1500g and the supernatant 
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was decanted. The iodinated calcitonin in the pellet was 
counted in a gamma counter. 
Parathyroid hormone: As above but using guinea pig anti-
human (mid-molecule) antiserum, iodinated human PTH and 
goat anti-guinea pig gamma-globin antiserum. 
TISSUE PREPARATION AND THYMIDINE KINASE ASSAY. 
Tissues were homogenised in 10mM KC1, 2mM MgC1 21  
10mM Tris-Cl pH 7.5, 1mM ATP, 10mM NaF and 50mM Amino 
cuproic acid. Extracts were centrifuged at 10,000 rpm for 
10 minutes at 4 °C and the Supernatants were stored at 
-70 °C. The assay was carried out as described by Brinster 
et al, (1981) but with the following modification, 0.4mM 
TTP was added to the reaction mix to block endogenous 
thymidine kinase activity (J. Burke unpublished and Al-
Shawi et al, 1988). Samples were assayed in duplicate. 
Briefly 12.2tl of tissue extract was incubated in 72.8jl 
of reaction mix (10mM MgC1 2 , 150mM Tris-Cl pH 7.5, 10mM 
ATP, 25mM NaF, 10mM 13-mercaptoethanol and 4p.Ci tritiated 
thymidine 3H TMP: 90Ci/mMol) at 37 °C for 30 minutes and 
60 minutes. At these time points 25tl of sample was 
spotted onto DEAE-81 paper (Whatman). The discs were 
washed 3 times for 10 minutes each in 10mM Tris-Cl pH 
8.0. After being dried under vacuum the 3H TTP on the 
discs was quantified by scintillation counting. Protein 
concentrations in the tissue extracts were determined by 
the Bradford method (Bradford, 1976). 
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PROTEIN ANALYSIS. 
Western blot analysis. 
The tissues were homogenised in the same buffer as 
described for the thymidine kinase assay but with the 
addition of a proteinase inhibitor, lOmN Para-
hydroxymercuribenzoate (Sigma). Protein concentration in 
the tissue extracts were determined by the Bradford 
method (Bradford, 1976). Tissue extracts were run on a 
17cm x 14cm x 0.75mm, 12% bis-polyacrylamide laemmli 
discontinuous gel (Laemmli, 1970), with a 3cm, 4% 
stacking gel in 0.5M Tris-Ci pH 6.8 and a 14cm resolving 
gel of 12% polacrylamide, 1.5M Tris-Cl pH 8.8. Samples 
were prepared by adding an equal volume of sample buffer 
(0.15M Tris-Ci pH 8.8, 0.2% (w/v) SDS, 10% (v/v) 
glycerol, 5% (v/v) 2-mercaptoethanol, 0.001% (w/v) 
bromophenol blue) and heating at 95 °C for 4 minutes. The 
gel was run for 16 hours at lOmA constant current. The 
proteins were transferred onto nitrocellulose by the 
semi-dry blotting method (Khyse-Andersen 1984), using a 
home made electroblotting apparatus, for 1.5 hours at 
4°C. Buffers used were as follows: Anode 1 - 0.3M Tris, 
20% methanol, pH 10.4; Anode 2 - 25mM Tris, 20% methanol, 
pH 10.4; Cathode - 25mM Tris, 20% methanol, 40mM hexanoic 
acid, pH 9.4. The gel was stained with coomassie blue to 
check that the proteins had been transfer. 
The nitrocellulose membrane was challenged with a 
1:250 dilution of rabbit HSV1-TK antiserum overnight at 
room temperature (a gift of Dr W. Summers), 1:400 
dilution biotinylated anti-rabbit Ig (3 hours at room 
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temperature:. Amersham) and a 1:1000 dilution strepavidin 
alkaline phosphatase (1 hour room temperature: Amersham). 
After each antibody incubation, the filter was washed (2 
x 15 minutes) in phosphate buffered saline and 0.1% 
tween20 . The immunoreactive product was detected by Nitro 
blue tetrazolium (sigma)! Bromo-chloro-indolyl phosphate 
(Boehringer) substrate (Leary et al., 1983). All antibody 
dilutions were carried out in "Blotto" (5% "marvel" in 
Phosphate buffered saline - Johnston et al.,1984). 
Isoelectric focusing gel. 
Agarose IEF gels were cast according to the 
ampholine manufacturer's instructions (Pharmacia). The 
gel comprised 1% IEF agarose, 12% sorbitol and 6% 
ampholines of which 86% were 4.2-4.9 and 14% were 3.5-
5.0. The cathode and anode buffers were 1M NaOH and 0.05M 
H2SO4 respectively. 20l urine samples were focused for 
1.5 hours with limited voltage (1 500V). The gel was fixed 
in 5% sulphosalicylic acid, 10% trichloroacetic acid for 
30 minutes and stained in coomassie blue (0.2% (w!v) 
coomassie brillant blue R-250; 50% methanol; 10% acetic 
acid). The gel was destained in 25% ethanol; 8% acetic 
acid and dryed. 
HISTOLOGY. 
Thyroid glands were fixed in Bouins (Sigma) for 24 
hours then dehydrated in 70%, 90%, and 95% ethanol for 
one hour each. Then 100% ethanol for 2 hours and xylene 
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for a further hour. The gland was embedded in fibrowax 
(BDH). 5jim sections were cut, fixed, dewaxed and stained 
with haematoxylin and 1% Eosin (BDH). (haematoxylin:-
0.2% (w/v) haematoxylin, 0.02% (w/v) sodium iodate, 5% 
(w/v) potassium alum, 2.1% (v/v) acetic acid, 0.5% (v/v) 
ethanol). 
Adipose tissue. 
Thyroid glands were removed from the mouse and 
immediately frozen in O.C.T. compound in an isopropanol 
dry ice bath. o-pm sections were cut and fixed in 4% 
formaldehyde for 2 minutes. Sections were rinsed in 70% 
ethanol and stained in sudan black B stain (saturated in 
70% ethanol) for 30 minutes. The sections were then 
rinsed in 70% ethanol and then water prior to being 
mounted in glycerol. 
IMMUNOCYTOCHEMI STRY. 
Calcitonin. 
Thyroid glands were fixed in 1% formalin, 0.65% 
(w/v) Na2HPO4 , and 0.4% (w/v) NaH2PO4 for 24 hours. The 
glands were embedded as above. 3m sections were cut, 
fixed and dewaxed. Endogenous peroxidase activity was 
blocked with 3% (v/v) H 202 and 97% (v/v) methanol for 30 
minutes. Sections were washed in distilled water then 
trypsinised for 30 minutes at 37 °C (trypsin 0.1% (w/v) in 
CaC1 2 (0.1% w/v) pH 7.8). Sections were rinsed in water 
then 0.05M Tris buffered saline pH 7.6 (TBS:- 0.05M Tris-
Cl, 0.15M NaCl) and incubated with 1:5 normal swine 
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serum, diluted in TBS, for 10 minutes. 1:500 calcitonin 
antibody (Dako), diluted in 1:5 swine serum, was added 
and incubated for 30 minutes. The sections were rinsed 
twice in TBS. 1:500 dilution of biotinylated anti-rabbit 
Ig antibody diluted in 1:5 swine serum (Dako) was 
incubated for a further 30 minutes. After washing in TBS 
the sections were incubated with an avidin-biotin complex 
for 30 minutes (made according to the manufacturer's 
instructions - Dako). The sections were developed with 
Diaminobenzidine (DAB - 2.5mg DAB (Sigma) dissolved in 
5m1 of 0. 05M Tris, 0.03M HC1, 0.07% imidazole (w/v,Sigma) 
pH 7.6, and 0.02% (v/v) H202 ). The sections were counter 
stained in haematoxylin. 
Thymidine kinase. 
Thyroid glands were fixed in Bouins solution for 24 
hours then embedded in fibrowax as above. 3jim sections 
were cut, fixed and dewaxed and the sections were treated 
with H 202 as above, then 1mM EDTA, 0.05% tween20 in 
phosphate buffered saline (PBS) for 10 minutes. Sections 
were washed in 2% egg albumin in PBS for 30 minutes and 
incubated with 1:1000 rabbit anti-HSV1-TK serum, diluted 
in 1% BSA/PBS, over night at 4 °C. After washing the 
sections twice in TBS (see above) for 10 minutes each, 
the sections were incubated for 1 hour with a secondary 
antibody:- 1:50 swine anti-rabbit Ig biotinylated (Dako). 
Again the sections were washed in TBS twice, for 15 
minutes each, followed by a further incubation of 30 
minutes with the avidin biotin complex (Dako). Sections 
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were developed using DAB (see above) and counter stained 
in haematoxylin. 
Cell division. 
Thyroid glands were fixed in Bouins solution for 24 
hours then embedded in fibrowax as above. 3im sections 
were cut, fixed and dewaxed and the sections were treated 
with H202 as above. Sections were washed in 2% egg albumin 
in PBS for 30 minutes and incubated with 1:80 dilution of 
the proliferating cell nuclear antigen (Boehringer) 
overnight at 4°C. Dilution was in 0.1% BSA/PBS. Sections 
were then washed in 2% egg albumin in PBS for 30 minutes. 
1:900 anti-mouse Ig horseradish peroxide labelled 
secondary antibody (diluted in 0.5% BSA/PBS) was 
incubated for 90 minutes at room temperature. Again the 
sections were washed in 2% egg albumin for 30 minutes 
then washed in TBS for 10 minutes. Sections were 
developed using DAB (see above) and counter stained in 
haematoxylin. 
RNA PREPARATION AND NORTHERN BLOTTING. 
Total cellular RNA from livers was prepared by the 
method of Chirgwin et al., (1979). Briefly, approximately 
1 gram of liver was homogenised in 4mls of 4M guanidinium 
thiocyanate, 25mM sodium citrate pH 7.0, 0.5% (w/v) 
sarkosyl, 0.33% (v/v) sigma antifoam A. The pH of the 
solution was adjusted to 7.0 and 0.32% (v/v) of 13-
mercaptoethanol was added prior to homogenisation. The 
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RNA was purified by centrifugation through a 1.2m1 CsC1 
cushion (5.7M CsCl, 25mM NaAc) using a SW50 rotor 36,000 
rpm, 20°C for 12 hours. The RNA pellet was resuspended in 
imi of 7.5M guanidine hydrochloride pH 7.0, 25mM sodium 
citrate, 125mM DTT. The RNA was precipitated by adding 
25jil of iN acetic acid and 0.5ml ethanol and incubated at 
-20 °C overnight. After centrifuging, in a HB4 rotor at 
10,000 rpm 4°C for 30 minutes, the RNA pellet was 
resuspended in imi dH20 and precipitated at -20 °C with the 
addition of 1/10th  volume 2M NaAc pH 5.0. and 3 volumes 
of ethanol. Following centrifugation for 30 minutes (see 
above) the RNA pellet was resuspended in dH 20. 
Thyroid RNA was prepared using the RNazol method of 
Chomczynski and Sacchi, (1987). Stock solution was made 
containing 1 volume solution A (0.72% (v/v) of 13-
mercaptoethanol was added prior to use); 1/10th volume 
solution B; 1 volume water saturated phenol. Solution A:-
47.28% (w/v) guanidium thiocyanate, 25mM sodium citrate 
pH 7.0, 1% (w/v) sarcosyl. Solution B:- 2M Na Acetate pH 
4.0. The tissue was homogenised in lml of stock solution, 
100p.1 of chloroform was added and the sample was shaken 
vigorously for 15 seconds before being left on ice for 15 
minutes. After being microfuged for 15 minutes at 4 °C the 
aqueous phase was transferred to a clean tube. The RNA 
was precipitated with an equal volume of isopropanol for 
45 minutes at -20 °C. The RNA pellet was washed twice with 
75% ethanol and finally dissolved in dH 20. 
RNA samples were run in a gel containing 1.8% 
agarose, 6% formaldehyde, 10mM sodium phosphate buffer pH 
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7.0. Prior to being loaded onto the gel RNA samples were 
denatured at 60 °C for 5 minutes in 24% formamide, 6.3% 
formaldehyde, 10mM sodium phosphate buffer pH 7.0. The 
gel was run at 30V for 24 hours. The RNA was transferred 
to Hybond-N (Amersham) by capillary blotting and 
covalently bound by U.V. cross-linking as in the 
maufacturer' s instructions. 
LABELLING OF PROBES. 
A 714bp group I MUP gene cDNA, MUP 11, was isolated 
from pUC by EcoRI and BamHI digests (A. Chave-Cox, 1986). 
30ng of the DNA was labelled as described by Feinberg and 
Vogelstein (1983). Briefly the DNA was made up to 12l 
with water and boiled for 3 minutes to denature the DNA. 
This was added to 6il of OLB, 1.2il of lOmg/ml BSA 
(enzyme grade), 4il (40jiCi) of cx-32P dCTP (> 3000Ci/mMol) 
and lpl  of kienow (1 unit). The reaction was incubated 
overnight at 25 °C. 
OLB; 2:5:3 mixture of A:B:C. A) 625j.il 2M Tris-Cl pH 8.0, 
25.tl 5MMgC1 2 , 350l H20 1  181l 13-mercaptoethanol, 53.Ll each 
of dATP, dTTP, dGTP (0.1M in 3mM Tris-Ci, 0.2mM EDTA pH 
7.0). B) 2M HEPES pH 6.6. C) HexadeoxyribonucleOtides 
(Pharmacia) 900D units/ml in 3mM Tris HC1, 0.2mM EDTA pH 
7.0. 
30ng of an a 2 -globulin specific oligonucleotide (5'-
CAAATATAGTTCCCTGCACTCTCCATTTTCCTTAATACGGAACTTGAAGC 3 1 ) 
was end labelled (Maxam and Gilbert, 1980) in 25j.l using 
80tCi of gamma 32P dATP (>5000Ci/mMol), 5 units of T 4 
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polynucleotide kinase and 2.5jl of buffer (10mM MgC1 21  
50mM Tris-Ci pH 7.6). The reaction was incubated at 37 °C 
for 10 minutes then terminated by the addition of 1/5th 
volume 0.2M EDTA. 
Unincorporated nucleotides were removed using a NAP-
5 column (Pharmacia). The number of radioactive 
nucleotides incorporated was estimated by quantifying the 
activity in 1jl of probe by counting Cherenkov counts in 
a scintillation counter. Routinely > 10 8 counts/fig were 
obtained. 
HYBRIDISATION AND WASHING OF FILTERS. 
Hybridisations and washes with MUP11 were carried 
out largely as described by Church and Gilbert, (1984). 
Filters were prehybridised in 0.5M NaHPO 4 pH 7.2, 7% SDS, 
2mM EDTA (68 °C 1 hour) and hybridised in the same 
solution plus labelled, denatured probe at 68 °C 
overnight. The filters were washed in 40mM NaHPO 4, 5% 
SDS, 1mM EDTA (68 °C, 2 x 10 minutes) and 40mM NaHP0 41  1% 
SDS, 1mM EDTA (68 °C, 2 x 20 minutes). The filters were 
exposed to X-ray film at -70 °C for the times indicated in 
the figure legends. 
Pre-hybridisation and hybridisation using the 
oligonucleotide was as above but the procedure was 
carried out at 60 °C 
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SUB-CLONING. 
2.5ig of pTG-TK was digested with MscI and Ec0RV 
(New England Biolabs & Boeringer respectively). A 312bp 
fragment was isolated by gel electrophoresis in a 5% 
acrylamide gel. The fragment was eluted from the gel 
slice in 100.il buffer (0.5M ammonium acetate, 10mM 
magnesium acetate, 1mM EDTA (pH 8.0) and 1% SDS at 37 °C 
for 2 hours. Following a phenol /chloroform extraction the 
DNA was precipitated with ethanol. 
Ligations were carried out at room temperature for 
2 hours in 20p1 containing >0.5 pmol/ml of pBluescript II 
sk' (Stratagene LTD) cut with Ec0RV and >1 pmol/ml of 
fragment. Ligation buffer was 66mM Tris pH 7.6, 6.6mM 
MgCl 2 , 10mM DTT, 0.5mM ATP. The ligation mix was used to 
transform competent E.Coli HB101 (Bolivar and Backman, 
1979). Transformants were selected by ampicillin 
resistance. Orientation and copy number of the insert was 
determined by enzyme digests of DNA mini-preparations 
(lysis was carried out by boiling - Sambrook et al, 
1989). 
Large scale plasmid DNA preparations were prepared 
as follows: 25m1s of an overnight culture containing the 
plasmid was used to innoculate 250m1s of L-Broth and 
ampicillin (100)ig/ml) and incubated overnight at 37 °C. 
The culture was centrifuged at 10,000 rpm for 30 minutes 
at 4°C. The pellet was resuspended in 20m1 of 10mM Tris-
Cl, 1mM EDTA pH 7.0 and centrifuged at 10,000 rpm for 3 
minutes. The pellet was resuspended in 4m1 of sucrose mix 
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(25% sucrose, 50mM Tris-Ci pH 8.1, 40mM EDTA pH 8.1) and 
1.2 ml of 10mg/mi lysozyme in sucrose mix. Following 
incubation on ice for 15 minutes 1.2mi of 0.5M EDTA pH 
8.1 was added and incubation continued for a further 5 
minutes. 10.8m1 of triton mix (0.2% triton, 125mM EDTA pH 
8.1, 0.1M Tris-Ci pH 8.1) was added. Genomic DNA was 
removed by centrifugation at 20,000 rpm for 60 minutes. 
To 18m1 of supernatant 17.1g of CsC1 and 1.8m1 of EtBr 
(10mg/mi) was added. The plasmid DNA was banded by 
centrifuging in an A50 rotor at 35,000 rpm for 72 hours 
at 25°C. The plasmid band was withdrawn with a syringe 
and needle and washed with isopropanol saturated with 
water and caesium chloride to remove the EtBr. Following 
dialysis overnight at 4 °C against 10mM Tris-Cl pH 8.0 the 
plasmid DNA was precipitated with 2 volumes of ethanol. 
IN VITRO TRANSCRIPTION OF RNA. 
Purified plasmid (above) was linearised with a 
HindIII digestion. The in vitro transcription reaction 
was in 100p1 containing 40mM Tris pH 7.5, 6mM MgCl 2 20mM 
DTT, 2mM spermidine, 10mM NaCl, lOOu RNase, 2.5mM each of 
ATP, GTP, CTP and UTP, 2.5jtg linearised plasmid DNA and 
50u T3 RNA polymerase (Promega). This was incubated at 
37 °C for 1 hour. The DNA template was removed by 
digestion with RNase free DNase (1u/g DNA - Promega) at 
37°C for 15 minutes. Following a phenol/chloroform 
extraction the RNA was precipitated with 2 volumes of 
ethanol. The yield of RNA was estimated by running a 
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sample against DNA of known concentration on a 1 .8% Tris-
acetate gel. 
PRIMER EXTENSION. 
Analysis of the transgene transcription start site 
was carried out using a modification of the method of 
Ghosh et al., (1980). A 20mer oligonucleotide, 
complementary to +438 to +419 of the HSV1-tk gene was 5' 
end-labelled (Maxam and Gilbert, 1980) using gamma- 32p 
dATP (>5000Ci/mMol). The RNA was mapped as follows:- in 
viLro transcribed RNA (described above - lOpg, lpg, 0.2pg 
mixed with 4jig carrier RNA) or thyroid RNA from either 
control (5j.tg) or transgenic (5)ig or 1g) male mice. The 
RNA and the oligonucleotide were annealed in lOpl, with 
0.2ng of end-labelled primer and 2p.1 of 5x hybridisation 
buffer (0.2M PIPES pH 6.5, 2M NaCl, 5mM EDTA pH 8.0 and 
80% formamide). Samples were denatured at 90 °C for 5 
minutes and incubated at 42 °C over-night. The 
oligonucleotide was extended with the addition of 901il 
buffer per tube (50mM Tris-Cl pH 8.2, 10mM DTT, 6mM 
MgC1 21  2.0% Actinomycin D, 0.5mM each of dCTP, dGTP, 
dTTP, dUTP and 50u reverse transcriptase), at 42°C for 60 
minutes. Following a phenol/chloroform extracted the 
extention product was ethanol precipitated. After the 
samples were microfuged for 20 minutes at 10,000 rpm the 
pellet was dissolved in 3jil sequencing gel loading buffer 
(United states Biochemical corporation) and denatured at 
90°C for 4 minutes prior to being electrophoresed in a 5% 
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acrylamide-7M urea 1 x TBE gel. The gel was fixed in 10% 
methanol, 10% acetic acid for 30 minutes and vacumn 
dried. The gel was exposed to X-ray film at -70 °C for the 
time indicated in the figure legend. 
Sequencing of the M13mp18 was carried out using 
"Sequenase" according to the manufacturers instructions 
(United States Biochemicals). Briefly the annealing 
reaction used lp.g DNA, made up to 71.tl with water, 2l of 
sequencing buffer and lj.il primer. This was incubated at 
65°C for 2 minutes, then allowed to cool to 35°C. To the 
annealed DNA mix ijil 0.1M DTT, 21 diluted labelling mix 
(1:5). 0.5jl [ 35S]dATP and 2p.l diluted sequenase (1:8) 
were added and incubated at room temperature for 5 
minutes. 3.5jil of each reaction was transferred to a 
termination tube (ddGTP, ddCTP, ddATP, ddTTP), mixed and 
left to incubate for a further 5 minutes at 37 °C. The 
reaction was stopped by the addition of 4pl of stop 
solution, the samples were heated to 75 °C for 2 minutes 
prior to being loaded on a gel as above. 
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ABBREVIATIONS USED IN TEXT. 
ATP adenosine 5' triphosphate 
BCIP 5-bromo- 4-chloro-3- indolylphosphate 
bGH bovine growth hormone 
bisacrylamide N, N,-methlene bis acrylamide 
C cytidine 
cAMP cyclic adenosine (3' 	-5') monophosphate 
CBA/ca inbred strain of mice 
cDNA complementary deoxyribonucleic acid 
C/EBP transcription 	factor: 	CAAT/enhancer 
binding protein 
C-erb thyroid hormone receptor oncogene 
CRE cAMP response element 
CREB cAMP response element binding protein 
CT calcitonin 
C57BL/6 inbred strain of mice 
dATP deoxyadenosine triphosphate 
dCTP deoxycytosine triphosphate 
ddATP dideoxyadenosine triphosphate 
ddCTP dideoxycytosine triphosphate 
ddGTP dideoxyguanosine triphosphate 
ddTTP dideoxythymidine triphosphate 
DEAE diethylaminoethyl 
dGTP deoxyguanosine triphosphate 
dH20 distilled water 
DIT diiodotyrosine 
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DNA deoxyribonucleic acid 
DNase deoxyribonuclease 
DT-A diphtheria toxin A subunit 
DTT dithiothreotol 
dTTP deoxythymidine triphosphate 
dUTP deoxyuridine triphosphate 
EDTA diaminoethanetetra-acetic acid 
EGF epidermal growth factor 
ERE oestogen response element 
ES embryonic stem 
EtBr ethidium bromide 
FIAU (1,_(2-deoxy--2-fluOrO -13 - 6 - 
arabinofuranosyl) -5-iodouracil 





GH growth hormone 
GRE glucocorticoid response element 
GRF growth hormone releasing factor 
Hepes N-2-HydroxyethylPiperaZine-N'-2 - 
ethane-sulphonic acid 
HPRT hypoxanthine phosphoribosyl transferase 
HRE hormone response element 
hsp heat shock protein 
HSV herpes simplex virus 
H202 hydrogen peroxide 
IEF isoelectic focusing 
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IGF-I insulin-like growth factor I 
IGF ii insulin-like growth factor II 
1P3 inositol tris-phosphate 
Jun nuclear protooncogene 
kb kilobase pair 
kDa kilodalton 
kienow large fragment Mr 68,000 of E. Coil DNA 
polynierase I 
MHC myosin heavy chain 
MIT monoiodotyrosine 
mRNA messenger RNA 
MUP major urinary protein 
NaF sodium fluoride 
NBT nitroblue tetrazolium 
nGRE negative glucocorticoid response element 
page polyacrylamide gel electrophoresis 
PBS phosphate buffered saline 
pH -log [H+] 
PIP2 phosphatidyl inositol 4,5,-biphosphate 
PIPES piperazine_N,N'-bis[2-ethane5U 1 f 0niC 
acid] 
Pit-i /GHF-1 pituitary specific trans-acting factor 
PKA protein kinase A 
PKC protein kinase C 
PRE progesterone response element 
PRL prolactin 
PTH parathyroid hormone 
RNA ribonucleic acid 
RNase ribonuclease 
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RNASIN ribonuclease inhibitor 
rpm revolutions per minute 
SDS sodium dodecyl sulphate 
si specific nuclear binding protein I 
SV40 simian virus 40 
TBE Tris-borate, EDTA buffer pH 8.3 
TBS Tris buffered saline 
Temed N,N,N' ,N'-tetremethylethyleflediamifle 
Tg thyroglobulin gene 
TK thymidine kinase 
TMP thymidine monophosphate 
TRE thyroid hormone response element 
TRH thyrotrophin releasing hormone 
Tris tris- (hydroxymethyl) -aminomethane 
TSH thyroid stimulating hormone 
TTF-I thyroid specific trans-acting factor 
TTP thymidine triphosphate 
T4 thyroxine 
T3 3, 5, 3 ' -triiodothyronine 
rT3 reverse T3 
V volts 
v/v 	 volume per volume 
u.v 	 ultra-violet 
vol. 	 volume 
w/v 	 weight per volume 
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The Herpes Simplex Virus Type 1 Thymidine Kinase Is Expressed 
in the Testes of Transgenic Mice under the Control of a 
Cryptic Promoter 
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We reported previously that the herpes simplex virus type I (HSV-I) thymidine kinase reporter gene (1k) was 
expressed in the testes of transgenic mice when coupled to the promoter of a liver-specific mouse major urinary 
protein (MUP) gene. Here we show that HSV.I tk is also expressed in the testis when coupled to a MU!' 
pseudogene promoter, to a truncated MUP promoter that is not active in the liver, and to the promoter of the 
bovine thyroglohulin gene. Furthermore. HSV-1 1k itself was expressed in the testis, although its normal 
expression had been disabled by removing an upstream regulator of transcription. In every case, the same 
multiple transcripts were observed, with their 5' ends located downstream of the normal I-ISV-I 1k translation 
initiation codon. We conclude that the transcription of HSV-1 tk in the testis is directed by a cryptic TATA 
box-independent promoter located in the coding region of the gene. The longest I-ISV-I thymidine kinase (TK) 
polypeptides synthesized in the testis were shorter than full-length TK and probably result from translational 
initiation at Met"' and Met", the second and third ATG codons of the 1k reading frame. Male mice of most 
transgenic lines were sterile, and the severity of the lesion in spermatogenesis was directly related to the level 
of TK expression. In the most highly expressing lines, sperm counts were low and morphologically defective 
sperm were common. In other sterile lines. TK was expressed at a lower level and sperm counts were normal 
but sperm motility was greatly reduced. Lines with the lowest levels of HSV-I TK expression were fertile. 
HSV-I TK was expressed in germ line cells, mainly in the haploid spermatids. However, low-level HSV-I TK 
activity was found in the testis before the first germ cells entered meiosis, showing that if expression is confined 
to the germ cells, it also occurs in spermatogonia. 
The coding region of the herpes simplex type 1 (HSV-1) 
virus thymidine kinase gene (tk) has been used extensively 
as a reporter sequence in cell transfection (30. 4) and was 
one of the first reporters used in work with transgenic 
animals (8, 43. 44). More recently it was adopted as a 
component of a system for destroying (ablating) specific cell 
types in transgenic animals (4, 5. 22). The basis of the 
procedure is to place HSV-1 tk under the control of a 
tissue-specific promoter and introduce the compound gene 
into the mouse genome. HSV-1 thymidine kinase (TK) is 
expressed in target tissues when the promoter becomes 
active. At this time, target cells may be killed by adminis-
tering an antiherpetic agent to the transgenic mouse. Several 
potentially useful antiherpetic agents are available, the most 
effective of which seems to be Ganciclovir (9-[1.3-dihy-
droxy2propoxy(methyl)]-guanine EDHP(;). The agent is 
phosphorylated quite efficiently by HSV-1 TK, and the 
phosphorylated DHPG derivatives are lethal to the cell. 
DHPG is phosphorylated very inefficiently by cellular nucle-
oside kinases, and this explains its lack of toxic effects on 
nonexpressing tissues and nontransgenic animals. 
In addition to an agent which is nontoxic to nonexpressing 
cells, the ideal ablation system would employ an enzyme 
which has no deleterious effect in the absence of the agent. 
The apparent lack of deleterious effects of HSV-1 TK (4) is 
* Corresponding author.  
quite surprising in view of its nonphysiological mode of 
action: unlike the major cellular enzyme. it phosphorylates 
cytidine as well as thymidine (11. 26). and it also phospho-
rylates pyrimidine nucleotides (10. 41). We reported previ-
ously that in combination with a mouse major urinary 
protein (MUP) gene promoter sequence. HSV-1 tA was 
expressed in the testis and caused male sterility (1). We have 
now coupled HSV-1 iA to other promoters and find that it is 
invariably expressed in the testis. The severity of the defect 
in spermatogenesis correlates positively with the level of TK 
expression. 
MATERIALS AND METHODS 
Plasmid constructs and transgenic mice. The different hy-
brid genes with animal promoters and the HSV-1 tA coding 
region are described elsewhere (1. 2. 44a. 44h). All contain 
the same 1.759-bp fragment of HSV-1 tA between a BglII site 
in the 5 noncoding region and a BstElI site 430 hp down-
stream of the polyadenylation signal (Fig. 1). The BglIl site 
was joined to each cellular promoter at a site in the 5' 
noncoding region of the transcription unit and in each case 
the bacterial supF gene was attached beyond the BstEll site 
as described previously (1). The 1,887-bp EcoRI-BstEII 
fragment of HSV-1 tA (Fig. 1) was excised from plasmid 
pTK1 (46). DNA fragments for microinjedtion were prepared 
as described. Transgenic mice were identified by polymerase 
chain reaction of tail-cut DNA. 
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FIG. 1. (A) Diagram of the HSV-1 ik gene. DS1 and DS2 are the transcriptional control regions (38): M'. M 46 . and M60 are the first three 
ATG codons of the reading frame. The testis transcription initiation sites (TESTIS SITES) are described in the text. The fragment used as 
a reporter sequence with cellular promoters was always the same BgIIl-to-BsiEll fragment, with the promoter attached at the BgIIl site and 
the bacterial supF gene at the BstElI site. Both sites were eliminated during construction. (13) The MUP BS6-tk-.supF gene. The reporter 
sequence is attached to the HSV ik gene at the BglIl site, which was first blunted with DNA polymerase 1. P1 and P2 are polylinkers at the 
junctions with plasmid vector DNA. 
RNA analysis. Testis RNA was prepared and Northern 
(RNA) blot analysis was performed as described previously 
(1). The probes used were (i) pTK1. which could react with 
up to 1,256 nucleotides of full-length transcript (BglIJ site to 
polyadenylation site), (ii) probe A (Fig. 1). an 841-hp Psil 
fragment of pTK1. and (iii) probe B. RNA transcribed from 
a 419-hp EcoRl-EoRV fragment of HSV-1 1k ( - 80 to +339) 
cloned in pT7-2 (U.S. Biochemicals). Primer extension anal-
ysis was carried out as described previously (16). using as 
primer a 5'-end-labelled (32) 23-nucleotide oligonucleotide 
complementary to the region from 4-369 to +347 of HSV-1 
1k. RNase protection assays were carried out as described 
previously (28) with use of probe C (Fig. 1). RNA tran-
scribed from a 450-hp Asp700I-EuoRV fragment of BS6-tk-
.ciipF(-142 to +348) cloned in pBluescript II SK+ (Strata-
gene Ltd.). Approximately S x 105 dpm of antisense probe 
was hybridized overnight at 45°C with 5 l.Lg of total testis 
RNA. Digestion was with 40 p.g of RNase A and 650 U of 
RNase T 1 per ml for 30 min at 37°C. 
Protein and enzyme analysis. Tissue extracts were pre-
pared and HSV TK assays were performed as described 
previously (1). Where indicated, the protease inhibitors 
3.4-dichioroisocumarin (DCI) or tosyl phenyl chioroketone 
(TPC) and p-hydroxymercurihenzoate (PHMB( were added 
at the time of homogenization. Sodium dodecyl sulfate-
polyacrylamide gel electrophoresis was carried out with 12% 
separating and 4% stacking gels. Proteins were transferred to 
nitrocellulose (0.2-p.m pore size: Schleicher & Schuell(. and 
Western immunoblots were carried out as described previ-
ously (27), using a 1/250 dilution of rabbit anti-HSV-1 TK 
serum (provided by W. P. Summers) as the primary antibody 
and hiotinylated goat anti-rabbit imniunoglohulin G (Amer-
sham) as the secondary antibody. Filters were treated with 
streptavidin-alkaline phosphatase conjugate (1/1tXlO dilution: 
Amersham) for 45 min at room temperature and developed  
with 7 mM 5-bromo-4-chloro-3-indolyl phosphate and 6 mM 
nitroblue tetrazolium in 0.1 M Tris-HCI, pH 9.5. at room 
temperature for about 20 mm. 
Immunostaining of testis sections. Deeply anesthetized 
mice were perfused with 2% paraformaldehyde, and tissues 
were postfixed with modified Bouin fixative, dehydrated in 
graded alcohols, and embedded in paraffin wax. Dewaxed 
4-p.m sections were treated with 1% H2O, in methanol to 
block endogenous peroxidase. treated with 1 mM EDTA-
0.05% Tween 20 in phosphate-buffered saline for 10 mm, 
flooded with 2% egg albumen, and incubated overnight at 
4°C after addition of rabbit anti-H SV-1 TK serum. Peroxi-
dase-conjugated goat anti-rabbit immunoglobulin G was 
added for 90 mm, and slides were developed with 3.3'-
diaminohe nzidine. 
RESULTS 
Expression of [ISV-I 1k in the testis in conjunction with 
active and inactive tissue-specific promoters. We previously 
described a construct (BS6-tk-.supf) in which the expression 
of HSV-1 tk was directed by a MUP gene promoter (1). This 
gene was expressed consistently in the livers and preputial 
glands of transgenic mice (four of five transgenic lines in 
each case). It was also expressed very consistently in the 
testis (five of five transgenic lines), and males of all five 
transgenic lines were sterile. We next made a comparative 
study of a number of other constructs in which the same 
HSV-1 tk reporter sequence was coupled to different pro-
moters (Fig. 1). Two of these contained defective MUP 
promoters: BS2-tk-,supF contained a fragment of a MUP 
pseudogene homologous to the BS6 promoter. and 
13S6Sau2-tk-supF contained only the proximal part (to nu-
cleotide —314) of the BS6 promoter. Another, TG-rk-ctpF. 
contained a 3.05-kb promoter fragment of the bovine thyro- 
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TABLE 1. Expression of HSV-1 TK in tissues of lines of transgenic mice carrying constructs with different 
promoters linked to the HSV-1 ik reporter 
TK activity (pmol/minlmg of protein) 
Construct Fertility" Ill,  Testis Liver Preputial gland 
Mean m SE' Ranges Mean = SE Range Mean ± SE Range 
BS6-tk-supF S 5 84.0 ± 20.7 31-140 4.39 ± 2.04 0.05-12.7 27.4 ± 13.3 0.04-83 
BS6-tk-.supF (TR) 5 4 195 ± 40.8 68-286 5.86 ± 3.68 0.62-18.5 70.9 ± 37.6 14.4-200 
F 2 2.52 1.77-3.26 
B52-ik-supF S 3 60.7 ± 9.2 47-83 0.47 ± .005 0.46-0.48 0.01 ± 0.01 0.0-43.04 
BS6Swi2-tk-supF S 6 60.6 ± 10.9 17.4-91 0.09 ± 0.03 0.014.16 166 ± 1.29 0.0-7.8 
F 1 2.0 0.06 1.53 
TG-tk-supF S 3 54.5 ± 9.0 40.4-73.3 0.01" 0.35 
S. sterile males; F. fertile males. 
Number of transgenic lines studied. 
Mean of line means. 
"Range of line means. 
Mean of two lines. Values typically observed in extracts from nontransgenic mice are shown in Table 3 
globulin (TG) gene (13). BS6-1k-supF (TR) contains two 
copies of 13S6-ik-supF, each lacking a short 5' region and 
separated by a 500-hp fragment of mouse DNA, which were 
integrated at a single chromosomal site in a line of transgenic 
mice (2, 27a). The complete tandem dimer together with 
flanking DNA sequences was recovered from two bacterio-
phage lambda clones and reintroduced into the mouse ge-
nome (2). These constructs displayed different patterns of 
tissue-specific expression (Table 1). In addition. TG-tk-SupF 
was expressed in the thyroid gland (44a). 
Expression in the testis was remarkably consistent: the 
male offspring of every transgenic G 1 , female expressed 
HSV-1 fK in the testis. Furthermore, most of the lines were 
male sterile, and sterility was invariably associated with a 
higher level of expression in the testis. Altogether. 21 
transgenic lines representing five constructs expressed 
HSV-1 TK at a high level and were male sterile, while three 
transgenic lines expressed the enzyme at a low level and 
were fertile. When the expression of each construct wa 
averaged over all transgenic lines for which data were 
available, the level of expression of the reporter gene in the 
testis was nearly the same in most cases. The single excep-
tion was 13S6-tk-.supF (TR. which had a level of expression 
roughly twice that of the other lines. This may relate to the 
fact that 13S6-lk-supF (TR) was microinjected as a tandem 
dimer (see above). The relatively uniform expression of 
HSV-1 ik when coupled with a variety of promoters suggests 
that expression in the testis is a function of the tk sequence, 
which was the same in all cases. 
Some lines of each series were extensively screened for 
expression in other tissues. Low-level expression of MUP 
promoter constructs was very occasionally found in the 
lachrymal gland. Other tissues were negative. Although all 
of the constructs carried the bacterial .supF gene, this was 
not the cause of their expression in the testis: a construct 
identical to BSÔ-tk-supF but without the supF gene was 
expressed in the testis at similar levels (1). The data thus 
confirm our conclusion (1) that sterility correlates with 
expression of HSV-1 TK in the testis, not with expression in 
the liver (constructs BS6Stiii2-rk-supF and TG-rk-supF) or in 
the preputial gland (constructs 13S2-tk-supF and TG-tk-
.cupF). 
Truncated forms of HS%'- 1 1k RNA and IISV- 1 TK protein 
are expressed in testes of transgenic mice. We reported 
previously that two main size classes of HSV-1 1k-specific 
RNA were present in testes of transgenic mice carrying 
BS6-1k-supF ( 1). A 900-hp transcript, first observed by 
Roberts and Axel (39), was not labelled by an antisense 
probe (Fig. 2A and C. lane 1) and must therefore be a reverse 
transcript, possibly related to a reverse transcript previously 
observed in cells infected with HSV-1 (18. 25). Line L78 
carries a full-length copy and a second truncated copy of the 
5' end of the 13S6-ilk-supF gene (2). L78 uniquely has a third 
short (500-hp) testis transcript (Fig. 2A. lane 1) which was 
labelled by a probe directed against the 5' part of the HSV-1 





FIG. 2. Mapping of HSV-1 1k-specific RNA in extracts of line 78 
testis. Identical RNA transfers were probed with a full-length 
HSV-1 tk double-stranded DNA probe (A). a 5' double-stranded 
DNA probe (B). and a 5' single-stranded antisense RNA probe (C). 
Lanes contain RNA samples as follows: 1. line 78 testis: 2. BHK 
cells stably transformed with a plasmid with an active BS6-tk gene; 
and 3, nontransgenic testis. Lane 4. runoff RNA size markers. 1.830. 
1.320. 957. and 444 nucleotides long. 
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ik gene (Fig. 213). We interpret the 500-bp transcript which is 
peculiar to L78 as being from the second truncated copy of 
the gene. A 1,200-bp transcript is the predominant transcript 
in testis from all transgenic lines examined. It is the only 
transcript that can act as template for the synthesis of active 
TK but is shorter than the 1.350-hp transcript expected if 
transcription was initiated at the cap site of the BS6 gene. 
Primer extension (not shown) and nuclease protection 
experiments were carried out to determine the effective cap 
site of the 1.200-hp transcript. Lines L40, L46, and L78 (all 
carrying BS6-tk-supF) were used in different experiments. 
Apart from the additional short transcript present in L78 
RNA, these lines showed the same band pattern in Northern 
blots. In liver RNA. the 5' ends of transcripts mapped in 
approximately equal amounts to two sites, one within 1 
nucleotide of the predicted MUP gene cap site (-1) and a 
second site 73 nucleotides downstream (Fig. 3. lane 3. 
markers B and D). In testis RNA, no transcripts originated at 
the MUP gene cap site. At least six different 5' ends mapped 
to sites between about ±130 and +205. the most prominent 
being at about +150 and +160 (Table 2 and Fig. 3, lane 6. 
markers E to 1). All of these sites lie between the normal 
initiation codon of HSV-1 ik (M 1 ; Fig. 1) and the second 
methionine codon (M 4 ': Fig. 1). The same 5' ends were 
observed in experiments with testis RNA from transgenic 
mice carrying BS6-Sau2-1k-supF and TG-tk-supF (Fig. 3. 
lanes 10 and 12). 
In L46, the BS6-tk hybrid gene was highly expressed in 
both the testis and the male preputial glands. We examined 
the pattern of anti-TK antibody-reactive polypeptides in 
extracts of these two tissues. Several polypeptides present in 
a standard preputial gland extract reacted with anti-TK 
antiserum (Fig. 4. lane 3). The most prominent was a 
proteolytic product, since it was absent when the extracts 
were prepared in the presence of protease inhibitors (Fig. 4. 
lanes 4 to 6). In the presence of protease inhibitors (19). the 
most prominent component was the full-length M r 43.000 
(43K) HSV-1 TK. A similar amount of a 37K polypeptide 
and a smaller amount of a 39K polypeptide were also 
present. These polypeptides are present in cells infected 
with HSV-1 (31). The truncated forms are due to initiation of 
translation at two internal ATG codons corresponding to 
M46 and M60. They were produced in increased amounts 
when M' was deleted (20) or if a stop codon was introduced 
between M' and M4o  (19. 23), and at least one of them has 
TK activity (12. 19). The origin of an additional 35K poly-
peptide is not known, but it is also observed in extracts of 
HSV-1-infected cells and may result from initiation at the 
fourth ATG codon of the reading frame. M. Overall, the 
pattern of polypeptide expression in the preputial gland was 
similar to that observed in HSV-1-infected cells (Fig. 4. lanes 
1 and 6). 
The testis pattern was unaffected by the addition of 
protease inhibitors, indicating that testis extracts do not 
proteolyze HSV-1 TK (Fig. 4. lanes 7 to 10). The predomi-
nant components were the 39K and 37K polypeptides, 
consistent with the initiation of transcription between ATG 1 
and ATG 2 . In most cases full-length (43K) HSV-1 TK was 
not observed, but in some experiments a very small amount 
of antigenically reactive protein migrated with the appropri-
ate mobility. This may represent the translation of a small 
amount of the 43K protein from rare transcripts initiated 
upstream of ATG'. Testis RNA from lines carrying MUP 
gene constructs contains a small amount of transcript which 
may originate within the MUP promoter sequence upstream 
of the TATA box (Fig. 3, lanes 6. 9 and 10. marker A). 
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FIG. 3. Mapping of 5' ends of HSV-1 1k-specific RNA in livers 
and testes of transgenic mice. The RNA riboprohe was transcribed 
from a fragment of BS6-tk-supF which overlaps the MUP gene cap 
site (see Materials and Methods). Lanes: 1 and 7. iRNA controls: 2. 
RNA from nontransgenic liver: 3. RNA from line 78 (BS6-tk-supF) 
liver: 4, undigested probe: 5, sequencing ladder: 8. RNA from 
nontransgenic testis: 6 and 9 to 12. RNA from transgenic testis from 
line 78 (lane 6). line 40 (BS6-Ik-supF) (lane 9). line S87 (BS6Sau2-
Ik-supE) (lane 10). line TK16 (HSV-1 IkDS2-) (lane 11). and line 
TG66 (TG-th-supF) (lane 12). Note that the 3' end of the riboprohe 
is not complementary to the region around the cap Sites of con-
structs HSV-1 ikDS2- and TG-zk-supF: the furthest 5' position of 
these constructs that could be mapped with this probe is shown as 
marker C. 
Similarly, the RNA from TG-rk-.supF mice shows a pro-
tected hand at the point at which homology between probe 
and target ends, presumably derived from transcripts origi-
nating upstream of the junction (Fig. 3. lane 12. marker C). 
These longer transcripts, which are present in very small 
amounts relative to the shorter transcripts. may account for 
the production of small amounts of full-length HSV TK. 
Since the testes of transgenic mice carrying different 
HSV-1 tk constructs contained the same truncated RNA 
transcripts, it was expected that they would also contain the 
same HSV-1 TK polypeptides. This was found to be the 
case. Testis extracts from five different transgenic lines 
which carry the BS6-tk-supF hybrid gene (lines L40, L46. 
TABLE 2. Transcription initiation sites in liver and testis of 
line L78 transgenic mice" 
Tissue 
	 Transcription initiation sites as determined by: 
Primer extension 	 Nuclease protection 
1234567 
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Liver 	 —1 
+73 
+129 	 +133 
+144 +153 
Testis 	 +159 	 +160 
+169 +168 
+208 	 +203 
Methionine initiation codons are as follows: W. +79; Me'. +214: M60 . 
+256. 
FIG. 5. HSV-1 TK-specific polypeptides in testis extracts from 
different lines of transgenic mice. The positions of the 39K and 37K 
polypeptides are marked. Lanes contain testis extracts as follows: 1. 
nontransgenic control; 2. line 64 (BS6.tk-supF(: 3. line 78 (BS6-1k-
supF); 4, line 46 (BS6-tk-cupF); 5. line TK16 (HSV-1 :kDS2—); 6, 
line TG66 (TG-:k-supfl; 7. line S87 (BS6Sau2-tk-supF). 
L58, L64. and L78) and from lines carrying the different 
constructs listed in Table 1 exhibited the same pattern of 
truncated HSV-1 TK polypeptides (Fig. 5). 
Expression of a promotorless HSV.I tk gene in testes of 
transgenic mice. The identical patterns of aberrant transcrip-
tion in the testes of transgenic mice carrying HSV-1 tk with 
different tissue-specific promoters suggested that the cellular 
promoters are not involved in the initiation of transcription 
in the testis. To test this possibility, an 1,887-bp EcoRl-
BstEII fragment (-79 to +1808) of the HSV-1 tk gene (Fig. 
1) was excised and introduced into the mouse genome by 
microinjection. This fragment (HSV-1 tkDS2—) terminates 
at the same 3' site in the HSV-1 genome as the HSV-1 ik 
fragment used in the constructs listed in Table 1. At the 5' 
end it carries the HSV ik TATA box, but it lacks the more 
distal of two upstream control elements which are both 
required for full expression of the gene in frog oocytes and 
HSV-1-infected cells (14. 34). Removal of the distal element 
by deleting the 5' end of the gene down to position —85 
reduces expression in frog oocytes by approximately 20-fold 
(33). 
HSV-1 TK expression was measured in four G 0 transgenic 
1 2 3 4 5 6 7 8 9 10 11 12 
.1 	" 
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1 K Avpeptides 
in extracts of tldnsgcnlc prcpuual glands and tetc. Each lane was 
loaded with 50 i.Lg of protein. Proteins were transferred to a filter and 
developed with anti-HSV-1 TK antibody as described in Materials 
and Methods. The positions of the 43K, 39K. and 37K polypeptides 
are marked. Lanes: 1 and 12. HSV-1-infected cells; 2 to 6, preputial 
gland extracts from a nontransgenic control mouse (lane 2), and 
from line 40 mice (HSV-1 tk-supF construct) (lanes 3 to 6), without 
added protease inhibitor (lane 3), with 20 mM DCI (lane 4), with 10 
mM TPC plus 10 mM PHMB (lane 5), and with 20 mM TPC plus 20 
mM PHMB (lane 6); 7 to 11, testis extracts from a nontransgenic 
control mouse (lane 11), and from line 40 mice (lanes 7 to 10) with 20 
mM TPC plus 20 mM PHMB (lane 7). with 10 mM TPC plus 10 mM 
PHMB (lane 8), with 20 mM DCI (lane 9). and without added 
protease inhibitor (lane 10).  
males carrying the HSV-1 tkDS2— fragment and in male 
transgenic offspring of a G 0 female (founder of line TK16). 
Three of the G 0 males and the line TK16 males expressed 
HSV-1 TK at moderate to high levels in the testis (Table 3). 
Expression in other tissues was sporadic and, other than in 
the brain and lachrymal glands of TK16 males, at very low 
levels. Two of the expressing males were fertile nontrans-
mining, like many G ) males carrying tk constructs (1). Such 
males are probably mosaics with nontransgenic precursor 
cells in their germ line (see below). The third expressing G 0 
male and line TK16 males were sterile (Table 3). In nuclease 
protection experiments, testis RNA from line TK16 showed 
the same pattern of 5' ends within the HSV ik coding region 
as did testis RNA from mice carrying the promoter con-
structs (Fig. 3. lane 11). Furthermore, line TK16 testis 
contained the same shorter HSV TK polypeptides that were 
observed in the testis of those mice (Fig. 5, lane 5). These 
results argue convincingly that the expression of HSV-1 TK 
in the testes of transgerric mice is not due to the various 
tissue-specific promoters when these are present. Instead, it 
appears to be due to a cryptic promoter within the HSV-1 tk 
reporter gene, located downstream of the TATA box-con-
taining promoter which is utilized during HSV infection. 
Sites of HSV-1 TK expression in the testis. To determine 
whether HSV-1 TK is expressed in spermatogenic cells or in 
ancillary cells. sections of testis from mature male transgenic 
mice were immunostained with anti-TK antiserum as the 
primary antibody. The sections consistently showed expres-
sion in the postmeiotic haploid spermatids (Fig. 6). No 
evidence was obtained of expression at earlier stages of 
spermatozoan development or in Sertoli cells, and staining 
was observed only rarely and sporadically outside the tu-
bules. 
Developmental onset of HSV-1 TK expression. During post-
natal development in the male mouse, some germ cells in all 
of the testicular tubules begin to advance toward the first 
meiosis at about the same time (35). The first spermatocytes 
in meiotic prophase are observed between 8 and 10 days 
after birth. Between days 10 and 12, the most advanced cells 
observed are in mid-pachytene: at 15 to 17 days. 30% of 
tubules contain cells in late pachytene: and at 22 to 24 days, 
spermatids are observed for the first time in about 357c of 
tubules. Thus, by assaying the testis at different times during 
the first 3 weeks of life, an indication can he obtained of the 
developmental stage at which a gene product is first formed. 
At 7 days after birth, when the testis first becomes large 
enough to permit the assay, the specific HSV-1 TK activity 
(units per milligram of testis protein) was significant (Fig. 7). 
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TABLE 3. TK activities in tissues of transgenic mice carrying the promoter-truncated HSV-1 IkDS2- fragment 
TK activity (pmol/minlmg of protein) 
Tissue Nontransgenic G 	transgenic males Line TK16 
control TK10. fertile" TK22. fertile TK39. sterile TK40. fertile" male, sterile 
Testis 0.11 23.15 0.16 	 37.75 4.25 97.23 
Liver 0.06 0.46 0.0() 0.04 0.00 0.07 
Preputial gland 0.16 0.00 0.00 	 0.00 0.00 0.28 
Kidney 0.08 0.27 0.20 0.00 0.00 0.08 
Brain 0.20 ND" ND 	 0.35 0.07 2.99 
Muscle 0.00 ND ND 0.00 0.08 0.00 
Lachrymal gland 0.07 NI) ND 	 0.03 0.00 8.01 
Submaxillary gland 0.03 ND ND 0.00 0.00 1.02 
Fertile nontransmitting 
ND, not determined. 
The lack of HSV-1 TK imrnunostaining in ancillary cells of 
mature testis suggests that this TK activity is present in the 
spermatogonia. However the possibility that HSV-1 TK is 
expressed in ancillary cells in immature testis has not been 
excluded. Between 10 and 20 days after birth, a higher level 
of 1-ISV-1 TK was present, possibly due to a continuing 
increase in the proportion of the testis made up of sper-
matogonia and spermatocytes (35). At about 21 days, the 
time at which the first haploid spermatids appear, a more 
abrupt increase in HSV-1 TK activity occurred. This finding 
suggests that there may be renewed expression in the round 
spermatids, a stage at which de novo synthesis of spermio- 
genesis-specific proteins is frequently observed (17. 21. 36, 
40). 
Effects of HSV-I TK expression on spermatogenesis. In 
lines which expressed HSV-1 TK at a low level, the male 
mice were fertile. One of seven BS2-tk-supF lines and two of 
six BS6-tk-snpF(TR) lines had relatively low levels of HSV-1 
TK expression and were male fertile, and males transmitted 
the foreign gene to their progeny (Table 1). This finding 
suggests that sterility ensues only above a threshold level of 
HSV TK (7). However, the highest level of expression 
among the male-fertile lines was five times less than the 
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FIG. 7. Time course of HSV-1 TK expression in testis during sexual maturation. Testes of pups from crosses of line 40 and line 46 females 
with nontransgenic males were assayed as described prior to determining their transgenic status. Ordinate. I-ISV-i 1'K activity, expressed as 
picomoles ofTMP synthesized per minute per milligram of protein. PP.. after birth. The bars show the average HSV-1 TK activity for cases 
in which more than one pup was measured. The numbers of transgenic L40 (•) and L46 (Li) and nontransgenic L40 (Ell) and L46 (Ill) pups 
are shown above the bars. The times at which meiotic figures lleptotene of first mciosis. L(Ml)J and haploid meiotic products (spermatids. 
H) are first observed are indicated. These are the stages to which the most advanced tubules have progressed at that time. 
This large discontinuity raises the possibility that there are 
two modes of expression of HSV-1 tk in the testis, for 
example two independent mechanisms of transcriptional 
activation or possibly expression in two different cell lin-
eages. If so, it is possible that only one of the two modes is 
active in the male-fertile lines while the other causes steril-
ity. 
Although the levels of testis expression due to different 
constructs were similar when averaged over several lines, 
different lines carrying the same construct exhibited substan-
tial differences. Three transgenic lines carrying the BS6-tk-
,rupF gene were therefore examined. Line L78 mice have an 
intermediate level of expression in the testis (62 U/mg of 
protein). In L78. development of the spermatozoa appeared 
normal (Fig. 6). The sperm counts of L78 mice were also 
normal, but the motility of the spermatozoa was reduced and 
furthermore faded very rapidly in vitro. 
In lines L40 and L46, which have a high level of HSV TK 
expression in the testis (140 U/mg of testis protein), testis 
weight was lower than in nontransgenic controls and the 
sperm content of the epididymides was lower by a factor of 
25 to 500 (Table 4). Very few sperm were found in the vas 
deferentia of these animals and those observed had very 
abnormal morphology and were nonmotile (Fig. 8). Thus the 
severity of the spermatogenic lesion is greater when the 
expression level of HSV-1 TK in the testis is higher. 
Sterility of G 0 transgenic males. In the lines that express 
moderate levels of HSV-1 TK and produce normal numbers 
of nonmotile sperm. the heterozygous male offspring of 
transgenic females were sterile although half of the sperm 
should not carry the foreign gene. This outcome could be 
expected if the lesion which results in sperm incapacitation 
occurs prior to meiosis. However, the cells descended by 
mitosis and meiosis from each committed spermatogonium 
remain together as a syncytium with cytoplasmic bridges 
between the cells (6). Transfer of HSV TK across the bridges 
could be expected to lead to complete sterility of heterozy-
gous males even if the lesion due to HSV-1 TK expression 
occurred only in the haploid spermatids (7). 
Two classes of 6 0 transgenic males were obtained with 
each of the constructs listed in Table 1. Taken together. 47% 
of the transgenic G 0 males were sterile, while 53% were 
fertile but did not transmit the foreign gene to any of their 
offspring. The sterile transgenic males are taken to be 
descended from injected embryos in which at least one 
insertional event occurred prior to DNA replication at the 
one-cell stage, leading to a uniformly heterozygous individ-
ual G 11 pup, comparable to the heterozygous male offspring 
of transgenic females. The fertile nontransmitting males are 
taken to be germ line mosaics, in which integration of foreign 
DNA occurred at some time after the first round of DNA 
synthesis. The transgenic cells of such individuals are het- 
TABLE 4. Defects of spermiogenesis in severely affected sterile mice 
Line L40 	 Line 46 
Determination 	 Controls 
Mouse 1 	 Mouse 2 	 Mouse 1 	 Mouse 2 
Sperm weight (mg) 	 91.95 	 72 	 74 	 80 	 63 
Epididymal sperm 2-3 x 10' 10 S X iO 105 5 X 10 
Contents of vas deferens 	 Numerous sperm 	 Very few sperm 
801/t normal None with normal morphology 
Motility normal 	 Nonmotile 
HSV-1 TK activity" (line 	 140 ± 6.7 	 139 ± 17.6 
mean ± SE) 
From At-Shawi et at. (1) 
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FIG. 8. Normal and defective spermatozoa. -1 he contents of the 
vas deferens of nontransgenic (A) and line 40(B) mice were stained 
with eosin. The bar represents 10 p.m. 
erozygous and, by analogy with the heterozygous male 
offspring of transgenic females, are assumed to generate only 
defective spermatozoa. The nontransgenic germ cells pre-
sumably develop separate syncytia which generate compe-
tent spermatozoa. 
DISCUSSION 
HSV-1 1k contains a cryptic promoter which directs its 
expression to the testis. The observations described lead to 
the conclusion that the HSV-1 tk gene contains a cryptic 
promoter, independent of its own TATA box, which is 
particularly active in postmeiotic spermiogenic cells. The 
putative cryptic promoter, assumed to he located upstream 
of the sites of transcription initiation, possesses properties 
associated with promoters of housekeeping genes. Thus, 
transcription is initiated at several quite widely dispersed 
sites, and these are located within a region with a high G±C 
content which contains no discernible TATA box but resem-
bles an HTF (Hpall tiny fragment) island (3) in containing 
many potential methylation sites. However it is clearly not a 
true housekeeping promoter since it is consistently ex-
pressed at a detectable level only in the testis. The location 
of this promoter sequence is presently being investigated. 
In an interesting parallel. vigorous TATA box-indepen-
dent transcription of the metallothionein I gene is initiated at 
several sites between —134 and —28 in spermatocytes and 
spermatids (15). This observation and those reported here, 
together with at least one other example (42), suggest that 
the transcriptional activation of cryptic promoters which 
share properties with housekeeping promoters may be a 
property of postmeiotic male germ cells. 
In the testes of mice carrying a metallothionein promoter-
13-interferon—tk construct. Iwakura et al. (24) observed mi-
nority transcripts (about 209) which hybridized with both  
3-interferon and tk probes, while about 80% of the tran-
scripts reacted only with the ik probe and closely resembled 
the testis tk transcripts that we observed (Fig. 2). The cryptic 
tk promoter evidently did not abrogate (or abrogate com-
pletely) the activity of the upstream metallothionein pro-
moter, which was itself active in the testis. In contrast, our 
MUP and TG constructs produce minute amounts, if any, of 
full-length mRNA, presumably because these tissue-specific 
promoters are inactive in the testis. 
Synthesis of truncated HSV-1 TK polypeptides in the testis. 
In HSV-1-infected cells, the synthesis of HSV TK is nor- 
ally initiated not only at the first ATG codon but also, at 
iuch lower frequencies, at the second and third ATG 
idons (19. 31). possibly because both the first and second 
AM codons lie within consensus sequences which are 
inefficient translational initiators (19). The pattern of HSV 
TK synthesis in the preputial glands of MUP-tk transgenic 
mice closely resembled that observed in HSV-1-infected 
cells. 
In cells infected with HSV-1 carrying a deletion that 
removes the first ATG codon of the tk reading frame, the 
second and third ATG codons are utilized more efficiently 
(19). The truncated HSV-1 tk RNA molecules synthesized in 
the testis lack the first ATG codon, and to this extent they 
are equivalent to the mRNA synthesized from the deletion 
mutant. Accordingly, the most abundant HSV-1 TK poly-
peptide in the testis conligrates with the most abundant TK 
polypeptide (37K) present in cells infected with the deletion 
mutant (19). Translation of the 37K polypeptide is presumed 
to be initiated at M' ° , the third methionine of the reading 
frame, which lies within the strongest translational initiation 
consensus of the first three ATG codons. M' ° lies within a 
region of the enzyme shown by site-directed mutagenesis to 
be the ATP-binding pocket (29). Consequently, the enzy -
matic activity of the 37K protein is likely to he less than that 
of full-length TK. and the level of TK expression in the testis 
may be considerably higher than indicated by enzyme as-
says. Supporting this view, the level of HSV-1 tk mRNA in 
testis RNA is disproportionately high relative to that in 
preputial gland RNA in comparison with the ratio of TK 
activities in the two tissues (1). 
TK expression in the testis causes sterility. We previously 
concluded that male sterility in mice carrying an HSV-1 tk 
reporter gene was due to a high level of ectopic HSV-1 TK 
expression in the testis (1), and this was recently confirmed 
(7). The results presented here strengthen our previous 
conclusion. While the truncated HSV-1 tkDS2— gene caused 
male sterility (Table 3). transgenic mice carrying the HSV-1 
tk gene with the promoter region intact were male fertile (7). 
Thus, the property of causing sterility seems to he neutral-
ized by the HSV-1 tk promoter. In these fertile mice, the 
onset of TK expression was at a later stage in sperm 
development and the level of enzyme activity attained was 
lower than in sterile mice with similar levels of HSV-1 tk 
mRNA (7). This finding suggests that the effect of the HSV-1 
tk promoter was to postpone expression of the gene to a later 
stage in spermaocyte development when protein synthesis 
is less vigorous. Since transgenic mice which exhibit a low 
level of TK expression in the testis are fertile (Table 1), the 
fertility of the mice that carry the HSV-1 tk gene with its 
promoter intact may be due simply to reduced enzyme 
activity. 
The ectopic expression of HSV-1 ik in the testis has in the 
past led to erroneous conclusions being drawn. In one case. 
male sterility in mice transgenic for a cosmid containing the 
major histocompatihility complex class 11 E gene was at 
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first attributed to the expression of E,," (37). However the 
cosmid also carried an HSV-1 tk gene. and sterility was later 
found to be due to the expression of this gratuitous compo-
nent of the construct (7). In another case, a metallothionein-
13-interferon-tk foreign gene caused male sterility, which was 
attributed to the expression of 13-interferon (24). HSV-1 TK 
activity at levels similar to those we have observed was 
detected in the testes of the transgenic mice, and it was not 
convincingly demonstrated that 13-interferon rather than 
HSV-1 TK was the cause of sterility. 
Impaired fertility has been reported in transgenic mice 
carrying HSV ik directed by the immunoglohulin gene 
promoter and enhancer (22). Although it is unlikely that 
testis expression of HSV ik influenced the ablation Of the 
lymphocytes by DHPG or of the sornatotrophs of mice 
carrying a growth hormone promoter.-HSV tk reporter gene 
(5), it is clearly an undesirable potential complication in 
experimental animals. 
Causes of male sterility. Our data indicate that sterility in 
mice with an intermediate level of TK expression may be 
due to expression in the postmeiotic spermatids. Since 
mammalian sperm do not undergo postmeiotic mitosis, this 
would exclude effects involving the synthesis of DNA, such 
as hypermutation. The nonmotile sperm produced by these 
sterile mice are present in normal numbers and are mainly 
normal in appearance, suggesting that their lack of motility 
may be due to an impoverished energy source. HSV-1 TK is 
an aggressively promiscuous nucleoside kinase, is only 
poorly susceptible to end-product inhibition, and vigorously 
phosphorylates mononucleotides as well as nucleosides (10. 
41). Extracts of transgenic testis show elevated levels of 
both nucleoside kinase and nucleotide kinase activity (34a). 
Normal mouse sperm remain motile for several hours in the 
absence of an exogenous energy source, suggesting that they 
possess a sizable energy store (9). Thus, the lack of sperm 
motility may derive from a failure of energy storage due to 
ATP depletion during maturation. 
The gross morphological defects and almost complete 
failure of sperm maturation that are observed in mice with 
higher levels of testis HSV-1 FK activity are likely to have a 
more radical cause. Possibly the low-level TK activity 
present prior to the first meioses. and tentatively attributed 
to expression in premeiotic germ cells, interferes with DNA 
synthesis or some other vital cellular function in lines with 
higher levels of expression but not in lines with intermediate 
expression levels. 
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ABSTRACT. The coding region of the herpes simplex type 1 
virus thymidine kinase gene was coupled to the promoter of the 
bovine thyroglobulin gene and introduced into the genome of 
mice. The viral thymidine kinase (HSVI-TK) was expressed 
mainly in the thyroid glands and testis. Upon treatment of 
transgenic females with the antiherpetic agent Ganciclovir the 
thyroid regressed, while the parathyroid gland was unaffected. 
The number of thyroid follicle cells was greatly reduced after 3 
days, and they were completely absent after 7 days of treatment. 
After 14 days, the levels of circulating T 4 and T3 were below the 
limits of detection, total soluble protein recovered from the 
thyroid and parathyroid glands together was 10% of the control 
value, and the level of thyroid HSV1-TK was more than 100-
fold lower than that in transgenic controls. Levels of circulating 
PTH and calcitonin remained normal. At the time of treatment 
the mice were adults. Thus, the thyroid follicle cells were selec-
tively ablated after normal development with a functional thy-
roid gland. When treatment with Ganciclovir was terminated 
after 14 days, no circulating T 4 or T3 or other indications of 
thyroid regeneration were detected for a subsequent period of 90 
days. During this time the mice gained weight more slowly than 
controls, at a rate consistent with the suppression of GH syn-
thesis by thyroid deficiency. The production of mouse major 
urinary protein (MUP) ceased in the treated mice and was 
completely restored by the administration of T 4. MUP produc-
tion was not restored by GH, demonstrating that the expression 
of the Mup genes requires T4 in addition to GH. (Endocrinology 
129: 3217-3226, 1991) 
EVERAL hormones are produced by specialized cells 
5 that have no other known function than to produce 
;ingle hormone and secrete it appropriately. Neverthe-
;s, because cells with different specialized functions are 
Len physically close to and interspersed with each 
her, it is usually impossible to produce by surgery an 
perimental animal with a single hormonal deficiency. 
i example is the anterior pituitary, in which GH, PRL, 
H, gonadotropin, and other hormones are all produced 
different specialized secretory cells. This problem has 
en successfully addressed by the technique of trans-
nic ablation. For example, expression of the diphtheria 
xin A-protein was targeted to the pancreas with the 
astase promoter (1) and to the pituitary with the GH 
omoter (2). In the first instance the pancreatic exocrine 
ils and in the second the pituitary somatotrophs and 
ctotrophs were specifically destroyed. A disadvantage 
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of this method, however, is that the toxin is produced 
and takes its effect as soon as the tissue-specific promoter 
becomes active, thus eliminating any possibility of se-
lecting the time of hormone deprivation in relation to 
experimental requirements. An alternative method that 
potentially allows some control of the time of ablation is 
based on the special properties of herpes virus type 1 
thymidine kinase (HSV1-TK). When the expression of 
the herpesvirus gene (HSV1-tk) was targeted to the 
pituitary by means of the GH promoter, treatment of the 
transgenic mice with 1-(2-deoxy-2-fluoro--D-arabino-
furanosyl) 5 -iodouracil (FIAU) led to complete ablation 
of the somatotrophs and lactotrophs without impairment 
of other specialized secretory pituitary cells, such as 
thyrotrophs and gonadotrophs (3). In these experiments 
somatotrophs and lactotrophs regenerated when FIAU 
administration was discontinued. 
The potential of inducible transgenic ablation is con-
siderable. The main requirements are 1) that the foreign 
protein (HSV1-TK, above) should not affect the cells in 
the absence of the agent (FIAU, above), 2) that the agent 
should not be toxic in its own right or be converted to a 
toxic product by cellular enzymes in the absence of 
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HSV1-TK, 3) that the foreign protein should convert the 
agent to a toxic product (in this case phosphorylated 
FIAU), and 4) that the toxic product should not affect 
nearby cells. FIAU and Ganciclovir (9-[1,3-dihydroxy-2-
propoxy(methyl)]guanine; DHPG) were developed, like 
Acyclovir, to combat herpes virus infections. They are 
effective first, because they are nontoxic in their unal-
tered state but become lethally toxic when phosphory-
lated, and second, because they are efficiently phosphor-
ylated by HSV1-TK, but less efficiently or not at all by 
cellular nucleoside kinases (4, 5). 
Side-effects of HSV1-TK expression in the targetted 
cells have not been reported. However, transgenic HSV1-
tk reporter genes are expressed in the testis in addition 
to the target tissue regardless of the nature of the pro-
moter to which they are linked, and the transgenic males 
are almost invariably sterile (6-8). While this is incon-
venient from the viewpoint of husbandry and means that 
homozygotes cannot be obtained, possible complications 
due to the expression of HSV1-TK in the testis can be 
avoided by restricting the studies to transgenic females. 
Nucleotides are not taken up by cells. Consequently, 
the phosphorylated antiherpetic agents are unlikely to 
damage nearby cells when released by the death of the 
affected cells. However, nucleotides do pass between cells 
through gap junctions, and the selectivity of HSV1-TK-
mediated cell ablation is likely to depend on whether the 
target cells communicate with other cell types through 
gap junctions. 
Previously, HSV1-TK-mediated transgenic ablation 
was deliberately targeted to dividing cells (3, 9, 10), 
leaving open the question of whether nondividing cells 
can also be ablated in this way. However, the potential 
of the method would be greatly increased if nondividing 
differentiated cells could be killed. An ablation system 
capable of selectively killing differentiated target cells 
could be applied to mature animals that have developed 
normally and, consequently, lack defects brought about 
by congenital or neonatal hormonal deficiency. 
The thyroid is a suitable organ with which to explore 
the potential of transgenic ablation. It contains two 
known types of secretory cell, follicle cells which produce 
T4 and T:, and C-cells which secrete calcitonin (CT), 
and it is in intimate contact with the parathyroid gland 
which secretes PTH. By targeting HSV1-TK to the 
follicle cells, the effects of follicle cell ablation on C-cells 
and on the parathyroid can be determined. Furthermore, 
the follicle cells provide a means to test the efficacy of 
ablation of nondividing cells; in normal adult rats and 
mice, the follicle cells are essentially nondividing, with 
mitotic indices of less than 10 (11, 12), although they 
can be stimulated to divide both in vivo and in vitro by 
supranormal levels of TSH (13). 
We have targeted HSV1-TK expression to the thyroid 
follicle cells of transgenic mice by coupling the HS%' 
gene to the bovine thyroglobulin promoter (14). Expi 
sion was largely confined to the thyroid follicle cells 
females. Mature (up to 18-week-old) female mice infu 
with DHPG by minipump suffered a complete loss of 
production. The thyroid glands regressed, follicle c 
were destroyed, and follicle lumens were no longer pi 
ent. The levels of circulating PTH and CT were ur 
fected, showing that ablation was specific to the folli 
cells. 
Materials and Methods 
Transgenic and other mice 
The fragments used to assemble plasmid ptgTK were den 
from the following sources (sites that were made blunt-en 
with DNA polymerase-I Klenow fragment before ligation 
marked with an asterisk): 1, a 2297-basepair (bp) EcoRI-Pt 
fragment of pBR322 containing the replication origin and 
L-lactamase gene; 2, a 342-hp PvuI1HindIII*  fragment of s 
ian virus-40 containing the replication origin, enhancer, 
early promoter were taken together from pSV2gpt (15); 3, 
8-hp BamHI*  to HindIII polylinker fragment derived ft 
pPOLYIII-D (16) and pUC8 (17), containing the XhoI 
shown in Fig. 1; 4, a 3050-hp EcoRI-AluI fragment of the boy 
thyroglobulin gene containing the cap site, part of the 
noncoding region, and more than 3 kilobases (kb) of 5'-flank 
sequence (14); 5, a 1765-hp BglII*.BstEI*  fragment from pT 
(18) containing the HSV-tk coding sequence, part of the 
noncoding region, the polyadenylation site, and some 3'-fla: 
ing sequence; 6, a 10-bp Sa1I*BamHI*  fragment from 
M13tg130 polylinker (19); 7, a 408-hp AluI-XbaI fragment 
irVX containing the SupF gene (20); and 8, a 36-bp XbaI-Ec 
fragment of the M13tg130 polylinker containing the KpnI 
shown in Fig. 1. A DNA fragment containing the hybrid TC 
gene and the SupF gene was removed by restriction in 
polylinkers (XhoI-KpnI) and purified as previously descril 
(6), and approximately 2 p1 were injected at a concentratior 
1.5 ug/ml into either pronucleus of C57BL/6 x CBA/Ca 
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FIG. 1. Diagram of the thyroglobulin promoter- HSV-thymidjne kin 
reporter construct (TG-tk). The sequence of the AluI-BglII junct 
between the TATA box and the HS V-tk initiation codon is shown. 
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±ain reaction analysis of tail-cut DNA. Two hundred and 
-five embryos were transferred to pseudopregnant recipi-
90 pups were born, 15 transgenics were identified, and 4 
were established. One of these generated the high expres-
subline TG66.19, which was employed in the experiments 
ribed here. Thyroidectomy was performed by surgery, and 
pies were taken 7 days later. Mice were maintained and 
I in accordance with European Economic Community 
eiines, endorsed and implemented by the UK Home Office. 
E administration 
ransgenic female mice, all from line TG66.19, were 8-18 
ks of age when minipumps (Alzet model 2002, Alza Corp., 
Alto, CA) were implanted sc under general anesthesia. 
PG was administered at a rate of 4.5 mg/day for up to 14 
;. Control mice received saline-containing minipumps. T 4 
injected daily (5 2g/20 g BW, ip) (21) for the last 5 days of 
i-day DHPG administration. Controls were injected with 
T4 diluent (3 mm NaOH and 1% NaCl; 50 il/20 g BW, ip). 
me GH (bGH; 100 g/20 g) was injected ip at 12-h intervals 
5 days. 
mone, protein, and enzyme determinations 
and T3 levels were determined using Amerlite competitive 
jme-linked immunosorbant assays (Amersham, Amersham, 
TT4 and TT3), which employ enhanced luminescence to 
sure peroxidase-conjugated hormone with increased sensi-
:y (22). The sensitivities of these assays (2 SD of a zero 
dard) are reported by the manufacturer to be greater than 
id 0.15 nmol/liter, respectively. PTH and CT were deter-
ed by RIA. PTH was determined with Amersham kit 
3.800, which employs guinea pig antihuman (midmolecule) 
serum, radioiodinated human PTH, and goat antiserum 
Inst guinea pig -y-globulin. CT was determined with Amer-
in kit IMB.400, employing goat antihuman CT, radioiodi-
d synthetic (human) CT, and donkey antiserum against 
-y-globulin. Thymidine kinase assays were carried out as 
iously described (23), but 0.2 mm thymidine-5'-triphos-
te was added to inhibit endogenous thymidine kinase (24). 
tein was determined by the Bradford method (25). 
tology 
'hyroid glands were removed, fixed in Bouin's solution, 
)edded in paraffin wax, and stained with hematoxylin and 
zlysis of urinary protein 
Jrine was collected by bladder massage and dialyzed first 
inst 0.3 M NaCl-10 mm Tris-HC1 (pH 7.5) and then against 
•er. Twenty microliters of urine were applied to each lane of 
agarose gel containing pH 3.5-4.9 ampholines (Pharmacia, 
cataway, NJ). After focusing (15 kilovolt-amperes; 90 mm), 
gel was stained with Coomassie blue. 
Results 
sue-specific expression of HS VI - TK directed by a 
'roglobulin promoter 
['hyroglobulin, the protein from which T 4 is generated, 
ynthesized exclusively in thyroid follicle cells, and the 
promoter of the thyroglobulin gene directs the expression 
of the chloramphenicol acetyl transferase reporter gene 
to these cells (26). We attached the coding, 3'-noncoding, 
and 3'-flanking regions of the HS VI-tk gene to a 3.1-kb 
fragment containing the promoter and 5'-flanking re-
gions of the bovine thyroglobulin gene through a junction 
in the 5' noncoding regions of the two genes (Fig. 1) and 
introduced the hybrid gene into the germline of mice by 
direct microinjection. Four lines of transgenic mice were 
established, three of which expressed HSV1-TK in the 
thyroid gland at different levels (Table 1). In females, 
high level expression was confined to the thyroid glands, 
although there was consistently a very low level of 
expression in the submaxillary glands. In males there 
was high level expression in both thyroid glands and 
testis (data not shown). Expression in the testis is a 
common (probably universal) feature of hybrid genes 
that contain the HS VI-tk reporter (6, 7) and is due to 
the presence of a sequence, probably within the HSV1-
tk-coding region, which acts as a testis-specific house-
keeping-type promoter (8). The experiments described 
here were performed with females of a line (TG66.19) 
established from the G 0 female which showed the highest 
level of HSV1-TK expression in the thyroid (Table 1). 
The high expression level has been transmitted through 
several subsequent generations. The level of expression 
in the submaxillary glands of this line, relative to that in 
the thyroid, was about 0.2% (Table 1). 
Ablation of thyroid follicle cells by DHPG 
When transgenic female mice of line TG66.19 were 
treated with DHPG by minipump for 2 weeks, serum T 4 
and T3 levels fell to below the sensitivity limits of the 
assays (see Materials and Methods), and the luminometer 
readings were close to zero (Tables 2 and 3). Regular 
injection of T4 throughout the last 5 days of DHPG 
treatment restored the level of circulating T 3 to about 
half the normal level, that is to a level similar to the 
TABLE 1. Thymidine kinase activities in tissues of female transgenic 




TG62 	TG66.19 Control 
Thyroid 10.6 11.4 1.2 178.8 0.3 
Liver 0.05 0.04 0.03 0.04 0.03 
Brain 0.28 0.17 0.05 0.37 0.27 
Muscle 0.03 ND ND 0.01 0.02 
Submaxillary 0.17 0.11 0.11 0.32 0.01 
gland 
Kidney 0.05 ND ND 0.05 0.03 
Heart 0.07 ND ND 0.11 0.08 
Ovary - 	 0.51 0.29 0.3 0.43 0.33 
Thymidine kinase activity is expressed as picomoles per mm/mg 
protein. Control, Nontransgenic F 2 mice from a C57BL x CBA/Ca 
cross. ND, Not determined. 
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TABLE 2. Effect of DHPG treatment on levels of circulating T4 and T3 and on thyroid protein and HSV1-TK in TG66.19 transgenic female r 
Total 






After Before After Before 	After 
After 
Transgenic 	PBS 144 17.50 44.1 39.5 0.58 
DHPG 10 0.02 
DHPG + D 20 0.00 
29.8 0.0 ND 




0.33 3 0.01 
DHPG + GH 
10 0. 03 
20.1 0.0 000 7 0.02 
Control 	 DHPG 	 100 	 0.01 	 66.4 	40.4 	0.73 	0.48 
Controls were F 2 mice from a C57BL x CBA/Ca cross, equivalent in background to the transgenic mice. Treatments (see Materials 
Methods): PBS, implanted with a minipump containing saline; DHPG, with a minipump containing DHPG; D, injected with T 4 diluent; 
injected with T4 ; GH, injected with GH. Before, Before treatment; After, after treatment. Serum samples were pooled for hormone assay 
indicated. ND, Not determined. Total protein and total HSV1.TK units (picomoles of thymidine 5' -monophosphate synthesized per mm) refe 
total thyroid extracts. 
TABLE 3. Effect of DHPG treatment on levels of circulating T 4 in 




status Before 	After 
Transgenic 	PBS 	40.2 ± 11.2 	25.7 ± 9.0 
DHPG 52,1 ± 3.5 0.0 
Control 	PBS 	 44 	24 	1 
DHPG 45.5 ± 22.9 	28.3 ± 15.0 	3 
None 	45.8 ± 19.0 20 
Values are the mean and SD. PBS and DHPG, Implanted with 
minipumps containing saline and DHPG, respectively. n, Number of 
estimates. Untreated controls (Control, None), Five mice were sampled 
on four occasions. Before, Before treatment; After, after treatment. 
controls. As would be expected, administration of GH 
during the second week of treatment had no effect on 
circulating T 4 or T3 levels. 
When nontransgenic controls were treated with 
DHPG in the same way, the level of T 4 fell by about 
40%, on the average (Table 3), and the T 3 level also fell 
(Table 2). This effect seems to be due to surgery or to 
the effect of carrying the minipumps, since transgenic 
and control mice treated with saline showed a similar 
depression of circulating T 4 (Table 3). The levels of T 4 
and T3 in untreated control mice sampled at the same 
time of day on different days were also quite variable 
(see T4 values, Table 3). However in these mice, which 
were not implanted with minipumps, the variance be-
tween samples and within mice was similar to the vari-
ance between mice, signifying that differences in T 4 (and 
T) levels did not follow any obvious pattern. This con-
trasts with the consistent difference observed before and 
after minipump implantation. 
The thyroid glands of DHPG-treated transgenic m 
were greatly reduced in size (Fig. 2), and this was 
flected in the yield of protein obtained from them; 1 
total soluble protein obtained from treated transge 
thyroids was less than 10% that of untreated transge 
or DHPG-treated nontransgenic mice (Table 2). 
experienced difficulty in dissecting out the regres 
thyroids cleanly, and these values probably overestim 
the residual thyroid protein. The total HSV1-TK activ 
in the thyroid glands of untreated line TG66.19 m 
ranged between 6 and 17.5 U/thyroid. Any thyrocy 
not destroyed by DHPG treatment may be expected 
contain HSV1-TK, and we provisionally take the le 
of HSV1-TK activity as a measure of the success 
DHPG ablation. HSV1-TK activity varied betweer 
and 0.03 U/thyroid in the residual thyroid tissue fr 
DHPG-treated transgenic animals (Table 2). Since I 
sensitivity limit of the HSV1-TK assay is below 0.01 
thyroid, the results suggest that the administration 
DHPG for 14 days destroyed 99.5-99.8% of follicle ce 
The destruction of follicle cells was confirmed by 
amining stained sections of thyroid glands. Thyroids 
nontransgenic mice and untreated line TG66.19 m 
contain typical thyroid follicles filled with pink-staini 
thy roglobulin -containing colloid and surrounded by 
boidal follicle cells with large nuclei (Fig. 3, A, B, D, a 
E). In the thyroids of transgenic mice treated w 
DHPG, no follicles with included colloid were pres 
after 3 days. From day 7 onward, no follicle cells coi 
be recognized (data not shown). Figure 3, C and F, sho 
a typical thyroid section made after 14 days of treatme 
Some of the sparsely distributed cells with moderat 
sized nuclei can be identified as C-cells by specific i 
munostaining, but the origin of the others is uncerta 






2. Thyroid glands of normal female (A), untreated transgemc 
ale (B), and transgenic female treated with 4.5 mg/day DHPG for 
lays (C). 
this time, the glands contained structures that resem-
d empty follicle residues. However, these appeared de 
o between days 7-14, that is after the initial disap-
irance of the follicles and of typical follicle cells. They 
, therefore, unlikely to be follicles. The flattened cells 
:h condensed nuclei that surround the margins of the 
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11G. 3. Thyroid follicles of normal females (A and 1)), untreated trans-
genic females (B and E), and transgenic females treated for 14 days 
with DHPG (C and F). Magnifications: A-C, x100; D-F, x400. 
cells. Endothelial cells associated with thyroid adipose 
tissue are known to multiply during T4 deprivation (27). 
Whatever the origin of the residual cells, they are present 
in very much lower numbers than the follicle cells in a 
euthyroid animal. Thus, the physical destruction of fol-
licle cells is the main and probably the sole cause of the 
loss of circulating T 4 and T3 . 
Levels of PTH and CT are maintained in DHPG-treated 
line TG66.19 mice 
The parathyroid gland is closely associated with the 
t hyroid. In sections of thyroid rudiments from ablated 
animals, the parathyroids appeared to be unaffected (Fig. 
4). In agreement with this observation, no significant 
change in the level of PTH was observed in either trans-
genic or nontransgenic animals treated with DHPG (Ta-
ble 4). The production and secretion of PTH clearly do 
not depend upon circulating T 4 or T 3 . Furthermore, the 
products of DHPG phosphorylation or any other putative 
agents of ablation had not passed to the parathyroid in 
amounts sufficient to impair PTH secretion. 
The C-cells lie in localized clusters between the thyroid 
follicles. In the DHPG-treated transgenic mice, the level 
2LE CELLS IN ADULT MICE 	 Endo 
Vol 129• 
HI.E 4. Effect of DHPG treatment on levels of circulating T 4 
f-I in control and TG66.19 transgenic female mice 
Transgenic 





rnenjc 	PBS 	44.1 	39.5 	54 49 
44.9 15.8 ND 	36 
EPIPG 	29.8 	0.0 	71 	55 
51.4 0.0 ND 48 
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PBS and DHPG, Implanted with minipumps containing saline A 	I) H PG, respectively. ND, Not determined. Before, before treatm 
After, after treatment. 
FABLE 5. Effect of DHPG treatment on levels of circulating T 4 
CT in control and TG66.19 transgenic female mice 
T4 (nmol/li- 
CT (ng/litei Transgenic 
Treatment 	ter) 
status 
Before After Before Aft 
ll 	P 	20.3 	20.6 	36 	29 
I' 47.5 28.5 25 28 
1111i, 	48.3 	0.0 	24 	26 
P 	57.7 0.0 30 27 
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FIG. 4. Parathyroid glands i iurnl.jI ltuik 'Al, untreated transgenic 
females (B), and tranagenic females treated for 14 days with DHPG 
(C). 
of CT was effectively unchanged (Table 5). A thyroid-
ectomized control mouse showed no circulating CT. In 
view of the overall structural changes that must accom-
pany the shrinkage of the gland, it is perhaps surprising 
that CT levels did not fall during ablation. The results 
are consistent with the identification of apparently un-
affected C-cells in transgenic thyroid rudiments after 14 
days of DHPG treatment (see above) and suggest that 
there is little or no transfer of phosphorylated DHPG 
between follicle cells and C-cells across the epithelial 
Thyroidectomized 	None 	56.5 	8.1 	27 	0 
PBS and DHPG, Implanted with minipumps containing saline 
DHPG, respectively. P, Pooled samples (two mice). Before, Bei 
treatment; After, after treatment. 
basement membrane. 
The thyroidectomized mouse showed a residual 1 
level of T4 (Table 5). This may be due to incompl 
thyroidectomy. We have observed that the C-cells 
localized within the thyroid, so that in principle, most 
the C-cells might be removed without complete remo 
of follicle cells. The objective of the thyroidectomy v 
to generate a CT-negative mouse to validate the 
assay. 
Expression of Mup genes in the liver as an indicator 04 
reduced level of circulating T4 
Transcription of the mouse major urinary proti 
(MUP) genes in the liver is dependent on both T 4 
GH (21). The genes are expressed at much higher 1ev 
in males than in females, and this sex difference 
mediated by the different temporal patterns of circul 
ing GH in the two sexes (28). The pulsatile male patt 
can be mimicked by administering GH according t 
regular injection regimen. 
One of the many effects of T 4 is to stimulate transcr 
tion of the GH gene (29, 30). Since T 4 deprivation lei 
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marked decline in GH synthesis, thyroidectomized 
e lack both thyroid hormones and GH (31, 32). Con-
iently, T4 deprivation influences Mup expression not 
i directly, but also via GH. The administration of T 4 
Lild restore circulating GH, while the administration 
H does not restore circulating T 4 in the absence of 
inctional thyroid (Table 2). The administration of 
to thyroidectomized mice was reported to increase 
o expression, although not to maximal levels, and it 
therefore suggested that the T 4 requirement is not 
Diute, but rather that GH and T 4 act synergistically 
1. However, an alternative interpretation would be 
the requirement for T 4 is absolute, but that the mice 
a residual low level of T 4 due to incomplete thyroid-
)my. We therefore reexamined the regulation of Mup 
ression by T4 and GH in transgenically ablated 
66.19 mice. Since the MUPs (proteins) are secreted 
the plasma and rapidly excreted into the urine, we 
ially estimated Mup expression from the level of 
iary MUP. 
fter 14 days of DHPG treatment the level of MUP 
he urine of TG66.19 mice was very low (Fig. 5, lanes 
id 4). The levels of MUP were normal in urine from 
trol transgenic mice given saline by minipump and in 
trol nontransgenic mice treated with DHPG (Fig. 5, 
as 1, 2, 11, and 12). When T4 was administered to the 
66.19 mice during the second week of DHPG treat-
it, the thyroid follicle cells were again ablated, as 
wn by the low protein and zero HSV1-TK content of 
residual thyroid tissue (Table 2). However, the serum 
tamed near-normal levels of both T 4 and T3 (Table 
and the urine contained normal levels of MUP (Fig. 
anes 9 and 10). Thus, T4 administration completely 
ersed the suppression of Mup expression by thyroid 
1 2 3 4 5 6 7 8 9 10 11 12 
 dow _ 	- 	- -	-dwm~ 
- odw 48b. 	aw 	. 
4W MW 4W 4 
5. Isoelectric focusing gel of mouse urine samples collected before 
after DHPG or saline treatments supplemented by injection of GH 
74. Odd-numbered lanes, Before treatment; even-numbered lanes, 
r treatment. Lanes 1-10, TG66.19 transgenic female mice as fol-
: lanes 1 and 2, saline infusion; lanes 3 and 4, DHPG infusion; 
's 5 and 6, DHPG infusion, injection with T 4 diluent; lanes 7 and 
HPG infusion, injection with GH; lanes 9 and 10, DHPG infusion, 
ction with T4; lanes 11 and 12, nontransgenic control infused with 
PG. Variation in the MUP pattern between individual mice is due 
eterozygosity at the Mup locus in the C57/BL x CBA cross.  
ablation. 
The administration of GH during the second week of 
DHPG treatment did not inhibit ablation of thyroid 
follicle cells; the level of protein recovered from the 
residual thyroid tissue was low, the thyroid contained no 
HSV1-TK activity, and T 4 and T3 were undetectable in 
the plasma (Table 2). Unlike T 4 treatment, GH admin-
istration did not increase the level of urinary MUP above 
the very low level brought about by thyroid ablation (Fig. 
5, lanes 7 and 8). In an experiment to confirm its biolog-
ical activity, treatment of normal female mice with the 
same GH preparation and according to the same protocol 
raised MUP excretion to male levels (data not shown). 
Thus, biologically active GH did not induce Mup expres-
sion in the absence of T 4. This result demonstrates for 
the first time that T 4 is absolutely required for Mup 
expression. 
The levels of urinary MUP accurately reflected the T 4 
status of the control and experimental animals. The 
levels of Mup mRNA in liver correlated closely with the 
levels of urinary MUP (data not shown). Thus, the 
urinary MUP level could be employed as a noninterven-
tionist indicator of the success of thyroid ablation. 
Lack of thyroid regeneration after withdrawal of DHPG 
In the transgenic ablation of lymphocytes (10) and 
somatotrophs (3), repopulation of the tissue was observed 
after withdrawal of the antiherpetic agent. On the con-
trary, when DHPG was withdrawn from treated TG66.19 
mice, there was no recovery of circulating T 3 or T4 and 
no evident reappearance of thyroid tissue over a period 
of 90 days (data not shown). Thus, it seems that young 
adult mice do not contain a nondifferentiated stem cell 
population capable of regenerating the follicle cells, and 
this is consistent with the view that when follicle cell 
numbers increase as a result of disease, the increase 
occurs through slow division of the follicle cells them-
selves. We cannot exclude alternative explanations at 
this time, for example the existence of a stem cell popu-
lation that expresses HSV1-TK (in the transgenic mice) 
and is consequently sensitive to DHPG, but such expla-
nations are less likely. 
Effect of T 4 deprivation on body weight 
Thyroid deficiency can be induced by treatment with 
methimazole (MMI) or propylthiouracil (PTU), which 
prevent the iodination of thyroglobulin by inhibiting the 
oxidation of iodide (33). Successful treatment of young 
rodents results in the absence of normal weight gain. 
The effect of DHPG ablation was to reduce, rather than 
abolish, weight gain in 8-week-old mice (Fig. 6). During 
the first 2 weeks of treatment, weight gain did not differ 
from that of control mice infused with saline. Thereafter, 
however, the weight gain of the treated mice fell behind 
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FIG. 6. Weight gain in transgenic females during and after DHPG 
treatment. Data were gathered from eight mice, implanted at 8 weeks 
of age, two of which were killed on day 44. Open and shaded columns 
show mice implanted with minipumps containing DHPG and saline, 
respectively. 
that of the controls. Shivering, which frequently follows 
MMI treatment, was not observed after DHPG treat-
ment. These observations suggest that the complete lack 
of weight gain observed after MMI or PTU treatment 
may result from the inhibition of oxidation reactions 
other than the oxidation of iodide (34-39). 
T3 has a profound stimulatory effect on the expression 
of the GH gene (29, 30, 40-42). GH deprivation reduces 
growth by about 50% up to at least 8.5 weeks after birth 
(2, 43, 44), due partly to GH deficiency and partly to 
consequential deficiency of insulin-like growth factor-I 
(44). Thus, GH and insulin-like growth factor-1 defi-
ciency probably contribute to the slower growth observed 
in the ablated mice and may account for it entirely. 
Discussion 
Up to the present there has been no satisfactory animal 
model with which to explore the consequences of com-
plete thyroid deprivation. Surgical removal of the thyroid 
results in loss of the parathyroid and thyroid C-cells as 
well as the follicle cells. Drugs such as MMI and PTU 
inhibit T4 production inconsistently and often have side-
effects (34-39), while the genetically hypothyroid mouse 
suffers from secondary defects due to T 4 deficiency dur-
ing development (45, 46) and retains a significant level 
(10%) of circulating T4 (47). Although the administration 
of ''I is commonly used to ablate the thyroid gland in 
rats, it is seldom administered to mice and only in 
conjunction with thyroidectomy. This may be because in 
the mouse, minimal thyroid-lethal doses of radioiodine 
cause damage to nearby organs (tracheae and thymus). 
The same minimal doses also affect remote organs, caus-
ing a very high incidence of pituitary tumors and female 
sterilization (48), presumably because the administration 
of radioidodine must inevitably result in its delivery to 
the chromosomes of cells that carry thyroid receptors. 
Our results demonstrate the complete ablation of thy- 
roid follicle cells in a line of transgenic mice. The levi 
of circulating T3 and T4 fell below the limits of detecti 
during 14 days of treatment with DHPG by minipun 
total thyroid protein fell by 90-95%, and the level 
thyroid transgenic HSV1-TK activity fell by at le 
99.5%. At the same time, there was no effect on circul 
ing levels of PTH and CT. Ablation was, thus, autor 
mous to the cells that express HSV1-TK, with the i: 
plication that follicle cells and C-cells do not commui 
cate directly or indirectly across the epithelial baseme 
membrane. 
The experiments were carried out with adult mice tF 
had presumptively normal thyroids up to the time tF 
DHPG was administered. Consequently, they should r 
have incurred defects induced by T 4 deprivation dun 
development (45, 46). In contrast to the use of inhibit( 
of iodination, the ability to synthesize T 4 was not 
covered when DHPG treatment was terminated. No] 
generation of follicle cells or recovery of circulating 
or T4 was observed up to at least 90 days after remo 
of the minipumps. In addition, the mice showed 
evidence of side-effects, such as weight loss, which in 
accompany treatment with MMI or PTU. During the 
days after minipump removal that have so far be 
examined, the mice gained weight at about half the r 
of controls and showed no distress. Any trauma due 
minipump implantation and replacement may be 
sumed to have subsided. Thus, the postoperative mi 
provide an ideal model of total T 3 and T4 deprivati 
against a background of normal development. 
It is to be expected that the health of the thyroi 
ablated mice will deteriorate in the longer term. 
deprivation is known to lead to a large increase in c 
culating TSH (49, 50) and a large decrease in GH ( 
32) and to affect positively or negatively the transcripti 
of various genes in the liver and myocardium (51-56). 
longer term assessment of the mice is now required. 
At 18 weeks of age, the thyroid gland is essentiall) 
nondividing tissue, and mitotic figures are extremely r 
in thyroid follicle cells of normal mice (11). The succe 
ful ablation of the follicle cells, therefore, calls ir 
question the assumption generally made that phosph( 
ylated DHPG kills cells exclusively by being incorporat 
into DNA and preventing further extension of the pol 
nucleotide chain. Since DHPG is an analog of guanosil 
and different guanosine phosphate derivatives play se 
eral key roles in cellular metabolism, it is possible tl 
more than one mechanism comes into play. Our preli] 
mary results indicate that the rate of mitosis is ri 
elevated in the follicle cells of untreated TG66.19 mi 
The frequency of mitosis seems to increase during t 
first 2 days of DHPG treatment., but not sufficiently 
account for the approximately 50% death of follicle ce 
estimated to occur during that time. Experiments are 
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ress to further evaluate the involvement of cell di-
in the ablation of follicle cells. 
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The sexually dimorphic expressien of the urinary 
protein genes of mice (Mup genes) in the liver is 
mediated by the different male and female temporal 
patterns of circulating GH. Normal females were 
induced to male levels when GH was administered 
by injection to mimic the male GH pattern, showing 
that expression at the male level does not require a 
male sex steroid status in addition to intermittent 
GH. Two Mup-a,,-globulin hybrid transgenes with 
different Mup gene promoters showed sexually di-
morphic expression, and their expression in females 
increased to male levels upon testosterone treat-
ment. GH-deficient (lit/lit) mice did not express 
these transgenes, and GH-deficient females did not 
respond to testosterone treatment, showing that GH 
was required for induction. Both normal and GH-
deficient females were induced to male levels when 
GH was administered by injection. This is the first 
report of a transgene responsive to GH. A transgene 
consisting of a Mup promoter fused to a Herpes 
simplex virus thymidine kinase reporter sequence 
also showed sexual dimorphism, although to a 
lesser degree. It was expressed at the same level 
in normal females and GH-deficient mice of both 
sexes and was induced when GH-deficient mice 
were treated with GH. We propose that this trans-
gene has a basal constitutive expression, possibly 
due to the absence of any rodent DNA downstream 
of the promoter. Since expression of the transgene 
was significantly induced by GH, the GH response 
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is due at least in part to sequences in the promoter 
region. (Molecular Endocrinology 6: 181-190, 1992) 
INTRODUCTION 
The level of circulating GH changes with time. In rats 
the GH profile is quite different in the two sexes. Males 
are characterized by a low or zero basal level punc-
tuated by high-level spikes which occur at fairly regular 
intervals, while in females the basal level is higher and 
the spikes are more frequent and less pronounced (1, 
2). We will refer to these as male and female GH 
patterns. The different GH patterns are believed to 
result from different patterns of secretion (3). The syn-
thesis of GH is regulated, among other factors, by 
hydrocortisone and thyroxine (4). However, its secre-
tion is mainly directed by the action of GRF and soma-
tostatin on the pituitary somatotrophs (5). The GRF and 
somatostatin which impinge on the somatotrophs are 
secreted by hypothalamic neurones. Consequently it is 
believed that the secretory pattern of these neurones 
is different in males and females, and that this dictates 
the male and female GH patterns. Like other secondary 
sexual characteristics, the pattern of GRF secretion by 
the hypothalamus in rats seems to be regulated by the 
sex steroids (6, 7). 
Several genes are expressed differently in male and 
female liver, and it has been proposed that the male 
and female GH patterns are responsible for establishing 
and maintaining the sexual dimorphism of this tissue 
(8-10). Recently, induction of a male-specific form of 
rat liver cytochrome P450 was shown to depend cru- 
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cially upon the length of the troughs between the peaks 
of circulating GH (11). The mouse major urinary protein 
(MUP) genes (Mup) are among those that are expressed 
differently in the two sexes. MUP is encoded by a gene 
family, and the bulk of liver MUP synthesis is due to the 
expression of a subset of about 12 genes known as 
the group 1 genes (12, 13). Relative to total liver mRNA 
the level of Mup mRNA is 5-10 times higher in males 
than in females (14), and females can be induced to 
express male-like levels by treatment with testosterone 
(15). The different mRNA levels reflect different rates of 
transcription of the Mup genes in the two sexes (16, 
17), and masculinization of females by treatment with 
testosterone increases transcription to the male rate 
(17). Several observations suggest that the effect of 
testosterone on MUP expression is not due to a direct 
effect on the liver, but rather to the fact that it induces 
the male GH pattern. The most persuasive evidence 
comes from studying the expression of the Mup genes 
in GH-deficient mutant mice. Mice homozygous for the 
recessive mutation little (lit) have a low level of circulat-
ing GH (18) and small body size, while the levels of 
other pituitary hormones are normal (19). The mutation 
gives rise to a lesion which makes the pituitary refrac-
tory to stimulation by GRIP (20), and GH therapy re-
stores normal growth (21, 22). Despite having a normal 
level of circulating testosterone (23), lit/lit mice express 
MUP at a very low level (10, 24), demonstrating a 
requirement for GH. The link with sexual dimorphism 
was established by administering GH to GH-deficient 
mice in different ways. When GH was administered by 
injection to mimic the male GH pattern, the normal male 
level of MUP expression was restored (10, 24). In 
contrast, GH did not induce male expression when 
administered by infusion to mimic the female GH pat-
tern. Similarly, male mice with chronically high nonpul-
satile levels of circulating GH expressed MUP at a lower 
level (10). These experiments leave open the possibility 
that, in addition to their GH-mediated effect, sex ste-
roids also affect MUP expression by a direct effect on 
the liver. We have eliminated that possibility by showing 
that MUP expression is masculinized in normal female 
mice when they are treated with GH by injection. 
An important step in elucidating a transcriptional con-
trol mechanism is to define the cis-acting DNA elements 
which mediate the process. No liver cell culture system 
in which Mup genes are expressed has yet been de-
scribed, and there is no recognized method for simulat-
ing GH pulsatility in cell culture systems. We therefore 
performed experiments with transgenic mice as a first 
step to identifying cis-acting DNA sequences that re-
spond to different GH patterns. Mup hybrid genes were 
introduced into the mouse genome, and normal and 
GH-deficient (lit/lit) transgenic mice were generated by 
matings. The results show that expression of the trans-
genes is extremely sensitive to the GH status of the 
animals and that full induction of the transgenes is 
dependent on a male pattern of circulating GH. 
RESULTS 
Tissue-Specific Expression of Mup-a2-Globulin 
Hybrid Genes in Transgenic Mice 
The mouse Mup genes and the rat a2-globulin genes 
are homologous. In order to produce a gene with RNA 
and protein products that can be distinguished from 
those of the endogenous mouse genes, we constructed 
two Mup-a2-globulin hybrid genes (Fig. 1; also see 
Materials and Methods). BS6-cr207 is a group 1 Mup 
gene (BS6), with 2.2 kilobases (kb) of 5'-flanking se-
quence and 1.8 kb of 3'-flanking sequence, and with a 
region extending from a site in exon 2 to a site in exon 
6 replaced by the homologous region of a2.-globulin 
gene cr207. The second hybrid gene, BL1 -cr207, differs 
from BS6-cr207 only in that the promoter and 5'-flank-
ing sequence of a second group 1 Mup gene (BL1) 
were substituted for the homologous BS6 region. The 
BS6-a207 and BL1-a207 hybrid genes were injected 
separately into the pronuclei of C578L/6 embryos het-
erozygous for the little mutation (lit/+). Transgenic GH-
deficient (lit/lit) and normal (lit/± or +1+) offspring were 
generated for study by mating lit/+ transgenic mice 
with lit/± or lit/lit partners. 
Transgenic lines were established and examined by 
Northern blot analysis of RNA extracted from eight 
tissues of normal males. In 9 out of 11 lines expression 
was observed in male liver (Fig. 2A) at levels between 
10% and 110% (average 54%) of the level of expression 
Of a2-globulin mRNA in male rat liver (Table 1). Very 
low levels of expression were observed in the preputial 
glands of two lines (e.g. Fig 2A, lane 3), while in one 
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Fig. 1. Hybrid Genes 
Genes were constructed as described in Materials and 
Methods. a, BS6-a207; b, BL1 -cr207: c, BS6-tk. 0, MUP gene 
BS6 sequence: D, a, b, 2-globulin gene 207 sequence; El, 
b. MUP gene BL1 promoter: E. HSV-tk reporter: N, bacterial 
SupF gene. The positions of the cap sites are indicated by 
arrows. The positions of polyA sites are also indicated, Key 
restriction sites are abbreviated as follows: X, Xbal; H, Hindlll; 
R, EcoRl; A, Aval: K, Kpnl. 
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Fig. 2. Tissue-Specific Expression of Hybrid Genes BS6-207 
and BL1-207 in Male Transgenic Mice 
Unless stated otherwise each lane contained 30 jug total 
cellular RNA. Filters were probed with a labeled c2-globulin-
specific oligonucleotide (see Materials and Methods). A, Line 
BS6-24 (BS6-207). The autoradiograph was exposed for 24 
h (top) and 72 h (bottom). Lanes 1-8, Tissues from a line BS6-
24 transgenic mouse: 1, lachrymal gland; 2, salivary gland; 3, 
preputial gland; 4, striated muscle; 5, brain; 6, testis; 7, kidney; 
8, liver. Lane 9, Two micrograms of total adult male rat liver 
RNA. Lanes 10-12, Tissues from a nontransgenic mouse: 10, 
liver; 11, testis; 12, preputial gland. B, Line BL1-39 (BL1-
a207). Lanes 1-10, Tissues from a line BL1-39 transgenic 
mouse: 1, lachrymal gland; 2, submaxillary gland; 3, parotid 
gland; 4, striated muscle; 5, preputial gland; 6, brain; 7, testis; 
8, kidney; 9 and 10, liver (1 Ogg and 30 jig). Lanes 11 and 12, 
Total adult male rat liver RNA (0.5 Ag and 2 Mg). 
line (BI-11-5) the level of expression in the preputial 
gland was higher than in the liver. Since it occurred in 
only 1 out of 9 lines, high level expression in the 
preputial gland may be assumed to be due to mutation 
or rearrangement of the foreign DNA integrated in line 
BL1-5 or to a chromosomal position effect (25). No 
expression was observed in other tissues. Thus, to a 
large extent, expression of the transgenes was re-
stricted to the liver. 
In Northern blots of liver RNA from mice carrying 
either transgene two mRNAs were consistently ob-
served, both close to 800 base pairs (bp) in length and 
in approximately equal amounts. A single major primer 
extension product was observed (Fig. 3B), initiated at 
the Mup cap site described previously (26). The 3' ends 
of the transgenes were derived from Mup gene BS6, 
and Mup gene transcripts are known to have at least 
three different splice configurations in the 3' noncoding 
region and also several alternative polyadenylylation 
sites (27-29). Thus the two size classes of mRNA 
probably arise through differential processing of a single 
mRNA precursor. 
Sexually Dimorphic Expression of the Mup-cx2-
Globulin Hybrid Genes 
In 8 of the 9 expressing lines (Table 1) normal females 
did not express the transgene (e.g. compare lanes 3 
Table 1. Sexually Dimorphic Expression of BS6-a207 and 
131-1-,207 Hybrid Genes 
Relative expression level 
Line Liver Preputial 
gland 
Male Female (male) 
BS6-3 0.2 0.0 ND 
BS6-6 0.0 0.0 0.0 
BS6-10 0.9 0.0 0.0 
BS6-24 0.5 0.0 0.0* 
BS6-25 0.7 0.0 0.0* 
BS6-26 0.2 0.0 0.0 
BS6-36 0.2 0.0 ND 
BL1-5 1.1 0.0 2.4 
BLI-35 0.1 0.0 0.0 
BL1-39 1.0 0.4 0.0 
BL1-41 0.0 0.0 0.0 
Northern blots were probed with an a2-globulin-specific oh-
gonucleotide (see Materials and Methods), except that in the 
case of BL1 -39 the same oligonucleotide was used as primer 
in a primer extension assay. Autoradiographs were scanned 
densitometrically and related in each case to the signal ob-
tained from the same quantity of adult rat liver RNA (taken as 
1.0); 0.0*  indicates a faint band which could be detected by 
eye but was not registered by the densitometer; ND, not 
determined. 
and 6 of Fig. 3A). Females of the ninth line (line BL1-
39) expressed the transgene at a level lower than males 
of the same line (Table 1). The general result (6 out of 
6 lines) is that expression of BS6-207 was extremely 
dimorphic, and that the data obtained with BL1-t207 
do not allow a distinction to be drawn between the two 
constructs. Hepatic Mup gene expression is on average 
5-10 times higher in males than in females. However, 
different Mup genes show different degrees of sexually 
dimorphic expression (14, 15, 24), and the expression 
ratio of the BS6 gene in the two sexes is not known 
because its products cannot be distinguished from 
those of approximately 5 other identical or near-identi-
cal group 1 Mup genes. The rat a2-globulin genes are 
highly expressed in male but not at all in female liver 
(30). Thus it is not possible at this time to distinguish 
the contributions of mouse and rat sequences to the 
expression of the hybrid transgenes. This does not 
detract from the value of the hybrid genes as constructs 
which show a large response to GH as transgenes. 
The effect of testosterone treatment on transgene 
expression was examined by Northern blot (not shown) 
and primer extension analysis (Fig. 3B) of hepatic RNA 
from line BS6-24. Testosterone treatment of normal 
females induced the expression of the transgene, and 
the mRNA had the normal cap site. The extent of 
induction was lower than that of normal males of the 
same line (Fig. 313, lane g), even though the endogenous 
Mup genes were fully induced (data not shown). How-
ever, prolonged (5-week) treatment of female mice with 
testosterone induced male-like levels of hybrid gene 
expression (data not shown). The results show that, 
like the endogenous genes, the transgene is induced 
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Fig. 3. Sexually Dimorphic Expression, GH Dependency. and 
Testosterone Induction of Hybrid Gene BS6-a207 in Liver of 
Transgenic Mice 
Sex: f, female; m, male. Genotype: +, Iit/+ or +/+; L, lit/lit. 
Mice treated or untreated with testosterone (Testos.): + and 
- respectively. Nontransgenic control: C. A, Lack of expres-
sion of BS6-a207 in the livers of females and GH-deficient 
males from line BS6-25. Northern blot analysis. Total liver 
RNA (30 g) was applied to each lane, and the filter was 
probed with the 02-gIobulin-specific oligonucleotide (top), 
stripped, and probed with an apolipoprotein-Al cDNA clone 
(bottom). Lanes 1-3, Female: 1, nontransgenic; 2, GH-deficient 
transgenic; 3, normal transgenic. Lanes 4-6, Male: 4, non-
transgenic; 5 GH-deficient transgenic; 6, normal transgenic. B, 
Effects of testosterone induction on expression of BS6-cr2O7 
in normal and GH-deficient females. All transgenic mice were 
from line BS6-24. Primer extension analysis was carried out 
as described using 10 jig total liver RNA in each case, except 
where stated otherwise. Lanes a-f, Normal females: a and b, 
untreated; c-f, individual females treated with testosterone. 
Lanes g and h, Male controls: g, normal male; h, GH-deficient 
male. Lanes i and j, GH-deficient females treated with testos-
terone. Lanes k, I, and n, Controls: k, male rat liver (1 gig): I, 
nontransgenic male mouse; n, no RNA. Lane m, Sequencing 
ladder (C-track). 
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Fig. 4. Effect of GH on the Expression of BS6-a207 and BL1 - 
a207 in the Liver of Transgenic Male GH-Deficient Mice 
Genotype: +, lit/+ or ±1+: L, lit/lit. Mice treated or not 
treated with GH: + and -, respectively. A and B, Thirty 
micrograms of total liver RNA was applied to each lane, and 
filters were probed with the 20-globulin-specific oligonucleo-
tide (A), stripped, and probed with an apolipoprotein-Al cDNA 
clone (B). Lanes 1-4, Nontransgenic controls: 1, mock-in-
jected; 2, GH-deficient, untreated; 3, GH-deficient, injected 
with GH; 4, normal, untreated. Lanes 5-7, Line BS6-24 (BS6-
a207): 5, GH-deficient, untreated; 6, GH-deficient, injected 
with GH; 7, normal, untreated. Lanes 8-10, Line BS6-25 
(13S6-is207): 8, GH-deficient, untreated; 9, GH-deficient, in-
jected with GH; 10, normal, untreated. Lanes 11-13, Line 
BL1 -39 (BL1 t207): 11, GH-deficient, untreated; 12, GH-defi-
cient, injected with GH; 13, normal, untreated. Lane 14, Male 
rat liver RNA (2 ag). C, Primer extension analysis was carried 
out as described using 10 g total liver RNA in each case. 
Lane a, No RNA. Lanes b-d, Nontransgenic controls: b, Gil-
deficient mock-injected; c, GH-deficient injected with GH; d, 
normal, untreated. Lanes e-g, Transgenic mice, line BS6-24 
(BS6-a207): e, GH-deficient, mock injected; f, GH-deficient, 
injected with GH; g, normal, untreated. Lanes h-j, Transgenic 
mice, line BS6-25 (BS6-(t207): h, GH-deficient mock-injected; 
i, GH-deficient, injected with GH; j, normal, untreated. Lane k, 
Male rat liver. Lanes I and m, Sequencing tracks: I, A-track; 
m, C-track. 
by testosterone, although there is a difference in the 
level of its response. 
GH Regulation of the Mup-a2 -Globulin Hybrid 
Genes 
The Mup genes were expressed at very low levels in 
both GH-deficient males and GH-deficient females (see 
Fig. 5A, lanes a and k). Similarly, the level of 8S6-a207 
and BL1-a207 mRNA in GH-deficient males and fe-
males was usually below the limit of detection (Fig. 3A). 
mRNA was detected at a very low level in a few GH-
deficient males, but the incidence of such males was 
not a feature of a particular transgenic line. Unlike 
normal females (with normal pituitary glands), GH-defi-
cient females were not induced by testosterone (Fig. 
3B, lanes i and j), consistent with the view that the 
effect of testosterone stimulation is mediated by GH. 
To confirm the central role of GH in inducing the 
expression of the transgenes, GH-deficient males were 
treated with GH by injection. The treatment induced 
transgene mRNA to levels similar to those present in 
transgenic normal males (Fig. 4A, lanes 6, 9, and 12), 
and the mRNA invariably had the expected cap site  
(Fig. 4C). These results demonstrate that, in common 
with the endogenous Mup genes, the hybrid transgenes 
contain sequences that respond to GH induction. 
Normal females express the endogenous Mup genes 
at a higher level than GH-deficient females, indicating 
that the female GH pattern also induces the Mup genes. 
Males and females express individual Mup genes at 
different relative levels (14, 15, 24), suggesting that the 
inducing effects of the male and female GH patterns 
are different. When induced with testosterone, normal 
females express individual Mup genes at male levels 
(15), presumably because their pituitaries develop the 
male pattern of circulating GH. Isoelectric focusing (IEF) 
analysis of urinary proteins showed that the resident 
Mup genes were consistently induced by GH in GH-
deficient females (Fig. 5A, lanes d and f). Thus the 
female liver can be masculinized by exposure to pul-
satile GH. 
In GH-deficient females there is no prior exposure to 
normal levels of GH and very little GH secretion, while 
normal females have prior exposure to the female GH 
pattern, and any injected GH supplements GH pro-
duced by ongoing pituitary secretion. Like GH-deficient 
females, normal females were induced to express the 
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Fig. 5. Effect of GH on the Expression of the BS6-a207 Hybrid 
Gene in Liver of Female Transgenic Mice 
Urine was collected from mice before and after treatment. 
RNA was extracted from the livers of the same mice after 
treatment. Sex: F, female; M, male. Genotype: +, lit/+ or ±/ 
±; L, lit/lit. Mice treated or untreated with GH: + and -, 
respectively. A, Urinary MUP5 resolved on an IEF gel and 
stained with Coomassie blue. Lanes a-j, Line BS6-24 females: 
a and b, GH-deficient, before and after mock injection; c and 
d, GH-deficient, before and after GH injection; e and f, same; 
g and h, normal, before and after GH injection; i and j, same. 
Lanes k-n, Male controls: k and I, GH-deficient, before and 
after GH injection: m and n, untreated normal males. Lanes 
o-r, Line BS6-26 females: o and p, normal, before and after 
GH injection; q and r, GH-deficient, before and after GH 
injection. The patterns shown are characteristic MUP patterns, 
identical to those observed with riontransgenic mice. The 
protein products of the hybrid genes cannot be visualized with 
Coomassie stain (see text). B, Northern blots of total liver RNA 
(30 g) probed with the a2u-globulin-specific oligonucleotide 
probe. Letters in parentheses indicate the corresponding MUP 
samples shown in A. Lanes 1-6, Line BS6-24 females: 1, GH-
deficient, mock-injected; 2 and 3, GH-deficient, injected with 
GH; 4, normal, mock-injected; 5 and 6, normal, injected with 
GH. Lanes 7-9, Line BS6-24 male controls: 7, normal, un-
treated; 8, GIl-deficient, injected with GIl; 9, GIl-deficient, 
untreated. Lane 10, Male rat liver RNA (2 pg). Lanes 11-13, 
Line 8S6-26 females: 11, normal; 12, normal, injected with 
GIl; 13, GH-deficient, injected with GH. Lanes 14-16, Con-
trols: 14, normal male; 15, nontransgenic normal male; 16, 
male rat liver RNA (2 mg). 
Mup genes at male levels by GH (Fig. 5A, lanes h and 
j). Thus, GH administered by injection to normal females 
overcomes any effects due to prior exposure and either 
overrides the female GH pattern or entrains the secre-
tion of GH, or both. 
The response of the BS6-cx207 gene to GH injection 
was investigated in females of lines BS6-24 and BS6-
26. In both GH-deficient and normal line BS6-26 fe-
males the transgene responded in the same way as the 
endogenous genes and was induced by GH (Fig. 5B, 
lanes 12 and 13). In contrast, although transgene 
expression was again induced in GH-deficient line BS6-
24 females (Fig. 513, lanes 2 and 3), it was not induced 
in normal females of this line (Fig. 5B, lanes 5 and 6), 
although the endogenous Mup genes were induced in  
the same individuals (Fig. 5A, lanes h and j). Thus, 
although there was essentially no difference in the 
response of the endogenous Mup genes, and none in 
the response of the BS6-a207 gene present in line 
BS6-26, the BS6-s207 gene present in line BS6-24 
responded differently to GH treatment depending on 
whether or not the female mouse carrying it was GH-
deficient. The probable cause of the lack of response 
of normal line 8S6-24 females is the dissimilar levels 
of endogenous GH in GH-deficient and normal mice. 
According to this view, although GH injection can ov-
erride or entrain the pattern of endogenous GH secre-
tion, either the new GH pattern does not conform 
closely enough to the male type, or else the response 
of the liver to the new GH pattern is incomplete. The 
former explanation is the more likely in view of the 
recent demonstration that the sexually dimorphic 
expression of rat liver cytochrome P450 depends cru-
cially on the occurrence of periods between the GH 
peaks when the GH level is low or zero (11). In addition, 
it is necessary to assume that the transgenic locus in 
line BS6-24 is less responsive to the incomplete 
change, whatever it is, than either the endogenous Mup 
genes or the transgertic locus in line BS6.-26. Since all 
the mice employed were bred on the C57BL back-
ground, there should be no effect of segregating or 
linked modifier genes, and the most likely cause of the 
different responses of the BS6-24 and BS6-26 loci is 
that one of the two is influenced by a chromosomal 
position effect. 
Expression of MUP-s2 -Globulin Hybrid Protein 
BS6-a207 and BL1-a207 code for the same urinary 
protein, which can be identified by challenging Western 
blots with anti-12-91obulin serum. The antiserum cross-
reacts at a low level with MUP, although, presumably 
because it has different affinities for different MUP 
proteins, the relative intensities of different MUP com-
ponents in the immunostained gels (Fig. 6, B and C, nt) 
were strikingly different from those obtained by Coom-
assie staining (data not shown). A novel antibody-re-
active protein which comigrated with a 2 -globulin was 
detected in the urine of most transgenic normal males 
but not in that of females or GH-deficient males, thus 
accurately reflecting the incidence of hybrid gene mRNA 
in the liver (Fig. 6, A and B). Similarly, treatment of GH-
deficient transgenic males with GH led to the secretion 
of the antibody-reactive protein (Fig. 6C, lane c). 
No protein with the same mobility as the antibody-
reactive protein could be detected in Coomassie-
stained agarose-IEF or sodium dodecyl sulfate poly -
acrylamide gels, showing that urinary levels of the 
hybrid protein were very low. In contrast, the level of 
hybrid gene mRNA in the liver was on the same order 
as the level of MUP mRNA. The relative deficiency of 
the hybrid protein in urine presumably relates to the 
structure of either the mRNA or the protein and may be 
due to any of a number of causes, for example, a low 
rate of translation or of renal clearance. 
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Fig. 6. Urinary Secretion of the MUP-2-Globulin Protein in 
Transgenic Mice Carrying the BS6-c207 and BL1 207 Hybrid 
Genes 
The Western blots were developed using anti-0 2 -globuIin 
serum as primary antibody (see Materials and Methods). Lines 
are denoted with the following abbreviations: 3, BS6-3; 24, 
BS6-24; 25, BS6-25; 36, BS6-36; 39, BL1-39; 41, BL1-41. 
nt, Nontransgenic mice; r, 0.1 zg male rat urinary protein. A. 
Lack of expression in the urine of female mice. Thirty micro-
grams of mouse urinary protein collected from individual nor-
mal mice were applied to each lane; m, male; f, female. An 
additional band present in most female samples is also present 
in nontransgenic female urine (not shown). B, Lack of expres-
sion in the urine of GH-deficient mice. Forty micrograms of 
mouse urinary protein collected from individual male mice were 
applied to each lane; a, normal mouse; b, GH-deficient mouse. 
C, Expression in the urine of GH-treated GH-deficient trans-
genic male mice. Urine from individual normal or GH-deficient 
transgenic (and nontransgenic control) mice was mixed with 
an equal volume of urine from Gil-deficient or normal nontrans-
genic mice, respectively, before dialysis to equalize the protein 
concentrations. Forty microliters of urine were applied to each 
lane. a, Normal mouse; b and c, GH-deficient mouse before 
and after GH injection; b' and c', GH-deficient mouse before 
and after mock injection. 
Expression of a BS6 Promoter-Thymidine Kinase 
(TK) Reporter Gene in GH-Deficient Mice 
We previously described a hybrid gene (BS6-tk) in 
which a 2.2-kb fragment containing the promoter and 
5'-flanking sequence of Mup gene BS6 was joined to 
the coding region of the HSV-1 thymidine kinase gene 
(17). Between its 5' end and the junction (in the 5'-
noncoding region) with the tk gene, BS6-tk is identical 
to BS6-ii207 and BL1-a207 (Fig. 1). BS6-tk was intro-
duced into the genome of C57BL/6 x CBA/Ca F 2 
embryos, and transgenic lines were maintained by mat-
ings with C57BL/6 x CBA/Ca F 1  offspring. In three out 
of four lines the hybrid gene was expressed in a sexually 
dimorphic manner in the liver as determined by TK 
assays, Northern blot analysis, and run-on transcription 
(17). Expression in males was about five times higher 
than in females, a ratio similar to that shown by endog- 
enous Mup genes, but much less than that shown by 
6S6-a207 and BL1-a207. 
In view of the sexually dimorphic expression of BS6-
tk, it was important to determine whether it would 
respond to GH. If so, the conclusion could be drawn 
that the response is due to the promoter and/or 5'-
flanking region of the Mup gene. GH-deficient and nor-
mal mice carrying the BS6-tk gene were produced by 
mating BS6-tk transgenic females [line 78 (17)] to 
C57BL/6 Iit/+ males and then back-crossing transgenic 
Iit/+ female offspring to lit/i- males. As determined by 
TK assays (Table 2), the male/female expression ratio 
of BS6-tk in normal back-cross offspring was about 2. 
This is lower than the ratio previously observed in mice 
from the G 1 and G 2  generations (17), possibly due to a 
change in the properties of the locus during propaga-
tion. The levels of expression in GH-deficient males and 
females were not significantly different, and in this 
respect the expression of BS6-tk mirrors that of the 
endogenous Mup genes. However, the level of expres-
sion in GH-deficient mice of both sexes was the same 
as that in normal females. In contrast, the endogenous 
Mup genes are expressed at a much lower level in GH-
deficient mice than in normal females (Fig. 5). We 
suggest that this difference is due to constitutive (GH-
independent) expression of BS6-tk. High constitutive 
expression could obscure a relatively much smaller 
difference in expression between normal females and 
GH-deficient males (see below). 
The difference between normal males and GH-defi-
cient males in the expression of BS6-tk was significant 
and greater than 2-fold. Treatment of GH-deficient 
males with GH induced expression by a factor of about 
3, to a level that was in fact significantly higher than 
that in the uninduced normal males. Thus about 50% 
of the expression of the hybrid gene in normal males 
appears to be GH-dependent. We attribute the remain-
ing 50% to GH-independent constitutive expression, 
which at this level would explain both the low sex ratio 
and our inability to detect a difference between normal 
females and GH-deficient mice. The HSV-tk reporter is 
not expressed in the liver when not appropriately at-
tached to a liver-specific promoter or when attached to 
a shorter region (314 bp) of the BS6 promoter (31). 
Thus both the GH-inducible and the proposed consti-
tutive expression of BS6-tk seem to be due to se-
quences residing in the BS6 promoter. 
DISCUSSION 
Expression of Mup Genes is Regulated by the 
Pattern of Circulating GH 
Data presented here confirm that the effects of the sex 
hormones on Mup gene expression are mediated by 
the different patterns of circulating GH in the two sexes 
(10). GH-deficient male and female mice express the 
Mup genes at the same very low level, which is lower 
than the levels of expression in normal males or fe- 
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Thymidine kinase activity 
Males (n) 	 Females (n) 
C57BLxCBA None 22.75 ± 1 . 29c (4) 10.10 ± 1 . 10c4 (4) 
C57BLxCBA Testosterone ND 21.10 ± 1.33° (3) 
C57BL lit/+ None 20.13 ± 1,301 (4) 12.77 ± 1.27 (3) 
C57BL lit/lit None 8.87 ± O.58 	(2) 12.67 ± 1.30'(3)  
C57BL lit/lit Buffer 11.15 ± 1.85 9 (2) ND 
C576L lit/lit GH 32.70 ± 117 9 (3) ND 
° Units of thymidine kinase activity, picomoles of TMP formed per mm/mg protein. 
b  Maintenance of line 78 on the C57BLxCBA background and transfer of the transgene to C57BL lit/lit and lit/+ genotypes is 
described in Materials and Methods. 
0-9 The significance of the differences between samples (t test)° are: c , P < 0.005; ', P < 0.001 °, P < 0.001; ', P < 0.002; 9, p < 
0.005; ND, not determined. 
males. When GH was administered in a regime that 
crudely mimics the endogenous GH pattern of males, 
expression of the Mup genes was induced, giving 
expression comparable to that of normal males. The 
Mup genes were induced by testosterone in normal but 
not in GH-deficient female mice, demonstrating a re-
quirement for GH. Furthermore, normal females could 
be induced by episodic GH administration alone, show-
ing that the sex steroid status of the female can be 
overridden in this way and also that male levels of 
testosterone are not required for expression when GH 
is administered episodically. Since the sex steroids 
control the secretion pattern of GRF (6, 7), it is likely 
that induction by testosterone is mediated by the mas-
culinization of the endogenous GH pattern of the 
treated females. 
On the basis of a study of dwarf rats it was proposed 
recently that the GH pattern may not regulate the sexual 
dimorphism of liver cytochrome P450, and that a con-
taminant of GH preparations may be the active agent 
(32). Although the basis of this claim has been chal-
lenged (11), the alternative explanation warrants ex-
amination here. Two considerations argue against it in 
the present case. First, GH treatment reverses the lit/ 
lit phenotype, which is believed to be due to a specific 
defect in GH release (20). Second, we have successfully 
induced Mup synthesis with human GH, bovine GH, 
ovine GH, and rat GH (our unpublished results). Thus if 
the inducing agent is other than GH, it presumably must 
nevertheless be linked to GRE stimulation, and it must 
be present in GH preparations from four species. This 
is not impossible but seems the less likely explanation. 
Hybrid Mup Transgenes Are Induced by Pulsatile 
GH 
In order to establish whether cis-acting DNA sequences 
are involved in the response of the Mup genes to GH, 
we generated lines of transgenic mice carrying two 
Mup-a2-globulin hybrid transgenes with different Mup 
gene promoters but otherwise with the same structure. 
No consistent difference in the expression of the two 
transgenes was observed. Their expression was highly 
dimorphic and dependent upon a male pattern of cir-
culating GH: GH-deficient mice of either sex failed to 
express the transgenes and were fully induced by epi-
sodic GH administration. Like the expression of endog-
enous Mup genes, transgene expression was not in-
ducible by testosterone in GH-deficient females. In at 
least one transgenic line the expression of the trans-
gene in normal females could be induced by episodic 
GH treatment, showing that, as in the case of the 
endogenous Mup genes, the sex hormone status of the 
animal can be overridden by GH. Also in line with the 
response of the endogenous Mup genes, this indicates 
that induction by episodic GH does not involve any 
direct effect of sex steroids on the liver. 
The BS6 Promoter Contains a GH-Responsive 
Element 
The expression of the BS6-tk hybrid gene was previ-
ously shown to be sexually dimorphic (17). Run-on 
transcription experiments demonstrated that sexually 
dimorphic expression of both the resident Mup genes 
and the BS6-tk transgene was due to different rates of 
transcription in the two sexes (16, 17). If sexually 
dimorphic expression is dictated by the GH pattern, the 
BS6 promoter region should contain a response ele-
ment which responds to GH stimulation. Here we veri-
fied this by introducing the BS6-tk transgene into a line 
of GH-deficient mice. Hepatic expression of BS6-tk in 
GH-deficient males was significantly lower than in nor-
mal males, and higher levels of expression were in-
duced when GH-deficient mice were treated with GH, 
confirming the presence of a GH-responsive element in 
the promoter. 
The response of the BS6-tk transgene to GH, and 
also the degree of sexual dimorphism it displayed, were 
small relative to the responses of the BS6-a207 trans-
gene. One possible explanation is that mouse or rat 
sequences downstream of the promoter, which are 
present in 13S6-a207 but not in BS6-tk, are responsible 
for the greater responses of BS6-a207. This explana-
tion is reinforced by the fact that a rat a207 transgene 
shows extreme sexual dimorphism in the mouse (33). 
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If so, the implication would be that there is a second 
response element in the downstream region. An alter-
native explanation, advanced above, is that BS6-tk has 
constitutive transcriptional activity, effectively a high 
GH-independent background level of transcription, 
which obscures the true extent of GH induction. If the 
putative downstream response element suppressed 
transcription in the absence of GH, the two explanations 
could relate to a single response element (or cluster). 
At this time the basis of the low response of BS6-tk 
remains unresolved. It is interesting to note that a 
fragment (-639 to +1395) of the rat a207 gene was 
actively transcribed in male but not in female rat liver 
nuclear extracts (34). 
Expression of the Resident Mup Genes and the 
MUP-207 Hybrid Genes in Female Mice 
Two observations suggest that in liver subjected to the 
female GH regime MUP expression is feminized rather 
than simply not induced: 1) The level of expression of 
the resident Mup genes is higher in females than in GH-
deficient mice of either sex. Furthermore, when individ-
ual urinary MUP5 were resolved by IEF it was apparent 
that some proteins are more abundantly expressed in 
males and others more abundantly expressed in fe-
males, relative to the basal patterns observed in urine 
from GH-deficient mice [(15) and Fig. 6A]. Similarly, 
rnRNA species derived from different Mup genes are 
expressed at different relative levels in males and fe-
males (14). 2) In one transgenic line (BL1 -39) a signifi-
cant level of BL1-a207 hybrid gene mRNA was de-
tected in normal females, but no or very low expression 
was detected in GH-deficient mice of the same line; 
thus, in this line the female and GH-deficient transgene 
phenotypes resemble the endogenous MUP pheno-
types. The most likely explanation of these observa-
tions is that female liver exposed to a relatively constant 
level of GH is feminized, while male liver exposed to 
pulses of GH is masculinized, both relative to the GH-
deficient state. Feminization may generate a different 
stable level of the same trans-acting protein(s) involved 
in masculinization, or may lead to the appearance of 
qualitatively different hepatic trans-acting proteins. 
Masculinization and feminization may involve different 
signal transduction pathways. Different pathways of 
signal transduction are involved in the GH induction of 
c-fos and insulin-like growth factor-I in preadipocytes 
(35). 
BL1 is the most highly expressed Mup gene in BALB/ 
c female mice, where it represents 75% of the total 
Mup mRNA (14). The expression level of the endoge-
nous BS6 Mup gene in female mice is not known, 
although translation of BS6 mRNA generates a protein 
which comigrates with a MUP present in female urine 
(Johnson, 0., unpublished observations). The BS6-
a207 hybrid gene was not expressed in female mice 
(six out of six lines), and only one Out of three lines 
expressed the BL1-a207 hybrid gene in females. Thus, 
the general pattern of expression of the two hybrid  
genes seems to be the same, given that the expression 
observed in females of one line (BL1-.39) is a special 
property of the foreign DNA or its site of integration in 
that line, that is, to mutation, to the arrangement of the 
foreign genes, or to a chromosomal position effect (25, 
36). However, because we established only three lines 
which expressed BL1-c207, we cannot completely ex-
clude the possibility that BL1-a207 is less sexually 
dimorphic and that failure of expression in females 
carrying the BL1-5 and BL1-35 integrations is due to 
one or more of the causes of aberrant expression listed 
above. 
Activity of the Mup Gene Promoter in the Preputial 
Gland Is Modulated by Sequences 3' of the Cap 
Site 
BS6-tk is expressed in the liver and also at high levels 
in the preputial glands and testis (17, 25), although the 
resident Mup genes are not expressed in the two latter 
tissues. The HSV-tk reporter directs its own expression 
to the testis, using a cryptic housekeeping-type, TATA-
independent, promoter (31). However, expression in 
the preputial gland appears to be a property of the Mup 
promoter because a Mup promoter-T antigen reporter 
gene is also expressed in the preputial gland (37) and 
because other hybrid genes containing HSV-tk as the 
reporter are not expressed in this tissue (31). With the 
exception of one line (see below), the BS6-a207 gene 
was not expressed or was expressed only at an ex-
tremely low level, in the preputial glands of transgenic 
mice. It therefore appears that a sequence which pre-
vents expression in the preputial gland is located in the 
BS6-o207 gene downstream of the promoter. In con-
trast to the Mup genes, the a2-globulin genes are highly 
expressed in rat preputial glands, and in contrast to 
BS6-a207, the a207 gene was expressed at high levels 
in the preputial glands of transgenic mice (33). This 
suggests that the sequence in question is located within 
one of the two Mup regions of BS6-a207 which are not 
shared with either BS6-tk or -207. The first maps from 
the junction between the BS6 promoter and HSV-tk in 
the 5'-noncoding region to the BS6-a207 junction at 
the EcoRl site in exon 2; the second is the region 3' of 
the Aval site in exon 6. 
One of the lines (BL1 -5) expressed the hybrid gene 
at high levels in the preputial gland. Since this is an 
isolated case (one out of nine lines), high level expres-
sion in the preputial gland may be assumed to be due 
to mutation, gene arrangement, or the chromosomal 
environment of the foreign DNA in line BL1 -5. In most 
transgenic lines the BS6-tk hybrid gene is expressed in 
the preputial gland, but in line 64 expression was not 
detected (17). We have shown that this was due to a 
chromosomal position effect; the transgene was reiso-
lated from line 64 and when reintroduced into the 
genome of mice, preputial gland expression was re-
stored (25). The expression of Mup transgenes in the 
preputial gland appears to be particularly volatile. 
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MATERIALS AND METHODS 
Hybrid Genes 
Hybrid genes were assembled by making use of restriction 
sites (EcoRl in exon 2 and Aval in exon 6) which are conserved 
between Mup and 2 -globulin genes. The BS6-207 hybrid 
gene was constructed from three DNA segments: a 2.75-kb 
Hindlll-EcoRl 5'-fragment of MUP gene BS6 (27), which ex-
tends from 2.2 kb upstream of the cap site to exon 2, was 
linked to a 1.9-kb EcoRl-AvaI fragment (exons 2-6) of the 
globulin gene 207 (38), and a 3.4-kb Aval-BamHl 3'-fragment 
of Mup gene BS6, which includes 1.8 kb of 3'-flanking se-
quences. A 408-bp BamHl-XbaI fragment containing the Esch-
erichia coil SupF gene is located immediately 3' of the MUP-
02 -globulin gene. The BL1 -c 2 -globulin gene was constructed 
by replacing the 2.2-kb BS6 promoter region with the homol-
ogous region of BL1. For microinjection, each hybrid gene 
together with SupF was released from the vector (17) by 
digestion with Xbal and purified by gel electrophoresis. 
Transgenic Mice 
Lit/lit mice were maintained on the C57BL/6 background. To 
produce transgenic mice carrying the lit allele, lit/lit male studs 
were mated with normal 3-week-old C57BL/6 superovulated 
female mice. The fertilised eggs (50-70% of the those re-
covered) were injected in the male or female pronucleus. From 
310 eggs injected with BS6-207, 46 pups were born, 11 
transgenic mice were obtained, and lines were established 
from 7 of these. Two hundred fifty-six eggs were injected with 
BL1-a207, 47 mice were born, 4 transgenic mice identified, 
and all were bred to establish transgenic lines. Founders were 
back-crossed with lit/lit mice or mice heterozygous for the lit 
mutation; lines were also maintained in this manner. Two lines 
of mice carrying the BS6-a207 hybrid gene (lines BS6-6 and 
BS6-1 0) were produced by injecting eggs recovered from 
C57BL/6 x CBA/Ca F 1 females mated with F 1 males; these 
lines were maintained by back-crossing transgenic with non-
transgenic F 1 mice. Transgenic mice were identified by South-
ern blot analysis or polymerase chain reaction of tail DNA, 
using a SupF probe or SupF-specific primers, respectively. 
Hormone Treatments 
Mice were treated with rat GH (a gift from the U.S. National 
Hormone and Pituitary Program, NIDDK, Baltimore, MD) by 
injecting 100 g/20 g body wt ip every 12 h for a period of 5 
days (10, 21, 24, 39). Testosterone was administered as a 30- 
mg sc implant, and the mice were examined after 10 days. 
RNA Analysis 
RNA preparation and Northern blot analysis were carried out 
as described previously (17). Blots were hybridized with an 
2 -globulin-specific 50-mer oligonucleotide (5' -CAAATATAG-
TTCCCTGCACTCTCCATTTTCCTTAATACGGAACTTGA-
AGC-3'), end labeled with I 32 P]ATP. The oligonucleotide 
corresponds to the antisense strand of the last 19 bp of exon 
2 and the first 31 bp of exon 3 of the 207 2 -globulin gene 
and differs from the Mup group 1 genes by 40% of its nucleo-
tide sequence. Northern blots were reprobed with an apoli-
poprotein-Al cDNA to check the integrity of the RNA samples. 
The apolipoprotein-Al genes show little sensitivity to GH. 
Primer extension analysis of transcriptional start sites was 
performed by a modification of a method described (40) using 
the a 2 -globulin-specific 50-mer oligonucleotide as a primer. 
Ten micrograms of total liver RNA and 0.2 pmol end-labeled 
primer were used in each extension reaction. Extension prod-
ucts were fractionated on a 6% acrylamide-7 M urea gel and 
visualized by autoradiography. 
Protein Analysis 
Mouse and rat urine was collected by bladder massage. The 
urine was dialyzed at 4 C against 0.1 M NaCl, 10 mm Tris-HCI, 
pH 7.6, for 24 h and subsequently against distilled water for a 
further 24 h. Samples were stored at -20 C until required. 
Agarose IEF gels were prepared and stained as recommended 
by the ampholine manufacturer (Pharmacia, Piscataway, NJ). 
Gels consisted of 1% agarose, 12% sorbitol, and 6.3% Phar-
malyte (86% Pharmalyte 4.2-4.9 and 14% Pharmalyte 3-5.5). 
The anode and cathode electrodes were soaked in 0.05 M 
H2SO4 and 1 M NaOH, respectively. Gels were stained with 
Coomassie Blue. Samples prepared for Western Blot analysis 
were run on a 15% sodium dodecyl sulfate polyacrylamide gel 
(41). Proteins were transferred onto Immobilon (Millipore, Wat-
ford, Hertsfordshire, UK) by the semidry blotting method (42) 
and challenged with rabbit anti-2-gIobuIin serum raised 
against crystallized a 2 -globulin (a gift of Lindsay Sawyer, 
Department of Biochemistry, University of Edinburgh). 
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